SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb2021) 
CONFIDENTIAL  Page 1 TITLE PAGE  
Protocol Title:  A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat 
Versus Placebo in Adult Patients with Progressing Desmoid Tumors/Aggressive Fibromatosis 
(DT/AF).  
Protocol Number:  NIR- DT-301 
Amendment Number:  5 
Compound Number:  PF-03084014 (nirogacestat) 
Study Phase:  Phase 3  
Short Title:  A Placebo -Controlled, Phase 3 Study of Nirogacestat in Adults with Desmoid 
Tumor/Aggressive Fibromatosis  (DT/AF).  
 
Acronym:  DeFi  
Sponsor Name: SpringWorks Therapeutics  
Legal Registered Address:  100 Washington Blvd, Stamford, CT 06902, United States  
Regulatory Agency Identifier Number(s)  
Registry  ID 
EudraCT  2018 -001991 -39 
IND 138207  
 
Approval Date: 09 February  2021  
 Confidentiality Statement 
The information in this document is confidential information of SpringWorks Therapeutics and 
is not to be disclosed without the prior written consent of SpringWorks. You are allowed to 
disclose the contents of this document only to your Institutional Revie w Board or Independent 
Ethics Committee and study personnel directly involved with conducting this protocol. Persons to whom the information is disclosed must be informed that the information is confidential and proprietary to SpringWorks and that it may not be further disclosed to third parties or used for any other purpose. The disclosure and use of information in this document are subject to a 
written confidentiality agreement between SpringWorks and your institution.
SpringWorks Therapeutics Protocol NIR-DT-301
Amendment 5 (09Feb2021)
CONFIDENTIAL Page 2

SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb2021) 
CONFIDENTIAL  Page 3 Protocol Amendment Summary of Changes Table  
DOCUMENT HISTORY  
Document  Date  Comment  
Amendment 5  09 February  2021 Global  
Amendment 4  07 July  2020  Not implemented and not 
released to sites  
Amendment 3  27 January 2020  Global  
Amendment 2 / CAN -2.1 04 February 2020  Canada only  
Amendment 2 / GBR -2.2 17 January 2020  Great  Britain only  
Amendment 2  14 October 2019  Global  
Amendment 1 / ITA -1 19 March 2019  Italy only  
Amendment 1  27 November 2018  Global  
Original Protocol  03 August 2018  Global  
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb2021) 
CONFIDENTIAL  Page 4 TABLE OF CONTENTS  
1. Protocol Summary ..........................................................................................................8  
 Synopsis ............................................................................................................................8  
 Schema  ............................................................................................................................12  
 Schedule of Activities (SoA) ..........................................................................................13  
1.3.1.  Double-Blind Phase SoA ................................................................................................13  
1.3.2.  Open -Label Extension Phase SoA  ..................................................................................19  
2. Introduction ...................................................................................................................24  
 Study Rationale ...............................................................................................................24  
 Background .....................................................................................................................24  
2.2.1.  Desmoid Tumors/Aggressive Fibromatosis ....................................................................24  
2.2.2.  Diagnosis.........................................................................................................................25  
2.2.3.  Treatment  ........................................................................................................................26  
 Rationale for Nirogacestat in Desmo id Tumors .............................................................29  
 Rationale for Participant Population and Placebo Arm ..................................................29  
 Benefit/Risk Assessment  ................................................................................................30  
3. Objectives and Endpoints  ............................................................................................31  
4. Study Design  ..................................................................................................................33  
 Overall Design  ................................................................................................................33  
4.1.1.  Overall Design for the Double-Blind Phase: ..................................................................33  
4.1.2.  Overall Design for the Optional OLE Phase: .................................................................34  
 Scientific Rationale for Study Design  ............................................................................35  
 Justification for Dose ......................................................................................................35  
 End of Study Definition ..................................................................................................36  
5. Study Population ...........................................................................................................37  
 Inclusion Criteria  ............................................................................................................37  
 Exclusion Criteria  ...........................................................................................................39  
 Lifestyle Considerations .................................................................................................41  
5.3.1.  Meals and Dietary Restrictions  .......................................................................................42  
 Screen Failures  ................................................................................................................42  
6. Study Treatment  ...........................................................................................................43  
 Study Treatment Administered  .......................................................................................43  
6.1.1.  Double-Blind Phase Dosing Administration ..................................................................45  
6.1.2.  Open-Label Phase Dosing Administration  .....................................................................45  
6.1.3.  Study Treatment Errors ...................................................................................................45  
 Preparation/Handling/Storage/Accountability ................................................................46  
 Measures to Minimize Bias: Randomization and Blinding  ............................................46  
6.3.1.  Randomization ................................................................................................................46  
6.3.2.  Blinding...........................................................................................................................47  
 Study Treatment Compliance .........................................................................................49  
 Concomitant Therapy .....................................................................................................49  
6.5.1.  Concomitant Medications and/or Procedures .................................................................49  
 Dose Modification ..........................................................................................................53  
 Treatment after the End of the Double-Blind Study .......................................................54  
6.7.1.  Optional Open-Label Extension Phase ...........................................................................54  
6.7.2.  Inclusion Criteria - Open -Label Extension Phase ...........................................................54  
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb2021) 
CONFIDENTIAL  Page 5 6.7.3.  Exclusion Criteria - Open -Label Extension Phase ..........................................................55  
7. Discontinuation of Study Treatment and Participant 
Discontinuation/Withdrawal........................................................................................56  
 Discontinuation of Study Treatment ...............................................................................56  
7.1.1.  Liver Chemistry Stopping Criteria  ..................................................................................56  
7.1.2.  QTcF Stopping Criteria...................................................................................................57  
7.1.3.  Pregnancy  ........................................................................................................................58  
 Participant Discontinuation/Withdrawal from the Study  ................................................58  
 Lost to Follow up ............................................................................................................58  
8. Study Assessments and Procedures .............................................................................60  
 Efficacy Assessments  .....................................................................................................72  
8.1.1.  Tumor Imaging ...............................................................................................................72  
8.1.2.  Definition and Assessment of Clinical Progression ........................................................74  
8.1.3.  Patient -Reported Outcomes  ............................................................................................74  
8.1.4.  Tumor Biopsy .................................................................................................................79  
 Safety Assessments  .........................................................................................................80  
8.2.1.  Demographics Data and Medical History  .......................................................................80  
8.2.2.  Physical Examinations and Eastern Cooperative Oncology Group Performance status  ..........................................................................................................80
 
8.2.3.  Electrocardiograms  .........................................................................................................80  
8.2.4.  Vital Signs  .......................................................................................................................81  
8.2.5.  Clinical Safety Laboratory Assessments  ........................................................................81  
8.2.6.  Pregnancy Testing ...........................................................................................................81  
8.2.7.  Monthly Wellness Checks ..............................................................................................82  
 Adverse Events and Serious Adverse Events .................................................................82  
8.3.1.  Time Period and Frequency for Collecting AE and SAE Information  .....................................................................................................................82
 
8.3.2.  Method of Detecting AEs and SAEs ..............................................................................83  
8.3.3.  Follow-up of AEs and SAEs ...........................................................................................83  
8.3.4.  Regulatory Reporting Requirements for SAEs ...............................................................83  
8.3.5.  Pregnancy  ........................................................................................................................84  
8.3.6.  Adverse Events of Special Interest  .................................................................................84  
 Treatment of Overdose  ...................................................................................................85  
 Pharmacokinetics  ............................................................................................................85  
 Pharmacodynamics  .........................................................................................................86  
 Genetics  ..........................................................................................................................87  
 Biomarkers  ......................................................................................................................87  
8.8.1.  RNA Transcriptome Research  ........................................................................................88  
8.8.2.  RNA Expression Research of a Subset of RNA 
 Species  ................................................88  
8.8.3.  Proteome Research ..........................................................................................................88  
 Health Economics OR Medical Resource Utilization and Health Economics .......................................................................................................................88
 
9. Statistical Considerations .............................................................................................89  
 Statistical Hypotheses  .....................................................................................................89  
 Sample Size Determination  ............................................................................................89  
 Populations for Analyses ................................................................................................89  
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb2021) 
CONFIDENTIAL  Page 6 
 Statistical Analyses  .........................................................................................................90  
9.4.1.  Efficacy Analyses  ...........................................................................................................90  
9.4.2.  Safety Analyses  ...............................................................................................................92  
9.4.3.  Other Analyses  ................................................................................................................92  
 Interim Analyses  .............................................................................................................92  
9.5.1.  Data Monitoring Committee  ...........................................................................................93  
10. Supporting Documentation and Operational Considerations  ..................................94  
 Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations ................................................................................................................94  
10.1.1.  Regulatory and Ethical Considerations ...........................................................................94  
10.1.2.  Financial Disclosure ........................................................................................................94  
10.1.3.  Informed Consent Process ..............................................................................................95  
10.1.4.  Data Protection ................................................................................................................95  
10.1.5.  Committees Structure ......................................................................................................95  
10.1.6.  Data Quality Assurance  ..................................................................................................96  
10.1.7.  Source Documents ..........................................................................................................96  
10.1.8.  Study and Site Closure ....................................................................................................97  
 Appendix 2: Clinical Laboratory Tests ...........................................................................98  
 Appendix 3: Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow-up, and Reporting .......................................................100
 
10.3.1.  Definition of Adverse Event (AE) ................................................................................100  
10.3.2.  Definition of SAE .........................................................................................................101  
10.3.3.  Recording and Follow-Up of AE and/or SAE ..............................................................102  
10.3.4.  Reporting of SAEs ........................................................................................................104  
10.3.5.  Definition of AR, SAR and SUSAR  .............................................................................105  
 Appendix 4: Contraceptive Guidance and Collection of Pregnancy Information  .................................................................................................106
 
 Appendix 5: Genetics....................................................................................................110  
 Appendix 6: Liver Safety: Suggested Actions and Follow-up Assessments  .................................................................................................................111
 
 Appendix 7: Eastern Cooperative Oncology Group Performance................................114  
 Appendix 8: RECIST (Response Evaluation Criteria in Solid Tumors) Version 1.1 Guidelines ...................................................................................115
 
 Appendix 9: Abbreviations ...........................................................................................119  
 Appendix 10: List of Contacts for Study ......................................................................122  
10.10.1.  Sponsor .........................................................................................................................122  
10.10.2.  Contract Research Organization  ...................................................................................122  
10.10.3.  Medical Monitoring ......................................................................................................122  
10.10.4.  Serious Adverse Event Reporting .................................................................................122  
10.10.5.  Biologi cal Specimens ....................................................................................................122  
11. REFERENCES ............................................................................................................123  
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb2021) 
CONFIDENTIAL  Page 7 List of Figures  
Figure 1  Liver Chemistry Stopping Criteria and Increased Monitoring Algorithm ........ 57  
 
 
 
List of Tab les 
Table 1  Study Objectives and Endpoints ....................................................................... 31  
Table 2  Study Treatments Administration  ..................................................................... 44  
Table 3  Restric ted/Excluded Medications and/or Procedures ........................................ 51  
Table 4  Dose Modifications or Interruptions for Selected Toxicities ............................ 53  
Table 5  Bundle Branch Block Discontinuation Criteria ................................................ 58  
Table 6  Double-Blind Phase Study Visits ...................................................................... 61  
Table 7  Open -Label Phase Study Visits  ......................................................................... 68  
Table 8  Double- Blind Phase: PRO Assessment Administration Schedule  .................... 76  
Table 9  OLE Phase: PRO Assessment Administration Schedule  .................................. 77  
Table 10  Adverse Events of Special Interest (AESI)  ....................................................... 84  
Table 11  PK Blood Draw Schedule ................................................................................. 86  
Table 12  Protocol- Required Safety Laboratory Assessments  .......................................... 99  
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb2021) 
CONFIDENTIAL  Page 8 1. PROTOCOL SUMMARY  
 Synopsis  
Protocol Title:  A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat 
Versus Placebo in Adult Patients with Progressing Desmoid Tumors/Aggressive Fibromatosis 
(DT/AF) . 
Short Title:  A Placebo -Controlled, Phase 3 Study of Nirogacestat in Adults with Desmoid 
Tumor/Aggressive Fibromatosis  (DT/AF) . 
Rationale: 
The NIR -DT-301 Phase 3, double-blind, placebo-controlled study is being conducted to 
determine the efficacy and safety of nirogacestat in participants  with progressing desmoid 
tumors. A Phase 1 solid tumor study provided preliminary efficacy ( Messersmith, 2015), 
including long- term du rable responses and safety of nirogacestat in desmoid participants 
(Villalobos, 2018). These encouraging results led to a Phase 2 study in pa rticipants  with 
progressing desmoid tumors ( Kummar, 2017). This study demonstrated  that nirogacestat resulted 
in a 29% response rate, significant tumor shrinkage as measured by m agnetic resonance imaging  
(MRI ) and no pa rticipants  progress ed while on therapy. Importantly, pa rticipants  in the 
responder group had failed previous systemic therapies (imatinib or sorafenib) indicating a need  
for alterative therapeutic options for this patient population. These results support the further 
study of nirogacestat in this population. 
Objectives and Endpoint s 
Key Objectives  Key Endpoints  
Primary  Primary  
To determine the efficacy  (as 
defined by progression- free 
survival [ PFS]) of nirogacestat in 
a
dult participants with 
progressing DT/AF. PF S defined as the time from randomization until the date 
of assessment of progression or death by any cause will be 
determined .  
Progression wil l be determined  radiographically using 
Response Evaluation Criteria In Solid Tumors ( RECIST ) 
version (v)1.1 ( Eisenhauer, 2009; Section  10.8)  or 
clinically  as assessed  by the investigator. 
Clinical progression is defined as the onset or worsening 
of symptoms resulting in a global deterioration of health 
status causing the permanent discontinuation from study treatment and the initiation of emergent treatment ( e.g., 
radiotherapy, surgery, or systemic therapy including chemotherapy or tyrosine kinase inhibitors) for DT/AF. 
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb2021) 
CONFIDENTIAL  Page 9 Key Objectives  Key Endpoints  
Secondary  Secondary  
To evaluate the safety and 
tolerability of nirogacestat in 
adult participants with progressing DT/AF as measured by the incidence of adverse events  (AEs); Safety endpoints will include incidence of treatment -
emergent AEs , changes in laboratory parameters, vital 
signs, physical examination findings, and electrocardiogram s (ECGs ). 
Tolerability will be assessed according to toxicities graded by National Cancer Institu te Common Terminology 
Criteria for Adverse Events (CTCAE ) v5.0;  
To determine the overall response rate (complete response [CR]
 + partial response [ PR]) of 
nirogacestat in participants with 
progressing DT/AF;  Over all response rate, defined as the proportion of 
participants with CR + PR assessed via c entral r eader 
using RECIST v1.1 C riteria;  
To determine the duration of 
response; Duration of response for participants whose best response 
is CR or PR; 
To compare tumor volume c 
hanges measured by M
RI in 
part
icipants with progressing 
DT/AF; and  Change  in tumor volume from baseline as assessed by 
MRI volumetric; and  
To evaluate desmoid tumor 
symptoms and impacts using patient -reported outcomes 
(
PRO
s). Symptoms and impacts will be assessed by evaluating 
change from baseline on the following PROs: 
• GOunder/Desmoid Tumor Research Tumor Foundation (DTRF) DEsmoid Symptom/Impact Scale (GODDESS) ; 
• Brief Pain Inventory ( BPI) short form ; 
• Patient -Reported Outcomes Measurement Information 
System Physical Function (PROMIS P F) short form 
10a plus 3 additional items from PROMIS item banks; and 
• European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC) QLQ -C30. 
SpringWorks Therapeutics Protocol NIR- DT-301
Amendment 5 (09Feb2021) 
CONFIDENTIAL  Page 10 Overall Design: 
This is a mul ti-center, randomized, double-blind, pl acebo- controlled, event-driven, Phase 3 study 
to compare the efficac y, safety, and tolerability of nirogacestat and placebo in adult participants 
with progressing DT/AF. This study w ill consist o f 2 phases, a doubl e-blind and an optional 
open-l abel extension (OLE) phase.  
Participants will be screened up to 28 days prior to the first dose of study treatment (nirogacestat 
or placebo) in the double-blind phase and eligibility will be based on t he inclusion and exclusion 
criteria (Sections 5.1 and 5.2). Refer to the double-blind schedule of activities (SoA) 
(Section 1.3.1) for t he required assessments and Table 6 for additional details regarding e ach 
scheduled study visit. 
If Central 
Imaging Review determines that a participant has progressive disease (using RECIST 
v1.1) during the double-blind phase of the study, the site will be notified by t he central imaging 
core laboratory. T he participant will return to the site f or an end of treatment (EOT) visit within 
14 days of t he notification. D uring the EOT visit, the participant will be unblinded and have the 
option to enter the OLE phase, i f eligible (Section  6.7.1 ).  
P
ar
ticipants who discontinue due t o reasons other than radiographic disease progression a s 
determined vi a central r eview wi
ll not be unblinded and will not be eligible for participation in 
the opt ional OLE phas
e of the study. 
At the completion of the double-blind phase (once the required number of events have been 
observed and t he pr imary PFS a nalysis ha s been completed), the remaining pa rticipant s in the 
double-blind phase will have their study t reatment  assignment unblinded and i f eligible , will 
have the option to enroll in the optional OLE phase (Section  6.7.1). Refer t o OLE S oA (Section  
1.3.2 ) for t he require d assessments and  for additional details regarding each scheduled study 
visit. 
See Section  1.2 for study schema. 
Disclosure Statemen t: This is a randomized, pa rallel t r eatment  study with 2 a rms tha t is 
participant  and investigator blinded. There is an optional OLE pha se for eligible pa rticipants.  
Number of  Participant s: 
Approximately 135 pa rticipants w ill be  screened ( assessed f or eligibility)  to achi eve  
118 pa rtic
ipants randomly assigned ( 1:1) t o s
tudy t reatment  (placebo or nirogacestat) . It is 
estimated tha t 51 obs erved progression events will be  needed t o meet the pri m ary P FS ana l ysis . 
Refer t o Section  9.2 for sample s ize de te rmination.  
Treatment Groups and Duration : 
Double-blind phase: 
At Cycle 1 D ay 1 (baseline), pa rticipant s will be  randomized (stratified by primary tumor 
location  [Section  6.3.1] ) to s tudy treatment ( nirogacestat or  placebo ) in a 1:1 ratio and  will 
receive 150 mg t wice daily ( BID) of study treatment, continuously in 28- da y cyc les. Participants 
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb2021) 
CONFIDENTIAL  Page 11 will remain in the double-blind phase until death, disease progression, they prematurely 
di
scontinue study treatment for any reason , the study is stopped by the sponsor for any reason, or 
the required number of PFS events hav e been observed and the primary PFS analysis has been 
completed  (based on current statistical assumptions, this is  anticipated to be a
pproximately 
2 years after the first pa rticipant  is randomized ). 
Open -label phase:  
Eligible part icipants ( refer to Section s 6.7.2 and 6.7.3 for OLE eligibility criteria ) may enroll in 
the optional OLE phase to r eceive 150 mg BID of nirogacestat (open -label study treatment) , 
continuously in 28-day cycles . Participants will remain in the OLE phase until death , disease 
progression, they prematurely discontinue study treatment  for any reason , the study is stopped by 
the sponsor for any reason, participant qualifies for Sponsor’s Continued Access Plan, or nirogacestat is commercially available.
 
Data Monitoring Committee: Yes
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb2021) 
CONFIDENTIAL  Page 12 
 Schema  
 
DT/AF = desmoid tumor/aggressive fibromatosis . 
1All eligible participants must have histologically confirmed DT/AF (by local pathologist prior to informed consent ) 
that has progressed by ≥ 20% as measured by RECIST v1.1 within 12 months of the screening visit scan (inclusion 
criteria 2). 
2Participants discontinuing study treatment due to clinical progression are not eligible for participation in the OLE.

SpringWorks Therapeutics                     Protocol NIR- DT-301
                 Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 13 
 Schedule of Activities  (SoA)  
1.3.1. Double -Blind Phase SoA  
Double -Blind Phase  
Cycle  Number  Screening1 Cycle 1  Cycle 2  Cycle 4  Cycle 7 & 
Every 3 Cycles26 
EOT27 Follow -
Up28 Cycle Da y  Day 1  
Baseline3 Day 8  Day 15  Day 22  Day 28  Day 1  Day 1  
Visit Week   Week 1  Week 2  Week 3  Week 4  Week 8 Week 13  Week 25 & On   
 
See footnote 
27 for visit 
window   
 
30 days  
after last dose  
(+7 days ) Calendar Day   
(up to 28 days 
before Day 1)  Day 1  Day 8  Day 15  Day 22  Day 56  Day 85  Day 169 & On  
(Visit Window)  (up to 48 hours 
prior to 1st dose) (± 2 days) (± 2 days) (± 2 days) (± 2 days) (± 7 days) (± 7 days) 
Informed consent2 X          
I/E criteria  X X         
Demography  X          
Medical history  including 
menstrual history for women  X          
ECOG perfo rmance status4 X X    X X X X X 
Physical examination5 X X X X X X X X X X 
Vital signs6 X X X X X X X X X X 
Weight/height7 X X X X X X X X X X 
12-lead ECG8 X X8a 
(pre-& post dose)  X8b 
(post dose)    X X X X X 
Laboratory            
Tumor biopsy9 X9a        X9b 
(optional)  
Blood for s erology10 X          
Blood for s erum pregnancy 
test (WOCBP only)11 X          
Blood for PK sampling12  X12a 
(serial) X12b 
(trough) X12b 
(trough) X12b 
(trough) X12b 
(trough) X12b 
(trough) X12b 
(trough)   
Blood for 
pharmacog enomics13  X 
(optional)          
Blood for genotyping14  X         
Blood for safety labs15 X X X X X X X X X X 
SpringWorks Therapeutics                     Protocol NIR- DT-301
                 Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 14 Double -Blind Phase  
Cycle  Number  Screening1 Cycle 1  Cycle 2  Cycle 4  Cycle 7 & 
Every 3 Cycles26 
EOT27 Follow -
Up28 Cycle Da y  Day 1  
Baseline3 Day 8  Day 15  Day 22  Day 28  Day 1  Day 1  
Visit Week   Week 1  Week 2  Week 3  Week 4  Week 8 Week 13  Week 25 & On   
 
See footnote 
27 for visit 
window   
 
30 days  
after last dose  
(+7 days ) Calendar Day   
(up to 28 days 
before Day 1)  Day 1  Day 8  Day 15  Day 22  Day 56  Day 85  Day 169 & On  
(Visit Window)  (up to 48 hours 
prior to 1st dose) (± 2 days) (± 2 days) (± 2 days) (± 2 days) (± 7 days) (± 7 days) 
Blood for female hormon e 
levels15 X X   X X X X X X 
Blood for male hormone 
levels15  X     X X X X 
Urinalysis16 X X    X X X X X 
Urine pregn ancy test  
(WOCBP only)17  X   X X  
(monthly)17a X X 
Patient -Reported Outcomes  (PROs)18          
Home ePRO device training  X          
GODDESS  (symptom scale)  
 
(refer to  Table 8)    
(monthly assessment, refer t o Table 8)  
 
(refer to  
Table 8) BPI short form   
PROMIS PF short form 10a 
plus 3 additional items from 
PROMIS item banks      
GODDESS  (impact scale)      
EOR TC QLQ -C30     
PGIS      
PGIC        
Imaging  and RECIST           
Pre-Randomization RECIST 
v1.1 Calculation Worksheet19 X          
CT or MRI scan for tumor 
measurement ( using RECIST 
v1.1)20 X20a      X20b X20b X20c  
MRI scan for t umor volume 
assessment20 X       X20b 
(every 6 cycles) X20c  
Local RECIST v1.1 read20  X20a      X X20b X20c  
SpringWorks Therapeutics                     Protocol NIR- DT-301
                 Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 15 Double -Blind Phase  
Cycle  Number  Screening1 Cycle 1  Cycle 2  Cycle 4  Cycle 7 & 
Every 3 Cycles26 
EOT27 Follow -
Up28 Cycle Da y  Day 1  
Baseline3 Day 8  Day 15  Day 22  Day 28  Day 1  Day 1  
Visit Week   Week 1  Week 2  Week 3  Week 4  Week 8 Week 13  Week 25 & On   
 
See footnote 
27 for visit 
window   
 
30 days  
after last dose  
(+7 days ) Calendar Day   
(up to 28 days 
before Day 1)  Day 1  Day 8  Day 15  Day 22  Day 56  Day 85  Day 169 & On  
(Visit Window)  (up to 48 hours 
prior to 1st dose) (± 2 days) (± 2 days) (± 2 days) (± 2 days) (± 7 days) (± 7 days) 
Enrollment and Study Treatment           
Randomization21  X         
Study treatment dispensing22  X     X X   
Study treatment 
administration /diary23     
Study treatment 
accountability        X X X  
Ongoing Monitoring            
Monthly wellness checks24    
ConMed review   
AE/SAE review25  
AE = adverse event; BID = twice daily; BPI = brief pain inventory; ConMed = concomitant medication; CT = computed tomography; ECG = electrocardiogram; ECOG = Eastern Cooperative Oncology 
Group; eCRF = electronic case report form; EORTC QLQ -C30 = European O rganisation for Research and Treatment of Cancer Quality of Life Questionnaire- Core 30; EOT = end of treatment; eP RO = 
electronic patient- reported outcome; FU = follow -up; GODDESS = GOunder/DTRF DEsmoid Symptom/Impact Scale ; ICF = informed consent form; I/ E = inclusion/exclusion; IRT = interactive response 
technology; MRI = magnetic resonance imaging;  OLE = open -label extension; PFS = progression free survival; PGIS = patient global impression of severity; PGIC = patient global impression of change; PK 
= pharmacokinetic; PRO = patient -reported outcome; PROMIS PF= Patient -Reported Outcomes Measurement Information System Physical Function; RECIST = Response Evaluation Criteria in Solid 
Tumors; SAE = serious adverse event; SoA = scheduled of activities; v = ve rsion ; WOCBP = wom en of child bearing potential .. 
1. Screening visit : Assessments may occur up to  28 days  prior to fi rst dose of study treatment  with a minimum screening period of 14 days to allow for  
participant completion of the screening and baseline PRO assessments ( refer to Table 8 for PRO administration schedule ). An extension to the screening period 
may be permitted on a case- by-case basis following discussion between the investigator and the medical monitor/sponsor. The reason(s) for the extension mus t 
be clearly documented.  
2. Informed consent  process : Includes  participant s igning the ICF  and must be conducted prior to any study related procedures being performed. The date the 
participant signs the ICF will be D ay 1 of the screening period. Refer to Section  10.1.3 for more detail o n the ICF process.  
3. Baseline visit : Assessments may be performed over a 48- hour period. All baseline assessment s are to be conducted prior to first dose of study treatment  except 
for the following assessments: post -dose 12- Lead ECG s and post -dose blood draw s for pharmacokinetic ( serial PK) sampling . 
4. ECOG performance status : At baseline, assessment  must be done prior to first dose of study treatment . Refer to Section  10.7 for ECOG scale. 
SpringWorks Therapeutics                     Protocol NIR- DT-301
                 Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 16 5. Physical exam ination : At baseline, assessmen t must be done prior to first dose of study treatment. Refer to Section 8.2.2 for detail regarding physical 
examination requirements . 
6. Vital sign s: Include s blood pressure, respiratory rate, pulse rate, and body temperature (following at least 5 minutes of rest). At baseline, assessment must be 
done prior to first dose of study treatment . Refer to Section 8.2.4  for more detail.  
7. Height : Required at s creening only.  Weight  to be collected at all visits.  
8. 12-lead ECG s: Will be administered in triplicate ( approximately 2-3 minutes apart and averaged) and read locally at the site. Participants should rest in semi-
recumbent supine position for at least 5 minutes prior to ECG col lection . Refer to Section  8.2.3  for more detail . 
8a. At baseline , triplicate  ECG s are required at two timepoints: (1) p rior to the first dose of study treatment  and (2) approximately 1- hour post -dose.  
8b. At Cycle 1 Day 8 , triplicate  ECG s are required  1-hour (±10 minute s) post-dose. 
9. Tumor (core need le) biopsy : If tumor biopsy and MRI are performed during the same study visit, the biopsy must  be done after MRI.  Refer to Section 8.1.3  
and central laboratory manual for sample processing details . 
9a. At screening, t umor biopsy is only required  if archival tissue is not availa ble for study procedures . Tumor biopsy will be reviewed centrally to 
reconfirm diagnosis, but participant enrollment is not dependent on central revi ew. 
9b. At EOT, tumor biopsy will be optional and additional pharmacogenomic consenting is required ( 10.1.3 ). 
10. Serology:  Only required at screening and to i nclude testing for hepatitis B virus  (hepatitis B surface antigen ), hepa titis C virus  (hepatitis C antibody [H epatitis 
C virus  polymerase chain reaction,  if hepatitis C antibody positive]), and human immunodeficiency virus . Refer to Section 10.2 and central laboratory manual 
for sample processing  details . 
11. Serum pregnancy  test: Only required a t screening for women of childbearing potential ( WOCBP ). Refer to Sections 8.3.5  and 10.4, and central laboratory 
manual for sample processing details.  
12. PK sampl ing: Refer to Section  8.5 and Table 11, and central labo ratory manual for sample processing details . 
12a. Serial PK: Required on Cycle 1 Day 1 at the  following timepoints:  pre-dose and 0.25-, 0.5-, 1-, 1.5-, 2- and 3- hours post -dose.  All efforts will be 
made to obtain the sample within 10% of the nominal time (e.g., within 6 minutes of a 60 -minute sample) from dosing. Out of window PK draws  
will not be captured as deviations if the exact time of the sample collection is noted on the source document s and eCRF.  
12b. Trough PK: The evening before applicable study visi ts,  participants will record the exact time study treatment was taken  in the eDiary using the 
home ePRO  device. Participants will not take their planned morning dose the day of the study visit. The morning dose will be taken following the 
pre-dose PK blood draw.  
13. Pharmacoge nomics : Blood sample will be optional and additional pharmacogenomic consenting is required (Section 10.1.3 ). At baseline, blood sample  must 
be drawn  prior to first dose of study treatment . Refer to Sections  8.8 and 10.5, and central laboratory manual for sample processing details.   
14. Genotyping : Required blood sample for a ll participants unless prohibited by local regulations . At baseline, blood sample m ust be drawn  prior to first dose of 
study treatment.  Refer to Section  8.7 and central laboratory manual for sample processing details.  
SpringWorks Therapeutics                     Protocol NIR- DT-301
                 Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 17 15. Safety Labs  (hematology, serum chemistry , and hormone levels ): At baseline, must be done prior to first dose of study treatment.  Refer to Section 10.2 for 
a complete list of analytes  and central laboratory manual f or sample processing details.  The time of hormone level blood draws should also be recorded . 
16. Urinalysis : At baseline, must be done prior to first dose of study tr eatment. Refer to Section 10.2  for a complete list of analytes and the central laboratory 
manual for sample processing details. Microscopy is to be performed only as needed based on positive dipstick test result s and only if blood or protein is 
abnormal . 
17. Urine pregnancy test s: Only required for WOCBP. At baseline, urine pregnancy test m ust be done prior to first dose of study treatment  to reconfirm 
eligibility . Refer to Section s 8.2.6 and 10.4 for more detail.  
17a. Following the C ycle 4 Day 1 study visit, all WOCBP participants will be required to return to the site  for a monthly urine pregnancy test . If it is more 
convenient  for the partic ipant , they may alternatively  visit a  local laboratory  that has been pre- approved by the sponsor (or designee) for this 
assessment  (refer to the study reference manual for additional details).  
18. PROs:  Participants will complete the q uestionnaires and record study treatment administration in the eDiary using a home ePRO device ( Section 8.1.2) . Refer 
to Table 8 for the  PRO administration schedule .  
19. Pre-Randomization RECIST v1.1 Calculation Worksheet (Section 8.1.1.1):  As part of documenting that participants have satisfied inclusion criteria 2 , sites 
are required to  complete a worksheet (provided by the sponsor). The worksheet must be submitted to the sponsor ’s designee during the screening period as 
soon as the data are available to complete the worksheet. All worksheets must be received  no later than 7 days prior to C1D1 to allow for review prior to 
randomization (refer to study reference manual for additional details).  
20. Tumor imaging : All scans will be submitted to the central imaging core laboratory and re ad by Central Imaging Review  throughout the study.  Refer to 
Section 8.1.1and imaging manuals for more detail.   
Tumor measurement using RECIST v1.1  assessment  (Section  8.1.1.2 ): CT scans (contrast required unless contraindicated) or MRI scans (no contrast 
required) will be acquired to assess tumor changes . The modality (CT or MRI) for tumor assessment  is to be determined by the investigator . The imaging 
modality used to  assess the tumor at s creening must be used at each subsequent visit. All scans will be submitted to the central imaging core laboratory and 
reviewed by Central Imaging Review , but participant enrollment is not dependent on central review. Tumor measurement will also be performed locally per  
RECIST v1.1 using the same target lesion(s) identified on the Pre -Randomization RECIST v.1.1 Calculation Worksheet.  
Tumor volumetric assessment  (Section  8.1.1.3 ): MRI scans (no contrast required)  will be acquired  to assess tumor volume . All scans will be submitted to the 
central imaging core laboratory and assessed by Central Imaging Review .  
If applicable, CT and MRI assessments may be conducted on the same day. However, MRI with no contrast must be performed prior to CT with contrast. MRI 
must be done prior to tumor biopsy if assessments occur on the same visit.  
20a. Screening visit scans : 
• MRI and CT scan s obtained during the screening visit will serve as the participant’s baseline scan for the study  (CT scan only required if it’s 
the chosen modality for RECIST v1.1 tumor measurement) . Scans should be submitted to central imaging core laboratory as early in the 
screening period as possible to confirm scan quality is acceptable for analysis prior to randomization.  
• Standard of care s can(s) acqui red prior to the participant signing ICF  may be used as the participant’s s creening  visit scan(s) if obtained 
within 28  days of the first  dose of  study treatment  and the quality of the scan s are acceptable for analysis ( as determined by the central 
SpringWorks Therapeutics                     Protocol NIR- DT-301
                 Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 18 imaging core laboratory ). These scans will then be colle cted, stored, and documented as the s creening visit scan(s). No other pre -enrollment 
images will be collected for central reading.  
20b. On study treatment scans: Starting at cycle 4, MRI or CT scans for tumor assessment  (RECI ST v1.1) will be obtained every 3 cycles.  Starting at 
cycle 7, MRI for tumor volume assessment  will be obtained every 6 cycles.  
20c. EOT visit scans:  only required  if not performed within the past 3 months.  
21. Randomization : Participants will not be randomized to study treatment using IRT until all I/E criteria (Sections 5.1 and 5.2) have been confirmed and all pre -
randomization baseline study assessments have been completed .  
22. Study treatment  dispensing : Participants will be dispense d study treatment using the IRT every 3 cycles  at applicable study visits.  
23. Study treatment  administration/diary : The f irst dose of study treatment (3 × 50 mg tablets) will be administered orally at the s ite at Cycle 1 Day 1  followed 
by a 3- hour observation period . Participants will administer study treatment  at 150 mg (3 × 50 mg tablets)  twice daily  (BID) (approximately every 12  hours, 
without regard to food) contin uously in 28- day cycles  throughout the study. Participants should record daily administration  of each study treatment dose in  the 
eDiary using the home ePRO device. Refer to Section  6.1 for more detail.  
24. Monthly wellness check s: Monthly telephone or email contact is required throughout the study (may be replaced by a fa ce-to-face interaction when study 
visits occur, provided the wellness information can be obtained during the visit).  Refer to Section  8.2.7  for more detail.  
25. AEs/SAEs : Will be monitored and documented from the time of informed consent  up to 30 days after the last dose of study treatment . Refer to Section 8.3  for 
more detail.  Females reporting AEs/AESIs/SAEs of primary ovarian insufficiency ( POI) and/or amenorrhea will h ave hormone levels assessed every 3  months 
until event resolution (or for at least 90 days after discontinuing study treatment).  
26. Every 3 c ycles  and on: Following Cycle 7 Day 1, participants will return every 3 cycles  for study visits  until death, progressi ve disease , discontinuation of 
study treatment for any reason, study is stopped by the sponsor for any reason, or required number of PFS events have been observed and primary PFS analysis 
has been completed . 
27. EOT visit:  EOT visit s hould be  conducted prior t o study treatment discontinuation to avoid a gap in study treatment for participants enter ing the OLE phase . 
All EOT a ssessments  must be conducted prior to unblinding ( if applicable  refer to Section  6.3.2.1).  
If Central Imaging  Review determines that a participant has progressive disease  (using RECIST v1.1) the  participant will be encouraged to return to the site as 
soon as possible  to complete the EOT visit assessments  (but no late r than 14 days of becoming aware of the progres sion). 
If the participant discontinues study treatment for any reason  other t ha n progressive disease  (as determined by Central Imaging Review  using RECIST v1. 1), 
they will be encouraged to return to the site as soon as possible to complete the EOT visit as sessments prior to study treatment discontinuation or as close as 
possible to the last dose of study treatment.  
28. Follow -up visit: Only required for participants who are not continuing into  the optional OLE phase and will occur 30 days (+7 days) after the  last dose of 
study treatment . 
SpringWorks Therapeutics              Protocol NIR- DT-301 
      Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 19 1.3.2. Open- Label Extension  Phase SoA  
OLE Phase  
 
Cycle Number  Cycle 15 
(Applicable only to participants previously randomized to 
placebo in the double -blind phase)  Cycle 25 Cycle s 4, 7, 10  Cycle 13 &  
Every 3 Cycles  EOT20 Follow -Up21 
Cycle Day  Day 1  
Baseline3 Day 8  Day 15  Day 22  Day 28  Day 1  Day 1  
Visit Week  Week 1 Week 2  Week 3  Week 4  Week 8 Weeks 13, 25, 37  Week 49 & On  
See 
footnote 
20 for visit 
window  30 days after last 
dose 
(+ 7 days)  Calendar Day  Day 1  Day 8  Day 15  Day 22  Day 56 Days 85, 169, 253  Day 337  & On 
(Visit Window ) Same day as,  
or up to 24 
hours after , 
double -blind 
EOT  (± 2 days)  (± 2 days)  (± 2 days)  (± 2 days)  (± 7 days)  (± 7 days)  
Informed consent1 X         
I/E criteria2 X         
ECOG performance status6 Same as 
double -blind 
EOT    X X X X X 
Physical examination7 Same as 
double -blind 
EOT X X X X X X X X 
Vital signs8 Same as 
double -blind 
EOT X X X X X X X X 
Weight Same as 
double -blind 
EOT X X X X X X X X 
12-lead ECG9 X9a 
(post dose)  X9b 
(post dose)    X X X X X 
Laboratory           
Blood for PK sampling10 X 
(serial)10a X 
(trough)10b X 
(trough)10b X 
(trough)10b X 
(trough)10b X 
(trough)10b X 
(trough)10b   
Blood for safety labs11 X11a X X X X X X X X 
Blood for female hormon e 
levels11 X11a   X X X X X X 
Blood for male hormone 
levels11 X11a     X X X X 
Urinalysis12 Same as 
double -blind 
EOT    X X X X X 
SpringWorks Therapeutics              Protocol NIR- DT-301 
      Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 20 OLE Phase  
 
Cycle Number  Cycle 15 
(Applicable only to participants previously randomized to 
placebo in the double -blind phase)  Cycle 25 Cycle s 4, 7, 10  Cycle 13 &  
Every 3 Cycles  EOT20 Follow -Up21 
Cycle Day  Day 1  
Baseline3 Day 8  Day 15  Day 22  Day 28  Day 1  Day 1  
Visit Week  Week 1 Week 2  Week 3  Week 4  Week 8 Weeks 13, 25, 37  Week 49 & On  
See 
footnote 
20 for visit 
window  30 days after last 
dose 
(+ 7 days)  Calendar Day  Day 1  Day 8  Day 15  Day 22  Day 56 Days 85, 169, 253  Day 337  & On 
(Visit Window ) Same day as,  
or up to 24 
hours after , 
double -blind 
EOT  (± 2 days)  (± 2 days)  (± 2 days)  (± 2 days)  (± 7 days)  (± 7 days)  
Urine pregnancy test  
(WOCBP only)13 Same as 
double -blind 
EOT   X X  
(Monthly)13a X X 
Patient -Reported Outcomes  (PROs)14         
GODDESS  (symptom scale)      
(Monthly assessment,  
refer to Table 9) (Quarterly 
assessment,   
refer to  Table 9)  
(Refer to  
Table 9) BPI short form       
PROMIS  PF short form  10a 
plus 3 additional items from 
PROMIS item banks       
GODDESS  (impact scale)       
EORTC QLQ -C30      
PGIS       
PGIC       
Imaging  and RECIST           
CT or MRI  scan for tumor 
measurement ( using RECIST 
v1.1)15 Same as 
double -blind 
EOT     X X15a 
(Cycle 13 and then 
every 6 cycles)  X15b  
Local RECIST v1.1 read15 Same as 
double -blind 
EOT     X X15a 
(Cycle 13 and then 
every 6 cycles)  X15b  
Enrollment and Study Treatment          
Enrollment/first dose of open-label study treatment
4 X         
Study treatment dispensing16 X     X X   
SpringWorks Therapeutics              Protocol NIR- DT-301 
      Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 21 OLE Phase  
 
Cycle Number  Cycle 15 
(Applicable only to participants previously randomized to 
placebo in the double -blind phase)  Cycle 25 Cycle s 4, 7, 10  Cycle 13 &  
Every 3 Cycles  EOT20 Follow -Up21 
Cycle Day  Day 1  
Baseline3 Day 8  Day 15  Day 22  Day 28  Day 1  Day 1  
Visit Week  Week 1 Week 2  Week 3  Week 4  Week 8 Weeks 13, 25, 37  Week 49 & On  
See 
footnote 
20 for visit 
window  30 days after last 
dose 
(+ 7 days)  Calendar Day  Day 1  Day 8  Day 15  Day 22  Day 56 Days 85, 169, 253  Day 337  & On 
(Visit Window ) Same day as,  
or up to 24 
hours after , 
double -blind 
EOT  (± 2 days)  (± 2 days)  (± 2 days)  (± 2 days)  (± 7 days)  (± 7 days)  
Study treatment 
administration/diary17    
Study treatment a ccountability       X X X  
Ongoing Monitoring           
Monthly wellness checks18    
ConMed review   
AE/SAE review19  
AE = adverse event; BID = twice daily; BPI = brief pain inventory; ConMed = concomitant medication; CT = computed tomography; ECG = electrocardiogram; ECOG = Eastern Cooperative Oncology 
Group; eCRF = electronic case report form; EORTC QLQ -C30 = European O rganisation for Research and Treatment of Cancer Quality of Life Qu estionnaire -Core 30; EOT = end of treatment; ePRO = 
electronic patient- reported outcome; FU = follow -up; GODDESS =  GOunder/DTRF DEsmoid Symptom/Impact Scale ; ICF = informed consent form; I/ E = inclusion/exclusion; IRT = interactive response 
technology;  MR I = magnetic resonance imaging;  OLE = open -label extension; PFS = progression free survival; PGIS = patient global impression of severity; PGIC = patient global impression of change; PK 
= pharmacokinetic; PRO = patient -reported outcome; PROMIS PF= Patient -Reported Outcomes Measurement Information System Physical Function; RECIST = Response Evaluation Criteria in Solid Tumors; 
SAE = serious adverse event; SoA = scheduled of activities; v = v ersion ; WOCBP = wom en of child bearing potential . 
1. Informed consent process : Includes  participant signing the ICF  (exclusive to the OLE study phase ) and must be conducted prior to administration of the first 
dose of open- label study treatment . Refer to Sect ion 10.1.3  for more detail on the process. 
2. I/E criteria : Exclusive to the OLE phase . Refer to Section s 6.7.2  and 6.7.3 for participant eligibility criteria specific to the OLE phase . 
3. Baseline visit : The C1D1 visit of the OLE phase should be  conducted on the same day as, or within 24 hours after , the double -blind EOT visit.  A longer 
window  between the double -blind EOT and OLE C1D1 visit  may be allowed with prior medical monitor approval ; however,  repeat assessments may be 
required with medical monitoring guidance depending on the length of time betwee n double -blind EOT and OLE C1D1. All double -blind EOT visit 
assessments , as d escribed in the double -blind SoA (Section  1.3.1 ), will be conducted prior  to unblinding the participant’s study treatment and prior to 
administration of the first dose of open- label study treatment.   
4. Enrollment and f irst dose o f open- label  study treatment : Participants will be enrolled in  the OLE phase  using the IRT  only after  (1) all ongoing AEs/SAEs 
from the double -blind phase have been  assessed for causality in a blinded manner by the investigator or qualified designee , and ( 2) all AE/SAE causality 
assessments have been entered into the eCRF . All double -blind E OT visit assessments must be completed prior  to unblinding and taking first dose of open-
label study treatment.  
SpringWorks Therapeutics              Protocol NIR- DT-301 
      Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 22 Participants who were randomized to receive placebo in t he double -blind phase will receive their first dose of  study treatment  at the site  followed by a 3- hour 
observation period .  
Participants who were randomized to nir ogacestat in the double -blind phase may take their first dose of open- label study treatment  at home  (observation 
period is not required ). 
5. Study visits at Cyc le 1 (Day 8, 15 and 22) and Cycle 2 (Day 28 ): Only applicable for participants who were previously randomized to receive placebo in the 
double -blind phase . If a participant was randomized to receive nirogacestat in the double- blind phase , these study visits  will not be conducted,  and the 
participant will not be required to return to the site until Cycle 4 Day 1 visit.  
6. ECOG performance status : Refer to Section 10.7 for the ECOG scale.  
7. Physical examination : Refer to Section 8.2.2  for more detail  regarding physical examination requirements . 
8. Vital signs : Include s blood pressure, respiratory rate, pulse rate, and body temperat ure (following at least 5 minutes of rest). R efer to Section 8.2.4  for more 
detail.  
9. 12-lead ECGs:  Will be administered in triplicate ( approximately 2-3 minutes apart and averaged) and read locally at the site. P articipants should rest in semi-
recumbent supine position for at least 5 minutes prior to ECG collection. Refer to Section  8.2.3  for more detail.  
9a. At baseline, triplicate ECGs are required approximately 1- hour post -dose (open- label study treatment). A pplicable only to participants who were 
previously randomized to receive placebo in the double -blind study phase.  
9b. At Cycle 1 Day 8  visit, triplicate ECG s are required 1 -hour (±10 minutes) post -dose. Applicable  to participants who were previously randomized to 
receive placebo in the double- blind study phase only.  
10. PK sampling : Refer to Section  8.5 and central laboratory manual for sample processing details .  
10a. Seria l PK: Only applicable to participants who were previously randomized to receive placebo in the double -blind study phase. PK samples should 
be collected  on OLE Cycle 1 Day 1 at the following timepoints: pre -dose and 0.25- , 0.5-, 1-, 1.5-, 2- and 3 -hours pos t-dose. All efforts will be 
made to obtain within 10% of the nominal time (e.g., within 6 minutes of a 60 -minute sample ) from dosing . Out of window PK draws  will not be 
captured as deviations if the exact time of the sample collection is noted on the source documents and eCRF.  
10b. Trough PK:  The evening before applicable study visit, participant s will record the exact time study treatment was taken  in the eDiary using the 
home ePRO device. Participants will not take their planned morning dose the day of the study visit. The morning dose will be taken following the 
pre-dose PK blood draw.  
11. Safety la bs (hematology , serum chemistry , and hormone levels ): Refer to Section 10.2  for a complete list of analytes  and central laboratory manual for 
sample processing details . The time of hormone level blood draws should also be recorded . 
11a. At baseline, blood draws for hematology , serum chemistry , and hormone levels  will be done as part of the double -blind EOT visit (prior to  
unblinding) . However, if hematology and serum chemistry safety labs have not been conducted  within the 14 days prior to C1D1 , an additional 
blood draw will be required for same day local laboratory processing to  reconfirm adequate organ and bone marrow function ( refer to OLE  
inclusion criteria  2) and must be done prio r to fi r st dose of open- label study treatment.  
SpringWorks Therapeutics              Protocol NIR- DT-301 
      Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 23 12. Urinalysis : Refer to Section 10.2 for a complete list of analytes  and the central laboratory manual for sample processing details . Microscopy is to be 
performed only as needed based on positive dipstick test results and only if blood or protein is abnormal.  
13. Urine pregnancy tests : Only required for WOCBP. Refer to Section s 8.2.6 and 10.4 for more detail.  
13a. Following Cycle 4 Day 1 study visit, all WOCBP participants will be required to return to the site for a monthly urine pregnancy test . If it is more 
convenient for the participant, they may alternatively  visit a local  laboratory that has been pre- approved by the sponsor (or designee) for this 
assessment  (refer to study reference manual for additional details). 
14. PROs : Participants will complete the questionnaires using a home ePRO device ( Section 8.1.2 ). Refer to  Table 9 for the PRO administration schedule . 
15. Tumor imaging: CT (contrast required unless contraindicated) or  MRI (no contrast required) using RECIST v1.1 (modality to be determined by the 
investigator) is required. Whichever imaging modality is used to measure the tumor by RECIST v1.1 at screening in the double -blind phase must be used at 
each subsequent visit throughout the OLE phase. All scans will be submitted to the central imaging core laboratory and reviewed by Central Imaging 
Review . Tumor measurement will also be performed locally per RECIST v1.1 using the s ame target lesion (s) identified on the Pre -Rando mization RECIST 
v.1.1 Calculation Worksheet.  
15a. Scan is required every 3 cycles until Cycle 13 Day 1, and then every 6 cycles thereafter.  
15b. At EOT, scan  is only required  if not performed within the past 3 months.  
16. Study treatment  dispensing : Participan ts will be dispensed study treatment using the IRT every 3  cycles during study visits.  
17. Study treatment  administration/diary : Participants will self -administer study treatment at 150 mg (3 × 50 mg tablets) BID  (approximately every 12 hours, 
without regard to food) , contin uously in 28 -day cycles  throughout the study . Participants should record daily administration of each study treatment dose in 
the eDiary using the home ePRO device. (Section  6.1). 
18. Monthly wellness check s: Monthly telephone or email contact is required throughout the study (may be replaced by a face -to-face interaction when study 
visits occur, provided the wellness information can be obtained during the visit).  Refer to Section  8.2.7  for more detail.  
19. AEs/SAE s: Will be monitored and documented from the time of informed consent and up to 30  days after the last dose of study treatment . Refer to 
Section  8.3 for more detail.  Females  reporting AEs/AESIs/SAEs of POI and/or amenorrhea will have hormone levels assessed every three months  until event 
resolution (or for at least 90 days after discontinuing study treatment).  
20. End of treatment (E OT) visit : Should be conducted prior to study treatment discontinuation or as close as possible to the last dose of open -label study 
treatment.   
21. Follow -up visit: Only required for participants who are not transitioning directly to  commercial nirogacestat (or sponsor’s Continued Access Plan) at time of 
discontinuation. The follow -up visit will occur 30 days (+7 days) after the last dose of study treatment.  
 
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 24 2. INTRODUCTION 
Nirogacestat (PF -03084014) is a potent, small- molecule, selective, reversible, noncompetitive 
inhibitor of gamma secretase (GS). Ni rogacestat is being investigated for the treatment of 
desmoid tumors/aggressive fibromatosis (DT/AF). 
 Study Rationale  
The NIR -DT-301 Phase 3, double-blind, placebo-controlled study is being conducted to 
determine the efficacy and safety of nirogacestat  in pa rticipants  with progressing desmoid 
tumors. A Phase 1 study in patients with solid tumors provided preliminary efficacy 
(Messersmith, 2015), including long-term durable responses and safety of nirogacestat in 
desmoid participants (Villalobos, 2018).  These encouragin g results lead to a Phase 2 study in 
participants  with progressing desmoid tumors ( Kummar, 2017). This study demonstrated  that 
nirogacestat resulted in a 29% response rate, significant tumor shrinkage as measured by magnetic resonance imagi ng (MRI ) and no pa rticipants  progressing while on therapy. 
Importantly, pa rticipants  in the responder group had failed previous systemic therapies (imatinib 
or sorafenib) indicating a need for alterative therapeutic options for this patient population. The se 
results support the further study of nirogacestat in this population. 
 Background  
2.2.1. Desmoid Tumors/ Aggressive Fibromatosis 
Desmoid tumors, also referred to as aggressive fibromatosis, are rare, locally invasive, slow growing soft tissue tumors. According to the World Health Organization, desmoid tumors are defined as “clonal fibroblastic proliferations that arise in the deep soft tissue and are characterized by infiltrative growth and a tendency toward local recurrence but an inability to metastasize” ( Kasper, 20 11). Desmoid tumors are considered benign; however, they cause 
significant morbidity by infiltrating or exerting mass effects on vital structures  (Lewis, 1999; 
Smith, 2000). Desmoid tumors include soft tissue masses arising in any part of the body in diffe rent varieties of connective tissue, including muscle and fascia aponeurosis. The most 
common primary tumor sites include abdominal walls, limbs, girdles, and mesenteric areas. Desmoid tumors infiltrate surrounding structures and spread along plains and muscle, which can lead to severe pain, functional impairment, and more rarely, life-threatening conditions ( Penel, 
2017). Despite the benign nature of desmoid tumors, they can behave aggressively, causing significant morbidity, with elevated  rates of local r ecurrence (as high as 60 %) despite wide 
excisions ( Penel,  2017). Mortality is occasionally observed owing to the local aggressive nature 
of some desmoid tumors that occur in the mesentery ( Smith, 2000).  
Desmoid tumors most commonly occur in individuals between the ages of 15 to 60 years, more often in young adults, with the peak age of about 30 years, and a 2- to 3-fold predominance in females  (de Camargo, 2010; Skubitz, 2017).  The incidence of desmoid tumors is about 2 to 4 
cases per million  per year in the general population, with fewer than 1000 cases diagnosed in the 
United States per year  (Hosalkar , 2006).  
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 25 The incidence of desmoid tumors is reported to be about 800- to 1000- fold higher in patients  with 
familial adenomatous polyposis (FAP  [Gardner Syndrome]), in which the adenomatous polyposis 
coli (APC) tumor suppressor gene is mutate d (Skubitz, 2017). Familial adenomatous polyposis -
associated desmoid tumor is more frequently associated with abdominal tumors, especially in the 
Gardner var iant of FAP, which is associated with intestinal polyposis, osteomas, fibromas, and 
epidermal inclusion cysts  (Skubitz , 2017).  Intra-abdominal desmoid tumors are one of the leading 
causes of death in patients  with FAP  (Quintini , 2012). Although common in patien ts with FAP, 
most cases of desmoid tumors occur spontaneously in adults and are associated with a mutation in β-catenin (CTNNB1)  (Lazar, 2008 ; Tejpar, 1999; Bo, 2012). β-catenin is an integral component 
of the Wnt/β -catenin/T -cell transcription factor signaling pathway, which is frequently 
dysregulated in cancer. Patients  with desmoid tumors carrying β -catenin have a worse 5 -year 
recurrence- free survival rate than patients  with wild -type tumors ( Kummar, 2017).  
Histologically, desmoid tumors appear as poorly circumscribed proliferation of myofibroblastic cells with variable collagen deposition, and tumor margins are difficult to assess at the time of surgery. Desmoid tumors are morphologically heterogeneous and may exhibit striking morphological intratumoral and intertumoral heterogeneity ( Skubitz, 2017). In some areas, 
tumors may resemble fibroblasts of inactive fibrous tissue, whereas other areas may resemble the active fibroblasts of wound healing. 
The clinical course of desmoid tumor may be unusual and heterogeneous, characterized not only 
by tumor growth, proliferation, and disease progression, but also by stabilization and spontaneous remission ( Kasper, 2011 ). Desmoid tumors can present almost anywhere throughout 
the body, and there are different factors by which desmoid tumors develop. They can have wide range of clinical symptoms, such as bloating, pain, or rectal bleeding, in the case of abdominal desmoid tumors; or extremity pain, decreased range of motion, and swelling, in the case of extremity desmoid tumors. Given the heterogeneity of desmoid tumor, predicting the desmoid tumor behavior and determining which treatment option is appropriate for a patient  remains 
challenging. 
2.2.2. Diagnosis 
There are several guidelines published on diagnosis, treatment, and follow-up of participants 
with soft tissue sarcomas (STS), including desmoid tumors. According to the clinical practice guidelines published in 2018 by the European Sarcoma Network Working Group, the basic principles for the diagnosis of STS applies to desmoid tumors ( Casali , 2018). Because of the 
ubiquitous nature of sarcomas and their site of origin, a multidisciplinary (e.g., radiologist, pathologist, surgeon, medical oncologist, etc.) approach to the diagnosis and management is warranted. Once a sarcoma mass is suspected, non -invasive imaging by MRI or computed 
tomography (CT) is performed. Additionally, a biopsy is performed, if feasible. Once the primary diagnosis of desmoid tumor is confirmed, the potential treatment options outlined below are evaluated.  
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 26 2.2.3. Treatment  
Treatment options vary for each patient depending on the size, location and morbidity associated  
with the tumor. The wait -and-see policy is currently recommended as the first approach in 
desmoid tumors ( Kasper, 2015).  In a prospective study comparing surgical versus non-surgical 
approaches in primary desmoid tumors conducted by the French Sarcoma Group ( Penel, 2017), 
the wait -and-see policy was implemented regardless of primary tumor location. For all patients, 
the 2-year event free survival (EFS) rate was 56% . The 2 -year EFS was 63% and 70% for 
patients  managed by wait- and-see approach  and for surgery with tumors in favorable locations 
(abdominal wall, intra -abdominal, breast, digestive viscera and lower limb) , respectively . 
However, in patie nts with unfavorable tumor locations ( chest wall, head and neck, upper limb) 
the 2 -year EFS was significantly improved in parti cipants initially  managed with the  wait -and-
see approach (52%) vs surgery (25%). The authors concluded that the wait- and-see appr oach 
may be preferred to surgical resection.  
Previously, surgery was the therapeutic option of choice for localized, extra -abdominal, small 
volume desmoid tumors. However, surgery is no longer regarded as the cornerstone of desmoid 
tumor treatment given th e high rate of relapse after surgery, which exceeds 60% in larger studies, 
and the frequent observation of spontaneous disease regression and stabilization ( Penel, 2017). 
Variables associated with local recurrence post -surgery include tumor location, age of the 
participant, and quality of the surgical resection ( Kasper, 2011 ). 
Radiotherapy has been used both in the adjuvant setting after surgery and in the primary setting, mainly for extra-abdominal tumors (Kasper, 2011 ).
  Radiotherapy after surgery is an independent 
positive prognostic factor for local recurrence and overall survival, and radiotherapy alone or in combination with surgery led to significantly lower recurrence rates ( Kasper, 2011).  
Modalities studied in clinical studies include hormonal therapy since virtually all desmoid tumors express nuclear estrogen receptor- β, albeit at low receptor levels  (Janinis, 2003);  and 
nonsteroidal anti-inflammatory drugs, such as indomethacin and sulindac; however, limited responses have been observed with these agents .  
In the case of unresectable, rapidly growing and/or symptomatic and/or life-threatening desmoid tumors, traditional chemotherapy may be considered. Kasper et al. ( 2011), provide d an overview 
of chemotherapy regimens that have been studied in part icipants with advanced disease  
For patients  with  relapsed or recurrent desmoid tumors, or for patients  with desmoid tumors that 
are not amenable to surgery or radiotherapy, or if surgery is potentially mutilating, various systemic therapy have been studie d, although little in controlled clinical studies. Schöffski et al 
conducted a survey of physician’s pr eference for systemic treatment for patients  with advanced 
desmoid tumors using a structured questionnaire ( Schöffski, 2018). Results indicated that dise ase 
progression and failure of local therapy were typical indications for the use systemic therapy.  
Thus, clinical studies with systemic agents should ideally select a homogenous population with 
advanced, progressive, and symptomatic desmoid tumors and/or functional impairment after failure of observation only strategies and/or local treatments such as surgery or radiotherapy. 
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 27 Due to the spontaneous regression observed in participants with desmoid tumors, studies should 
ideally be randomized, with physician’s choice or placebo as potential comparators.  
Meaningful responses have been observed with tyrosine kinase inhibitors, such as imatinib 
(Kasper, 2017) and sorafenib. Recently,  the results from a Phase 3 study of sorafenib compared 
to placebo were published in The New England Journal of Medicine ( Gounder, 2018). The study 
enrolled 87 participants with progressive, symptomatic or recurrent desmoid tumors that were 
randomized 2:1 to sorafenib (n=50) or placebo (n=37). The median PFS for placebo was 
11.3 months (95% CI [5.7, not evaluable]) and was not reached for sorafenib ( HR = 0.13, 95% 
CI [0.05, 0.31], p < 0.001). The objective response rate (ORR) for sorafenib was 33% (95% CI, 
20 to 48) and for placebo was 20%, (95%CI, 8 to 37). Spontaneous regressions are known to 
occur in desmoid patients . This study confirmed the need for a control group ( Schöffski, 2018) in 
desmoid tumor clinical studies particularly given the spontaneous response rate in the placebo group. 
Additional targeted agents such as sirolimus and pazopanib are also being studied in participants 
with desmoid tumors ([STUDY_ID_REMOVED] and [STUDY_ID_REMOVED], respectively). 
2.2.3.1. Clinical Studies with Nirogacestat 
 Study A8641014A: Phase 1 study of PF-03084014 in participants with advanced 
solid tumor malignancy and T- cell acute lymphoblastic leukemia/lymphoblastic lymphoma  
Messersmith and colleagues  conducted a Phase 1, dose-finding study to determine the 
maximum tolerated dose (MTD), the recommended Phase 2 dose (RP2D), and to evaluate 
safety of continuous administration of nirogacestat in participants with advanced solid 
tumors ( Messersmith, 2015). Sixty- four participants received doses of nirogacestat and the 
MTD was determined to be 220 mg, administered twice daily (BID). The RP2D was determined to be 150 mg  BID, g iven comparable NOTCH related target inhibition. The most 
common reason for discontinuation from nirogacestat was objective progression or relapse of disease (32  participants). The most common primary diagnosis was desmoid tumor 
(9 participants), with a me an duration since diagnosis of 7.7 years. All participants received 
surgeries and about half of the participants received radiation therapy. The majority (60 [93.8%] participants) received previous systemic therapies and more than half (35 [54.7%] particip ants) had systemic therapies for > 3 regimens. 
Of the 64 participants with solid tu mors, 62 experienced at least 1 adverse event (AE), and 
54 experienced at least 1 treatment -related  AE (1 participant with a Grade 1 AE of upper 
respiratory infection was ex cluded from the analysis due to a database error). The most 
common treatment- relate d AEs  were diarrhea, nausea, fatigue, hypophosphatemia, vomiting, 
rash, and decreased appetite. The majority of these AEs  were Grade 1 to Grade 3. Dose 
reductions due to tre atment- related AEs  were infrequent and were reported in 9 (14%) 
participants at var ious times during treatment (from Cycle 1 to Cycle 10). Across dose 
levels, 5 (7.8%) participants had Grade 2 or Grade 3 diarrhea that resolved with dose reduction. Temporary discontinuation occurred in 21 (32.8%) participants, 13 (20.3%) of which were for  a treatment- related AE . All treatment- related AEs  that led to temporary 
discontinuation (diarrhea, hypophosphatemia, rash, nausea, vomiting, and fatigue) or dose 
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 28 reduction were Grade 1 to Grade 3, and most resolved following temporary discontinuation 
or dose reduction. Seven (10.9%) participants  permanently discontinued treatment primarily 
owing to an AE ; of these, 4 (6.3%) pa rticipants  discontinued for a treatment- related AE: one 
each for Grade 4 anaphylactic shock (100 mg BID) (an event thought to be related to co -
administration of IV morphine), Grade 1 visual impairment (150 mg BID), Grade 3 drug hypersensitivity (220 mg BID), and Grade 3 rash (330 mg BID). The hypersensit ivity 
reaction (rash associated with chest tightening and shortness of breath) resolved with intravenous steroid therapy after discontinuation of study treatment. 
There were 46 participants with solid tumors evaluable for response. Overall, ORR was 
13.0% (95% CI [94.9, 26.3]) for these participants. Six participants had an ORR  with 1 
complete response ( CR) (participant with thyroid cancer) and 5 partial responses ( PRs). All 
5 PRs were reported by participants with desmoid tumors, who accounted for 71.4% (95% CI [29.0, 96.3] ) of the 7  participants with desmoid tumors evaluable for response. At the 
time of data cutoff, all 6  responders were censored in the calculation of duration of response. 
All 5 responders with desmoid tumors had not progressed and were censored at the time of data cutoff, with 4 still on study and 1 discontinued due to noncompliance. The participant with thyroid cancer with CR later had recurrence of disease but was censored at the last disease assessment of CR due to missed tumor assessments.  
Overall, nirogacestat was well tolerated with an  MTD determined to be 220 mg BID and a 
RP2D to be 150 mg BID. The best tumor responses were 5 PRs out of 7 evaluable participants with desmoid tumors.  
Villalobos and colleagues reported the long- term follow-up of the 7 participants with 
desmoid tumors from the Phase 1 study ( Villalob os, 2018). As previously described, 5 of the 
7 participants with desmoid tumors had a PR with a mean time to response of 11.9 months. All participants that achieved a PR contin ued to maintain response between 48 and 73+ 
months. Four participants who discontinued therapy remained free of progression between 11 and 53+ months. One participant had a PFS of > 42 months, with a 17% decrease in the target lesion. Prolonged disease control was observed for 6 out of 7 of the participants with desmoid tumors treated with nirogacestat.  
 National Cancer Institute Protocol 14-C-0007: Phase 2 study of gamma secretase 
inhibitor PF-03084014 in adults with desmoid tumors/aggressive fibromatosis 
([STUDY_ID_REMOVED]) 
A Phase 2 study was conducted by investigators at the National Cancer Institute (NCI) to evaluate the ORR  after therapy with nirogacestat in participants with recurrent, refractory, 
progressive desmoid tumors ( Kummar, 2017). Seventeen participants received daily doses 
of nirogacestat at 150 mg BID continuously in 3- week cycles. Response to treatment was 
evaluated at Cycle 1 and every 6 cycles (18 weeks) thereafter by Response Evaluation Criteria in Solid Tumors ( RECIST ) version (v)1.1. Of the 17 participants treated in the 
study, 15 had mutations in APC or CTNNB1 genes. Sixteen participants were evaluable for response; 5 participants experienced a confirmed PR and had been on study for more than 2 years, and the remaining 11 participants had stable disease. No participant progressed on 
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 29 study. The AE profile was consistent with previous reports ( Messersmith, 2015) and 
consisted of all participants experiencing at least 1 Grade 1 or Grade 2 AE ; and the most 
commonly reported AEs  were diarrhea and s kin disorders. Four participants had a dose 
reduction while on study. Two participants received a reduced dose of 100 mg BID as a 
result of persistent Grade 3 nausea and diarrhea, 1 participant developed urticaria nonresponsive to dose reduction and came off study, and 1 participant developed a Grade 2 maculopapular rash, which resolved with dose reduction. The only Grade 3 AE  attributable 
to study treatment  was hypophosphatemia, reported in 8 participants, and is a known class 
effect of  GS inhibitors. 
 Rationale for Nirogacestat in Desmoid Tumors  
Emerging evidence in recent years presents the Notch pathway as a promising target for treatment  of solid tumors. It has been reported that aberrant Notch activation and deregulated 
expression of Notch ligands and targets are associated with a broad panel of solid tumors. At least 3 Notch members (N OTCH1, NOTCH3, and NOTCH4) have been found to be involved in 
solid tumors.  
The molecular mechanism for the oncogenic activity of Notch intracellular domain ( NICD ) may 
include inhibiting differentiation, promoting survival, or accelerating proliferation. Potential 
oncogenic targets of N OTCH 1 include Myc, cyclin D1, and several other factors. In the case of 
Myc, evidence demonstrates that Myc is a direct target gene of N OTCH 1 and essential for 
development of both T- cell leukemia and mammary tumors in mice  (Sharma, 2006; Klinakis, 
2006).   
Recent studies suggest crosstalk between the Wnt and Notch pathways (Rodilla, 2009; 
Rampazzo, 2013). It has been shown that Notch activity is increased in colorectal cancer cells 
through upregulation of JAG1 mediated by β -catenin, and levels of hairy and enhancer of split-1 
(Hes1 ) messenger ribonucleic acid are significantly upregulated in APCmin/+ mouse intestinal 
cancer models  (Ungerback, 2011).  Expression of N OTCH1 and Hes1 have been observed in 
mesenchymal stromal cells found in desmoid tumor, suggesting that the Notch pathway is possibly related to desmoid tumorigenesis ( Shang, 2015). Importantly, nirogacestat has been 
shown to inhibit the Notch pathway in desmoid tumors by inhibiting N ICD and Hes1 expression 
and this blockade results in grow arrest rather than apoptotic cell death in desmoid tumors (Shang, 2015).  
This collective data suggests that Notch signaling plays an important role in cancer development. Hence, inhibition of Notch signaling is an important strategy for therapeutic treatment . 
 Rationale for Participant Population and Placebo Arm  
Desmoid tumors most commonly occur in individuals between the ages of 15 to 60 years, more often in young adults, with the peak age of about 30 years, and a 2- to 3-fold predominance in females  (de Camargo, 2010; Skubitz, 2017). This Phase 3 study will enroll participants 
≥ 18 years old. The pharmacokinetics (PK) and optimal dosing of nirogacestat in younger 
participants has not been established. A future study in pediatric participants is planned. 
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 30 There is no FDA-approved therapeutic option for the treatment of desmoid tumors, nor is there 
an accepted standard of care for patients with advanced progressing tumors. The population will be assessed by a wait -and-see approach and depending on the tumor growth and location, 
different therapeutic options may be considered. The recently analyzed Phase 3 study of sorafenib versus  placebo ( Gounder, 2018 ) showed a significant improvement in PFS in the 
sorafenib arm, but also demonstrated objective responses in the placebo group highlighting the 
need for this control in Phase 3 studie s. 
 Benefit/Risk Assessment  
To date, the safety profile of single- agent nirogacestat in participants with advanced cancer has 
been characterized by manageable and reversible t oxicities. The most frequently reported AEs  
were diarrhea, fatigue, nausea, vomiting, hypophosphatemia, cough, and rash. The majority of 
the events were mild -to-moderate in intensity. Additionally, a Phase 2 (investigator- initiated) 
study in adult participants with desmoid tumors showed a similar AE  profile  (Kummar, 2017 ). 
All participants in the study experienced at least one Grade 1 or Grade 2 AE; with the most 
commonly reported events being diarrhea and skin disorders. 
Based on the mechanism of action an d nonclinical/clinical study data, the important identified 
risks associated w ith nirogacestat administration include notch- related effects on reproductive 
function and fertility, notch-related effects on hematopoietic (immune) function, notch- related 
effects on gastrointestinal function, skin rash, and hypophosphatemia. Important potential risks 
include effects on the hepatic system, including potential liver cholestasis. These risks will be 
assessed  by routine pharmacovigilance measures .  
Additionally, me asures are in place to minimize potential risks to study participants, and rev iew 
of safety data will be conducted on an ongoing basis in order to identify new safety signals that may arise during the program. 
The results of the nonclinical toxicology and safety pharmacology studies, together with the 
clinical experience in participants with advanced cancers (Section s 2.2.3.1.1 and  2.2.3.1.2), 
support the hypothesis that nirogacestat may represent an important therapeutic approach in patients with desmoid tumors. Thus, the projected benefit/risk balance is considered favorable for further development in this patient population. 
More detailed information about the known and expected benefits and risks and reasonably 
expected  AEs of nirogacestat may be found in the Investigator’s Brochure.  
The s tudy will utilize an independent data monitoring committee (DMC) and will operate 
according to an established Charter (Section 9.5.1 ). In addition, a protocol steeri ng committee 
was established to support the development of nirogacestat for the treatment of desmoid 
tumor/aggressive fibromatosis. The purpose and provisions of the DMC will be specified in the 
DMC Charter.  
SpringWorks Therapeutics Protocol NIR- DT-301
Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 31 3. OBJECTIVES AND ENDPOINTS
Table 1 Study Objectives and Endpoints  
Objectives  Endpoints  
Primary  Primary  
To determine the efficacy (as defined by 
PFS) of nirogacestat in adult 
participants with progressing DT/AF. PFS defined as the time from randomization until 
the date of assessment of progression or death by any cause. Progression will be determined 
radiographically using RECIST v1.1 ( Eisenhauer, 
2009; Section  
10.8)  or clinically as assessed by the 
investigator.  
Clinical progression is defined as the onset or 
worsening of symptoms resulting in a global deterioration of health status causing the permanent 
discontinuation from study treatment and the 
initiation of emergent treatment ( e.g., radiotherapy, 
surgery, or systemic therapy including 
chemotherapy or tyrosine kinase inhibitors) for 
DT/AF.  
Secondary  Secondary  
To evaluate the safety and tolerability of 
nirogacestat in adult participants with progressing DT/AF as measured by the incidence of AEs; Safety endpoints will include incidence of  
treatment -emergent AEs , changes in laboratory 
parameters, vital signs, physical examination findings, and electrocardiograms ( ECGs ). 
Tolerability will be assess ed according to toxicities 
graded by NCI Common Terminology Criteria for Adverse Events  v5.0;  
To determine the overall response rate 
(CR + PR) of nirogacestat in participants with progressing DT/AF; Overall response rate, defined as the proportion of 
participants with CR + PR assessed by central reader using RECIST v1.1 C riteria; 
To determine the duration of response ; Duration of response for participants whose best 
response is CR or PR; 
To compare tumor volume changes 
measured by MRI in participants with progressing DT/AF; and  Change in tumor volume from baseline as assessed 
by MRI volumetric; and  
To evaluate desmoid tumor symptoms 
and impacts using patient -reported 
outcomes (PROs). Symptoms and impacts will be assessed by 
evaluating change from baseline on the following PROs:  
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 32 • GOunder/Desmoid Tumor Research Tumor 
Foundation (DTRF) D Esmoid Symptom/Impact 
Scale (GODDESS) ; 
• Brief P ain Inventory  short form; 
• Patient -Reported Outcomes Measurement 
Information System Physical Function 
(PROMIS PF) short form 10a plus 3 additional items from PROMIS item banks; and  
• European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire- Core 30 (EORTC) QLQ -C30. 
Exploratory  Exploratory  
To evaluate desmoid tumor symptoms 
and impacts using PROs; Symptoms and impacts will be assessed by 
evaluating changes using the Patient Global 
Impression of Severity (PGIS) and the Patient Global Impres sion of Change (PGIC) ; 
To perform genotyping for germline and 
somatic mutation in APC and CTNNB1 genes ; Assess the frequency and distribution of each 
mutation; 
To assess modulation of the Notch 
pathway by evaluating NOTCH 
response genes in tumor biopsies at 
screening and disease progression or 
end of treatment (EOT); Change in expression pre - and post-dose on Notch 
pathway genes;  
To assess MRI T2 hyperintensity at 
baseline and post- drug administration; Assess the percent change in MRI T2 intensity;  
To inform development of a population 
PK model of nirogacestat ; and  To optimally  collect spar se PK samples to  increase 
precision of model parameters; and   
To perform exposure -response analysis  
using a final population PK /PD 
(PopPK /PD) model. To determine the relationship between exposure 
and primary, secondary, and/or exploratory efficacy 
and safety endpoints. 
To evaluate the effect of nirogacestat on 
clinical events related to disease specific desmoid tumor co -morbidity . Summarize the incidence and frequency  of events 
which may include hospitalization due to small 
bowel obstruction, hospitalization due to desmoid 
tumor-related pain, surgery for desmoid tumor. 
 
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 33 4. STUDY DESIGN  
 Overall Design  
This is a m ulti-center, randomized, double-blind, placebo-controlled, parallel group, event -
driven, Phase 3 study to compare the efficacy, safety, and tolerability of nirogacestat and placebo 
in adult participants with progressing DT/AF. Approximately 118 eligible participants will be randomized to study treatment  (niro gacestat or placebo) in a 1:1 ratio. Randomization will be 
stratified by p rimary tumor location  (intra-abdominal or extra -abdominal [Section  6.3.1]).  
This study will consist of 2 phases : the double-blind phase and the optional open-label extension 
(OLE ) phase. R efer to the schedule of activities (SoA; Section s 1.3.1 and 1.3.2) for details on 
assessments and timing of study visits. 
Refer to Section 1.2 for the study schema. 
4.1.1. Overall D esign for the Double -Blind Phase:  
Participants will be screened up to 28 days prior to the first dose of study treatment  and 
eligibility will be based on inclusion and exclusion criteria ( Section s 5.1 and 5.2). P articipants 
will be randomized to study treatment  at Cycle 1 Day 1  using interactive response technology 
(IRT), and will orally administer 150 mg BID, continuously in 28-day cycles.   
Following the baseline visit (Cycle 1 Day 1), participants will return to the clinic for study visits 
at Cycle 1 (Days 8, 15, 22), Cycle 2 (Day 28), Cycle 4 (Day 1) and then on Day 1 of every 3 cycles thereafter.  
Participants  will remain in the double -blind phase until: 
• Participant experiences death ; 
• Central Imaging Review determines that the participant has  radio graphic progressive 
disease (using RECIST v1.1);
1 
• The investigator determines the participant is experiencing  clinical progression which is 
defined as the onset or worsening of symptoms resulting in a global deterioration of 
health status causing the permanent discontinuation from study treatment and the initiation of emergent treatment ( e.g., radiotherapy, surgery, or systemic therapy 
including chemotherapy or tyrosine kinase inhibitors) for DT/AF;
 2 
• Participant  prematurely discontinues study treatment for a ny reason; 
• The s tudy is stopped by the sponsor for any reason; or 
• The required number of PFS events have been observed and the primary PFS analysis has 
been completed  (based on current statistical assumptions, this is  anticipated to be 
approximately 2 year s after the firs t participant is randomized ).3 
1If Central Imaging Review determines that a participant has radiographic  progressive disease (using RECIST v1.1) 
during the double -blind phase of the study, the site will be notified by the central imaging core laboratory. The 
participant will return to the site for an end of treatment (EOT) visit within 14 days of the notifica tion from the 
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 34 central imaging core laboratory . During the EOT visit, the participant will be unblinded and have the option to enter 
the OLE phase if eligible (Section  6.7.1 ). 
2If a participant has clinical progression as determined by the investigator ; the participant will return to the site for 
an end of treatment (EOT) visit within 14 days of the date of clinic al progression. During the EOT visit, the 
participant will NOT  be unblinded; and will NOT be  eligible  to enter the optional OLE phase . 
3When the required number of PFS events have been observed and the primary PFS analysis has been completed, all 
remaining participants in the double -blind phase will be unblinded. And if eligible, they will have the option to enter 
the OLE phase. 
4.1.2. Overall D esign for the Optional OLE Phase: 
Only eligible participants may enroll in the OLE phase of the study. R efer to Sections 6.7.2 and 
6.7.3 for the OLE  phase eligibility criteria.  
The Cycle 1 Day 1 visit of the OLE phase should be conducted on the same day as,  or within 
24 hours after , the double-blind EOT visit. A longer window between the double-blind EOT and 
OLE C1D1 visit may be allowed with prior medical monitor approval; however, r epeat 
assessments may be required with medical monitoring guidance depending on the length of time 
between double-blind EOT and OLE C1D1. 
Participants will be enrolled in the OLE phase using the IRT only after (1) all ongoing 
AEs/SAEs from the double-blind phase have been assessed for causality in a blinded manner by the investigator or qualified designee, and (2) all AE/SAE causality assessments have been 
entered into the electronic case report form ( eCRF ). In addition, all double- blind EOT visit 
assessments must be completed prior to unblinding and administering the  first dose of open- label 
study treatment.  Refer to Section 6.3.2.1 for more detail on the required unblinding criteria.  
Participants who were randomized to receive placebo in the double- blind phase will receive their 
first dose of study treatment at the site followed by a 3-hour observation period.  
Participants  who were randomized to nirogacestat in the double-blind phase may take their first 
dose of open-label study treatment at home (observation period is not required). 
Following the OLE baseline visit (C ycle 1 Day 1), participants who were previously randomized 
to receive placebo in the double-blind phase will return to the clinic for study visits at Cycle  1 
(Day 8, 15, 22) and Cycle 2 (Day 28). Participants who were previously randomized to 
nirogacestat in the double-blind phase will not return to the clinic until the Cycle 4 Day 1 visit.  
All participants will have study visits at Cycle 4 Day 1 and then on Day 1 of every 3 cycles thereafter . 
Participants will remain in the OLE phase until: 
• Participant ex periences death ; 
• Central Imaging Review determines that the participant has  radio graphic progressive 
disease (using RECIST v1.1); 
• The investigator determines the participant to have clinical progression which  is defined 
as the onset or worsening of symptoms resulting in a global deterioration of health status 
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 35 causing the permanent discontinuation from study treatment and the initiation of 
emergent treatment (e.g ., radiotherapy, surgery, or systemic therapy including 
chemotherapy or tyrosine kinase inhibitors ) for DT/AF ; 
• Participant prematurely discontinues study treatment for any  reason ; 
• The s tudy is stopped by the sponsor for any reason;  
• Participant qualifies for sponsor’s Continued Access Plan; or 
• Nirogacestat is commercially available.  
 Scientific Rationale for Study Design  
Based on the promising, prolonged tumor responses and overall tolerability with nirogacestat observed in the Phase 1 and Phase 2 studies, this Phase 3 double-blind, placebo-controlled study is being proposed to determine the efficacy and safety in pa rticipants  with unresectable, recurrent 
or relapsed progressing desmoid tumors. Progression- free survival was selected as the primary 
endpoint based on the previous clinical studies with nirogaces tat in  desmoid pa rticipants  with 
progressing tumors and the observation that only one pa rticipant progressed after 15 months on 
therapy (1 out of 24 pa rticipants ) (Villalobos, 2018 and Kummar, 2017). The rate of progression 
in untreated desmoid patients  is about 11 months ( Gounder, 2018). A placebo group was chosen 
because of the known spontaneous regressions that can occur with desmoid tumors. Progressing desmoid tumors can be unrelenting to patients particularly when they are unresectable or unresponsive to systemic treatment and halting  progression, particularly when paired with tumor 
shrinkage, is a significant outcome for patients. Because of the size and location of desmoid tumors they can often be associated with pain, loss of range of motion, and impact on daily living. This study incorporates outcome tools to assess change from baseline in these outcome measures , as changes in pain, for example, have been observed in pa rticipants  treated with 
nirogacestat that had significant tumor shrinka ge (Kummar, 2017).  
Given the unique characteristics of DT/AF, applying RECIST v1.1 alone is not always an adequate means of  capturing the entirety of the disease progression and its clinical impact on 
participants . In particular, DT/AF tumors have been shown to grow in an asymmetric nature that 
can infiltrate multiple layers of fascia, neurovascular bundles and complex joint spaces (Gounder, 2017; Villalobos, 2017).  This asymmetric growth also impacts the plane in which 
RECIST v1.1 measurements are performed such that the plane selected for review at the beginning of the study may not match the plane which ultimately shows progressive disease. To address  the complexities of evaluating DT/AF lesions, progression will be determined both 
radiographically using Response Evaluation Criteria In Solid Tumors (RECIST) version (v)1.1 (Eisenhauer, 2009; Section 10.8) and  clinically as assesse d by the investigator.  
 Justification for Dose  
An open-label, non-randomized, Phase I dose finding study ( Messersmith, 2015) in participants 
with advanced solid tumors was conducted to determine the maximum tolerated dose ( MTD ) and 
recommended phase 2 dose ( RP2D) for future clinical development of nirogacestat. In the dose-
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 36 finding portion of the study, the MTD of nirogacestat administered BID continuously for 21 days 
was established at 220 mg BID in participants with advanced solid tumors. Additional participants were subsequently enrolled in the expansion cohort at 150 mg or 220 mg BID. The RP2D in participants with advanced solid tumors was determined to be 150 mg BID by comparing the tolerability, PK, and pharmacodynamic profile of nirogacestat at the se 2 doses. At 
a dose level of 150 mg BID, the most frequently reported AEs  were diarrhea (70%), fatigue 
(44%), nausea (39%), decreased appetite (26%), vomiting (26%), and hypophosphatemia (22%). Analysis of whole blood samples demonstrated that HES4 showed the most consistent PD response, with a greater than 2-fold down-modulation observed in 17 of 19 evaluable participants with solid tumors. Additionally, in participants with advanced desmoid tumors , there appeared to 
be a clear respo nse to nirogacestat treatment. Nirogacestat was also investigated as a single agent 
in a Phase 2 study in 19 participants with triple- negative breast cancer at the RP2D of 150 mg 
BID. Neither efficacy nor PK were summarized for this study, but the AE  profi le was consistent 
with the Phase 1 study. Lastly and importantly, nirogacestat at 150 mg BID was studied in another Phase 2 study conducted by the NCI in participants with progressing desmoid tumors (Kummar, 2017). In this study, nirogacestat activity was establi shed with 5 PR (29%) out of 16 
evaluable participants. The dose of 150 mg BID was chosen for this Phase 3 clinical study based on the safety profile at this dose as well as the encouraging tumor responses in participants with desmoid tumors. 
 End o f Study  Definition  
The end of the study is defined as the date of the last scheduled procedure shown in the SoA (Section 1.3) (including telephone contact) for the last participant in the study globally. 
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 37 5. STUDY POPULATION  
Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as 
protocol waivers or exemptions, is not permitted.  
 Inclusion Criteria  
The inclusion criteria apply to the double-blind phase of the study only. The inclusi on criteria for 
the OLE phase can be found in Section 6.7.2. 
Participants are eligible to be included in the double-blind phase only if all the following criteria 
apply: 
Age 
1. Participant must be at least 18  years of age at the time of signing the informed consent. 
Type of Participant and Disease Characteristics  
2. Participant h as histologically confirmed DT/AF (by local pathologist prior to informed 
consent) that has progressed by ≥  20% as measured by RECIST v1.1 within 12 months of 
the screening visit scan . 
3. Participant h as: 
a. Treatment naïve, measurab ly progressing DT/AF that is deemed not amenable to 
surgery without the risk of significant morbidity; 
OR 
b. Recurrent , measurably progressing DT/AF following  at least one line of therapy; 
OR 
c. Refractory , measurably progressing DT/AF following at least one line of therapy. 
4. Participant has a DT/AF tumor where continued progressive disease will not result in 
immediate significant risk to the participant.  
5. Participant a grees to provide archival or new tumor tissue for re -confirmation of disease. 
6. If participant  is currently being treated with  any therapy for the treatment of DT/AF , this 
must be complete d at least  28 days (or 5 half-lives, whichever is longer) prior to  first 
dose of study treatment . All toxicities from prior therapy must be resolved to ≤  Grade 1 
or clinical baseline. 
7. Participants who are receiving chronic nonsteroidal anti- inflammatory drugs  (NSAIDs ) 
as treatment for conditions other than  DT/AF must be receiving them prior to the 
documented DT/AF progressive disease ( inclusion criteria 2) and on a stable dose for at 
least 28 days prior to first dos e of study treatment.  
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 38 8. Participant h as an Eastern Cooperative Oncology Group (ECOG) performance status ≤  2 
at screening ( refer to Section 10.7 for ECOG performance status scale) . 
9. Participant h as adequate organ and bone marrow function as defined by the following 
screening laboratory values:  
a. Absolute neutrophil count ≥  1500 cells /µL; 
b. Platelets ≥  100,000µL;  
c. Hemoglobin ≥  9 g/dL; 
d. Total bilirubin ≤  1.5 ×  upper limit of normal (ULN) (isolated bilirubin >  1.5 x 
ULN is acceptable if bilirubin is fractionated and direct bilirubin <  35% ); 
e. Aspar tate aminotransferase (AST) (serum glutamic oxaloacetic 
transaminase)/alanine aminotransferase (ALT)  (serum g lutamic pyruvate 
transaminase) ≤  2 × ULN; and  
f. Serum creatinine ≤  1.5 ×  ULN or if creatinine >  1.5 ×  ULN then calculated 
creatinine clearance must be ≥  60 mL/min (using the Cockcroft- Gault formula);  
10. Participant can  swallow tablets and has no gastrointestinal conditions affecting 
absorption. 
Sex 
11. Male or Female  
Contraceptive use by men or women should be consistent with local regulations 
regarding the methods of contraception for those par ticipating in clinical studies.  
a. Male participants:  
Male participan ts are eligible to participate if they agree to the following during 
the treatment  period and for at least 90 days after the last dose of study treatment : 
• Refrain from donating or preserving sperm ;  
PLUS either : 
• Be abstinent from sexual  intercourse as their preferred and usual lifestyle 
(abstinent on a long term and persistent basis) and agree to remain abstinent;  
OR 
• Must agree to use a male condom  when having sexual intercourse with wom en 
of childbearing potential (WOCBP) . An additional form of contraception as 
described in Section 10.4  should also be used by the female partner, if she is of 
childbearing potential. Refer to Section 10.4 for definition of WOCBP.  
b. Female participants:  
A female participant is eligible to participate if she is not pregnant or 
breastfeeding, and at least one of the following conditions applies: 
• Is not of childbearing potential (not WOCBP ). 
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 39 OR 
• Is of childbearing potential but is abstinent or using 1 highly effective 
contraceptive method, as described in Section  10.4  during the treatment  
period and until 6 months after the last dose of active study treatment . A 
second method of contraception is required if the participant is using hormonal contraception, as coadministration with nirogacestat may alter the  
plasma concentrations of hormonal contraceptives resulting in  reduced 
efficacy. Additionally, the participant agrees not to har vest or donate eggs 
(ova, oocytes) for the purpose of reproduction during the treatment  period 
and for at least  6 months after the last dose of active study treatment . The 
investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study treatment .  
• A WOC BP must have a negative serum pregnancy test result at screening and 
a negative urine pregnancy test result at the baseline visit prior to  the first 
dose of study treatment . 
• The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy. 
Informed  Consent  
12. Capable of giving signed informed consent as described in Section 10.1.3 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. 
 Exclusion Criteria  
These criteria only apply to the double-blind phase of the study. The exclusion criteria for the OLE phase can be found in Section 6.7.3. 
Participants are excluded from the double-blind phase if any of the following criteria apply: 
Medical Conditions  
1. Participant has known malabsorption syndrome or preexisting gastrointestinal conditions 
that may impair absorption of nirogacestat (e.g., gastric bypass, lap band, or other gastric procedures that would alter absorption); delivery of nirogacestat via nasogastric tube or gastrostomy tube is not allowed. 
2. Participant has experienced any of the following within 6 months of signing informed consent:  
• clinically significant cardiac disease (New York Heart Association Class III or 
IV);  
• myocardial infarction ;  
• severe/unstable angina ;  
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 40 • coronary/peripheral artery bypass graft;  
• symptom atic congestive heart failure;  
• cerebrovascular accident ;  
• transient ischemic attack ; or  
• symptomatic pulmonary embolism. 
3. Participant has abnormal QT interval corrected by Fridericia’s formula (> 450 msec for 
male participants, >  470 msec for fe male partic ipants, or > 480 msec for participants with 
bundle branch block) after electrolytes have been corrected ( triplicate  ECG readings, 
done approximately 2-3 minutes apart  and averaged ) at screening.   
4. Participant is using concomitant medications that are known to  prolong the QT/QTcF 
interval  including Class Ia (e.g., quinidine, procainamide, disopromide) and Class III 
(e.g., dofetilide, ibutilide, sotalol) antiarrhythmics at the time of informed consent. Non -
antiarrhythmic medications which may prolong the QT/QT cF interval are allowed 
provided the participant does not have additional risk factors for Torsades de Pointes (TdP).  
5. Participant has congenital long QT syndrome. 
6. Participant has a history of additional risk factors for Torsades  de Pointes (TdP) (e.g., 
heart failure, hypokalemia, family history of Long QT Syndrome). 
7. Participant has had l ymphoma, leukemia, or any malignancy within the past 5 years at the 
time of informed consent, except  for any locally recurring cancer that has be en treated 
curatively (e.g., resected basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast), with no evidence of metastatic disease for 3 years  at the time of informed consent. 
8. Participant has current or chronic history of liver di sease or  known hepatic or biliary 
abnormalities ( except for Gilbert’s syndrome or asymptomatic gallstones). 
Prior/Concomitant Therapy  
9. Participant previously received or is currently receiving therapy with GS inhibitors or anti-Notch antibody therapy. 
10. Participant is currently using any treatment for DT/AF including tyrosine kinase 
inhibitors (TKIs), NSAIDs (chronic daily use – except as in inclusion criterion 7)  or any 
investigational treatment 28 days ( or 5 half-lives, whicheve r is longer) prior to the first 
dose of study treatment .  
OR 
Participant has started any  treatment for DT/AF after the docum ented  DT/AF progressive 
disease (inclusion criteria  2). 
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 41 11. Participant is currently using or anticipates u sing food or drugs that are known 
strong/moderate cytochrome P450 3A4  (CYP3A 4) inhibitors, or strong CYP3A inducers 
within 14 days prior to the first dose of study treatment. 
Prior/Concurrent Clinical Study Experience 
12. Participant is currently enrolled or was enrolled within 28 days of firs t dose of study 
treatment  in another clinical study with any investigational drug or device. P articipation 
in observational studies may be permitted  with prior approval from the medical 
monitor/sponsor. 
Diagnostic assess ments  
13. Participant has a p ositive human immunodeficiency virus antibody test. 
14. Participant has presence of Hepatitis B surface antigen at s creening . 
15. Participant has a p ositive Hepatitis C antibody or Hepatitis C ribonucleic acid ( RNA) test 
result at s creeni ng or within 3 months prior to starting study treatment.  
NOTE: Participants with positive Hepatitis C antibody due to prior resolved disease can 
be enrolled, only if a confirmatory negative Hepatitis C RNA test is obtained. 
Test is optional and participant s with negative Hepatitis C antibody test are not 
required to also undergo Hepatitis C RNA testing. 
Other Exclusions  
16. Participant is unable to tolerate MRI or for whom MRI is contraindicated . 
17. Participant with active or chronic infection at the time of informed consent and during the 
screening period. 
18. Participant has experienced other severe acute or chronic medical or psychiatric conditions, including recent (within 1 year of signing informed consent) or active suicidal ideation or behavior, or a laboratory abnormality that may increase the risk associated with study participation or study treatment  administration or may interfere with the 
interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study. 
19. Participant has known hypersensitivity to the active substance or to any of the excipients of nirogacestat or placebo ( Table 2).  
20. Participant is unable to comply with study related procedures (including, but not limited to, the completion of electronic patient report outcomes (ePRO s), or the ePRO 
questionnaires are not available in the participant’s preferred language) 
 Lifestyle Considerations  
1. No specific lifestyle restrictions are required in this study. 
2. Study treatment  may be taken without regard to food. 
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 42 3. Refer to Section  6.5 for more detail on concomitant therapy including exclusions and 
restrictions . 
5.3.1. Meals and Dietary Restrictions  
Participants must r efrain from consuming Sev ille oranges, grapefruit or grapefruit juice, 
pomelos, exotic citrus fruits, or grapefruit hybrids at least 14 days prior to the first dose of study 
treatment and throughout the double-blind and open- label phase. 
 Screen Failures  
Screen failures are def ined as participant s who consent to participate in the clinical study but are 
not subsequently random ized to study treatment  (nirogacestat or placebo) . A minimal set of 
screen failure information is required to ensure transparent reporting of screen failur e 
participant s to meet the Consolidated Standards of Reporting Trials  publishing requirements and 
to resp ond to queries from regulatory authorities. Minimal information includes demography, 
screen failure details, eligibility criteria, and any serious adve rse event  (SAE). 
Individuals who do not meet the criteria for participation in this study (screen failures ) may be 
rescreened  at any time if provided the participant has not  screen failed on any of the following 
exclusion criteria:  #1, 5, 6, 8, 9, 13, or  19. 
Participants do not need to wait the full 28 days of the screening  period to rescreen . There is no 
set limit to how many times a participant may be rescreened  if the investigator considers the 
rescreening medically and scientifically appropriate , and the screening assessments continue to 
be tolerable for the par ticipant. Rescreened participants must be re-consented and will be 
assigned a new participant number at the time of rescreening , which can be found on a new 
screening laboratory requisition form and will need to be entered into the IRT. 
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 43 6. STUDY TREATMENT 
Study treatment  for this study is investigational (nirogacestat or  placeb o) and intended to be 
administered to a study participant according to the study protocol. 
 Study Treatment Administered  
• Participants will be instructed to swallow tablets whole a nd not to chew them prior to 
swallowing. 
• No tablet should be ingested if it is broken, cracked, or otherwise compromised (e.g., not 
fully intact ). 
• Participants should take their dose BID  orally , approximately every 12 hours, without 
regard to food. 
• Partici pants will be instructed to record their daily administration of each study treatment 
dose in an  eDiary using a home electronic patient report outcome (ePRO) device, which 
will be provided by the sponsor.  
• If a participant misses a scheduled dose of study treatment, and it is within 6 hours of the scheduled dose, the participant should immediately administer the missed dose and resume study treatment in accordance with the normal administration schedule. If more than 6 hours have elapsed since the time of scheduled administration, the participant 
should be instructed not to administer the missed dose and to resume study treatment as prescribed.  
• Participants should not take 2 doses together to “make up” for a missed dose. 
• If a partici pant vomits any time after taking a dose, then they must be instructed not to 
take another dose to “make up” for vomiting, but rather to resume subsequent doses as prescribed.  
• If a participant inadvertently takes 1 extra dose, then the participant should not take the next scheduled dose of study treatment. 
• Delivery of nirogacestat via nasogastric tube or gastrostomy tube is not allowed. 
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 44 Table 2 Study Treatment s Administration  
ARM Name  Experimental  Control  
Treatment  Name  Nirogacestat   Placebo  
Type  Drug  Drug  
Dose Formulation  Tablet1 Tablet  
Unit Dose Strength(s)  50 mg  50 mg  
Dosage Level(s)  150 mg BID  150 mg BID  
Route of 
Administration  Oral Oral 
Sourcing  Sponsor will provide sites with 
study treatment  for individual 
participant distribution  Sponsor will provide sites with 
study treatment  for individual 
participant distribution  
Packaging and 
Labeling  Study treatment  will be provided 
in 90 count bottles . Each bottle 
will be labeled as required per 
country requirement Study treatment  will be 
provided in 90 count bottles. Each bottle will be labeled as required per country requirement  
Former Name  PF-03084014  Not Applicable  
Ingredients  Uncoated Tablets:  
PF-03084014-04; 
Microcrystalline Cellulose; 
Lactose Monohydrate; 
Sodium Starch Glycolate; and  
Magnesium Stearate.  
 Opadry
® QX Film C oated 
Tablets : 
Macrogol (PEG) Polyvinyl 
Alcohol Graft Copolymer, 
Talc,  
Titanium Dioxide,  
GMCC Type 1,  
Microcrystalline Cellulose; Lactose Monohydrate; Sodium Starch Glycolate; and 
Magnesium Stearate.  
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 45 Polyvinyl Alcohol – Part 
Hydrolyzed, 
Yellow #6 / Sunset Yellow FCF 
Aluminum Lake, 
Iron Oxide Y ellow  
1 Nirogacestat tablets may be uncoated or coated with a non -functional aqueous film coat  (Opadry® QX) in the OLE 
phase of the study. In the double -blinded phase of the study, nirogacestat will only be dispensed in an uncoated 
tablet.   
6.1.1. Double -Blind P hase Dosing A dministration  
The first dose of double-blind study treatment  (3 × 50 mg tablets) will be administered  at the site  
on Cycle 1 Day 1 fo llowed by a 3-hour observation period. T o minimize time required onsite, the 
observation period may be shortened to 2 hours temporarily during a public health emergency 
(e.g., COVID -19) with prior medical monitor / sponsor approval. 
Throughout the double-b lind phase, participants will administer 150  mg (3 × 50 mg nirogacestat 
tablets  or placebo ) of study treatment  BID  (approximately every 12 hours, without regard to 
food), continuously in 28- day cycles . 
6.1.2. Open -Label P hase Do sing A dministratio n 
Participants who were rand omized to receive placebo in the double- blind phase will receive their 
first dose of open- label study treatment at the site  followed by a 3-hour observation period.  
Participants who were randomized to nirogacestat in the double-blind phase may take their first 
dose of open- label study treatment at home.  An observation period at the site is not required. 
Throughout the OLE phase, participants will administer 150 mg (3 × 50 mg tablets) of study treatment BID (approximately every 12 hours, without regard to food ), continuously in 28-day 
cycles.  To minimize time required onsite, the observation period may be shortened to 2 hours 
temporarily during a public health emergency  (e.g. , COVID-19) with prior medical monitor / 
sponsor approval. 
6.1.3. Study Treatment  Errors  
Study treatment  errors may result from the administration or consumption of the wrong study 
treatment , by the wrong participant, at the wrong time, or at the wrong dosage strength. Such 
study treatment  errors are to be capt ured on the AE page of the e CRF and  on the SAE form when 
appropriate. In the event of a dosing error, the medical monitor/sponsor should be notified 
immediately.  
Study treatment  errors are reportable irrespective of the presence of an associated AE/SAE, 
including errors involving participant exposure to the product.  
Missed doses are not considered dosing errors. 
 
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 46 
 Preparation/Handling/Storage/Accountability  
• Study treatment  will be dispensed to participants every 3 cycles during scheduled study 
visits as described  in the SoA (Section  1.3) or unscheduled visits if study treatment is 
damaged/lost or a dose modification (Section 6.6) is necessary.  
• Participants  will be instructed to keep their study treatment  in the bottles provided and 
not transfer it to any other containers.  
• The investigator or designee must confirm appropriate temperature conditions have been 
maintained during transit for all study treatment  shipments received and any 
discrepancies are reported and resolved before us e of the study treatment . 
• Only participants randomized in the IRT may receive study tre atment  and only authorized 
site staff may supply study treatment . All study treatment must be stored in a secure, 
environmentally controlled, and monitored (manual or automated) area in accordance with the labeled storage conditions with access limited to the investigator and authorized site staff.  Study treatment should be dispensed at the study site; however, direct to 
participant (DTP) shipping may be allowed with advance approval from the Sponsor in the event of a public health crisis such as COVID -19. Direct to participant shipping is not 
allowed at the C1D1 visit in the double blind or OLE phase of the study. 
• The investigator, institution, or the head of the medical institution (where applicable) is responsible for study treatment accountability, reconciliation, and record maintenance (i.e., receipt, reconciliation, and final disposition records).  
• Study treatment  returned by the participant  will not be re-dispensed. 
• Further guidance and information about the handling, storage, and final disposition of unused study treatment  (bottles /tablets)  are provided in the pharmacy  manual . 
 Measures to Minimize Bias: Randomization and Blinding  
6.3.1. Randomization 
• Prior to  participan ts being randomized to study treatment, the following activities  must be 
completed : 
1. Participant must s ign the ICF ( Section 10.1.3) and complete all screening 
assessments (Section 1.3.1).  
2. Site must s ubmit the Pre -Randomization RECIST v1.1 Calculation Worksheet at 
least 7  days prior to Cycle 1 Day 1 (Section 8.1.1.1).  
3. Site must s ubmit the screening visit scan(s) to the central imaging core laboratory 
as early in the screening period as possible to confirm scan quality ( Section 8.1.1). 
4. Site must confirm that the p articipant  meets all study entry criteria (Sections 5.1 
and 5.2).  
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 47 5. Participant must complete all pre -randomization baseline visit assessments . Refer 
to Section 1.3.1 and  Baseline and Cycle 1 Day 1 (double-blind phase)  for 
additional details . 
• At Cycle 1 Day 1, once all o f the above activities have been completed, participants will 
be centrally assigned to randomized study treatment (nirogacestat or placebo) using the 
IRT. Before the study is initiated  at a site , instructions and log-in information for the IRT 
will be provid ed to appropriate site personnel. 
• Randomi zation will be stratified based on th e following tumor location s: 
1. Intra -abdominal (including mesentery and pelvis); 
OR 
2. Extra -abdominal (including head/neck, para-spinal, extremities, abdominal wall, 
chest wall, an d other locations). 
If the participant has multiple target tumors that are located both in the intra - and extra-
abdominal location, the tumor should be classified as intra-abdominal. 
• The tumor location used for stratification should be the same as the re ported target 
lesion (s) used for assessment of the primary endpoint. The location of the target tumor(s) 
will be selected by the investigators as the basis for inclusion in the study and will be documented on the Pre-Randomization RECIST v1.1 Calculation Worksheet (Section  8.1.1.1). 
6.3.2. Blinding  
For the double-blind phase, the participant, investigator, and all other clinical site personnel will be blinded to the assigned treatment  allocation. All sponsor personnel will also be blinded except 
for the sponsor’s quality assurance designee (s), safety designee (s), and clinical supply material 
designee (s).  
If Cen tral Imaging Review determines that a participant has  radiographic progressive disease 
(using RECIST v1.1) during the double-blind phase of the study, the site will be notified by the central imaging core laboratory. The participant will then return for the EOT visit which will be conducted in a completely blinded fashion. All EOT assessments and all ongoing AEs/SAEs must (1) be assessed for causality by the investigator or qualified designee in a blinded manner and (2) recorded in the eCRF  prior to the unblinding of the study treatment allocation (Section 
6.3.2.1). 
Study participants who discontinue due to clinical progression will NOT be unblinded and will 
NOT be eligible to enroll into the optional OLE phase of the study. These participants should be discontinued from the study after complet ing an EOT and FUP visit as specified in applicable 
SoA table.  
If a participant discontinues study treatment for any reason other than radiographic progressive disease as determined via c entral review , the study treatment allocation will not be unblinded.  
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 48 6.3.2.1. Breaking the Blind 
Sites will be provided instructions on how to break the blind in the IRT prior to study initiation. 
The study treatment blind is not  to be broken unless one of the following criteria apply 
(unblinding at the clinical site for  any other reason will be considered a protocol deviation and 
the unblinded participant will be permanently discontinued from the study):  
1. Emergency situations: • In case of an emergency, the investigator has the sole responsibility for 
determining if unblinding of a participant’s study treatment assignment is warranted.  
• Participant  safety must always be the first consideration in making such a 
determination.  
• If the investigator decides that unblinding is warranted, the investigator will make every effort to c ontact the medical monitor /sponsor prior to unblinding a 
participant’s stud y treatment assignment unless this could delay emergency 
treatment of the participant.  Refer to Section  10.10.3 for the medical monitor 
contact  information . 
• The sponsor or medical monitor must be notified within 24 hours after breaking the blind. The date and reason that the blind was broken must be recorded in the source documentation and eCRF, as applicable.  
• If the blind is broken for emergency  reasons, the unblinded participant will be 
permanently discontinued from the study and it not eligible to enter the OLE phase. 
2. Central Imaging Review determines that a participant  has radio graphic progressive 
disease (using RECIST v1.1); 
• Prior to unblinding in this situation, the following criteria must be met: 
o All double-blind EOT study assessments have been  completed in a blinded 
manner (refer to SoA table Section 1.3.1 for complete list of assessments).  
o All ongoing AEs/SAEs from the double-blind phase have been  assessed 
for causality by the investigator or qualified designee in a blinded manner 
and recorded  in the eCRF.  
o Sponsor designee has confirmed that the criteria above have been met and only then will the IRT allow the study treatment to be unblinded. 
• If eligible , participant s may enter the OLE phase ( Sections 6.7.2 and 6.7.3). 
3. The required number of PFS events have been observed and the primary PFS analysis 
has been completed.  
• If eligible, a ll ongoing participants at this time may enter the OLE phase.  
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 49 
 Study Treatment C ompliance  
Participant compliance with study treatment  will be monitored throughout the study. At each 
applicable study visit (Sections 1.3.1 and 1.3.2), the participant should be asked whether he or 
she has been compliant with dosing instructions. Compliance will also be assessed by counting 
returned tablets  at the applicable study visits . Any discrepancies will be discussed with the 
participant and will be recorded in the source document ation . The n umber of tablets dispensed, 
and the number of tablets returned will be recorded in  the eCRF .  
If the participant is not compliant with study treatment dosing, the site must re -educate the 
participant on proper dosing compliance and its importance. Continued non- compliance may 
lead to withdrawal of th e participant from the study, after consultation between the investigator 
and the medical monitor/sponsor. 
In the case of an overdose, r efer to Section 8.4 for instructions. 
 Concom itant Therapy  
6.5.1. Concomitant Medications and/or Procedures  
Any medication or vaccine (including over- the-counter or prescription medicines, vitamins, 
and/or herbal supplements) that the participant is receiving at the time o f informed consent 
and/or receives during the study through 30 days after the last dose of study treatment  must be 
recorded along with: 
• Reason for use; 
• Dates of administration including start and end dates ; and  
• Dosage information including dose and frequency . 
The m edical monitor/sponsor should be contacted if there are any questions regarding 
concomitant or prior therapy. Refer to Section  10.10.3 for the medical monitor contact 
information . 
6.5.1.1. Known Drug Interactions 
 Cytochrome P450 Inhibitors and Inducers 
Because inhibition of CYP3A4 isoenzymes may increase nirogacestat exposure leading to 
potential increases in toxicities, the use of known strong/moderate CYP3A4 inhibitors is  not 
allowed throughout the double-blind and OLE study phases  and must be stopped a t least 14 
days prior to the first dose of double-blind study treatment . 
Nirogacestat metabolism may be induced when taking strong CYP3A4 inducers resulting in reduced plasma concentrations. Therefore, co -administration of nirogacestat in combination 
with strong CYP3A4 inducers is not allowed throughout the double-blind and OLE study phases  and must be stopped at least 14 days prior to the first dose of double-blind study 
treatment . 
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 50 
 Cytochrome 3A4 Substrates 
Nirogacestat has been shown to increase exposure of a sensitive CYP3A4 substrate, 
midazolam, by approximately 50% following multiple daily doses of 95 mg QD. The potential for nirogacestat to inhibit CYP3A4 in vivo following BID dosing at 150 mg has not been evaluated in a clinical study. However, using physiological- based pharmacokinetic 
modeling, nirogacestat was predicted to be a moderate inhibitor of CYP3A4 metabolism when administered at 150 mg BID resulting in increases in midazolam exposures ranging from 2 - to 3.3-fold. Therefore, caution should be used when co-administering known 
CYP3A4 substrates with nirogacestat.  
Co-administration of CYP3A4 substrates with a narrow therapeutic index should be avoided 
if possible. If co-administration is unavoidable, the participant should be monitored closely 
for toxicity and investigator should consider reducing or titrating the dose of the substrate as necessary.  
 Anti-Emetic and Anti- Diarrheal Therapy  
The choice of anti -emetic drug(s) and anti-diarrheal drug(s), as well as the duration of 
treatment , is up to t he investigator assuming there is no known or expected drug-drug 
interaction (DDI) . If a DDI is expected, then the drug(s) use must be approved by the 
medical monitor /sponsor.  
 Other Concomitant Therapy 
Nonc linical studies suggest that nirogacestat may ind uce CYP3A4, CYP2B6, CYP2C8 and 
CYP2C9 enzymes. Drugs which are substrates of these enzymes may have a reduced exposure/efficacy when co- administered with nirogacestat. Dose adjustments of these 
medications should be considered when appropriate.  
The effect  of nirogacestat on the exposure of hormonal contraceptives has not been 
evaluated. However, induction of these CYP enzymes has been associated with reduced 
plasma exposure of various hormonal contraceptives resulting in reduced efficacy. 
Nonclinical studies have indicated that nirogacestat is a substrate for the drug efflux 
transporter P -glycoprotein (P-gp). Therefore, caution should be used when co- administering 
the study treatment  with known P-gp inhibitors such as amiodarone, azithromycin, captopril, 
carvedilol, elacridar, felodipine, mibefradil, nitrendipine, quinidine, ranolazine, talinolol, and valspodar. Nonclinical studies have indicated that nirogacestat may also be an inhibitor 
of P-gp and may increase the exposure of some P-gp substrates like digoxin, dabigatran , and 
fexofenadine ; participants receiving these medications should be closely monitored. 
Co-administration of gastric acid reducing agents such as proton pump inhibitors (e.g., 
omeprazole, esomeprazole, lansoprazole, etc.)  may reduce the absorption of nirogacestat. 
These drugs should be avoided if possible or, when necessary, administered 2 to 4 hours following the morning dose of study treatment. 
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 51 6.5.1.2. Excluded /Restricted  Concomitant Medications and/or Procedures  
Table 3 describes the concomitant medications and/or procedures that are excluded/restricted 
prior and/or throughout the duration of the study until the termination of study treatment. Contact 
the medical monitor /sponsor with any questions regarding excluded/res tricted medications.  
Table 3 Restricted/Excluded Medications and/or Procedures  
Medication/Procedure  Restriction/ Exclusion  Timeframe  
• Chronic daily use of NSAIDS for treatment 
of DT/AF ;1  
• Tyrosine kinase inhibitors; 
• Other antineoplastic therapy, including cytotoxic agents , targeted agents, endocrine 
therapy or other antibodies ; and  
• Any investigational treatment for DT/AF . • Not allowed after the documented DT/AF progress ive disease ( inclusion criteria  2) or 
within 28 days (or 5 half-lives, whichever is longer ) prior to first dose of double-blind 
study treatment; and  
• Not allowed  throughout the duration of the 
treatment period during the double-blind or OLE phase s. 
• Strong/moderate CYP3A4 inhibitors ; and 
• Strong CYP3A4 inducers. • Not allowed within 14 days prior to first 
dose of double-blind study treatment; and  
• Not allowed  throughout the duration of the 
treatment period during the double-blind or OLE phase s. 
• CYP3A4 substrates with a narrow therapeutic index . • Should be avoided if possible ; and  
• If co-administration is unavoidable, the 
participant should be monitored closely for toxicity and investigator should consider reducing or titrating the dose of the substrate as necessary . 
• Gastric acid reducing agents such as proton pump inhibitors. • Shou ld be avoided if a reasonable 
alternative is available; and 
• If administration is necessary, should be administered 2 to 4 hours after the morning dose of study treatment. 
• GS in hibitors ;  
• Anti-Notch antibody therapy; and  
• Gastric bypass, lap band, or other gastric 
procedures that would alter absorption. • No prior use, therapy or procedure is 
allowed; and  
• Not allowed throughout the duration of the treatment period during the double-blind or OLE phase s. 
• Antiarrhy thmic  medications  that are known 
to prolong the QT/QTcF interval including: Class Ia ( e.g., quinidine, procainamide, 
disopromide) and Class III (e.g., dofetilide, ibutilide, sotalol) antiarrhythmics ; 
• Potentially curative radiotherapy ; and  
• Surgical resection of DT/AF tumors. • Not allowed at the time of informed 
consent ; and  
• Not allowed throughout the duration of the treatment period during the double-blind or OLE phase s. 
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 52 Medication/Procedure  Restriction/ Exclusion Timeframe 
• Delivery of nirogacestat via nasogastric 
tube or gastrostomy tube. • Not allowed  throughout the double -blind or 
OLE phase s. 
• Enrollment in another clinical study with any investigational drug or device.
2 • Not allowed within 28 days prior to first 
dose of study treatment ; and  
• Not allowed  throughout the duration of the 
double-blind or OLE phases . 
1Participants who are receiving chronic NSAIDs as treatment for conditions other than DT/AF must be receiving 
them prior to the documented DT/AF progressive disease  (inclusion criteria 2) and must be on a stable dose for 
28 days prior to first dose of study treatment . 
Occasional use (defined as ≤  3 days per week) of NSAIDs for the treatment of pain or as an anti- inflammatory in 
conditions such as headache, arthritis, etc. , is allowed throughout the  treatment period during the  study. 
Dose increases of NSAIDs will not be permitted during the treatment period during the double -blind  phase of the 
study.  
2Participation  in an observational study may be allowed on a case -by-case basis with prior medical monitor/sponsor 
approval.  
6.5.1.3. Support ive Care 
 Phosphate Supplements 
Nirogacestat has been associated with hypophosphatemia which may  require phosphate 
supplementation. The choice of phosphate replacement, as well as the duration, is at the 
investigator ’s discretion . 
 Palliative Care  
During the double-blind and OLE phase of the study, systemic therapy or local therapy to 
the DT/AF tumors are not permitted.  
Medications for the standard management of symptoms or supportive care for the 
management of the effects of study treatment may be administe red at the investigator’s 
discretion; unless they are excluded concomitant medications (Section 6.5.1.2). 
Palliative radiation therapy may  be permitted in the OLE phase of the study after 
consultation with the medical monitor /sponsor. Radiation will be limited to non- target 
lesions only and will be documented in the eCRF and on the Pre-Randomization RECIST 
v1.1 Calculation Worksheet. 
Thus, the following therapies are not permitted during the double-blind or OLE phases of 
the stu dy: 
• Other anti -neoplastic therapy, including cytotoxic agents , targeted agents, endocrine 
therapy or other antibodies;  
• Potentially curative radiotherapy; 
• Surgical resection of DT/AF tumors; and  
• Any other investigational therapy. 
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 53 
 Dose Modification  
Every  effort will be made to administer study treatment (nirogacestat or placebo) at 150 mg BID. 
However, dosing will be interrupted and/or dose reduced for the AEs described in  Table 4. Study 
treatment may also be modi fied to manage other AEs in collaboration with the medical monitor.  
If a participant experiences an AE  as described in Table 4, hold st udy treatment until the AE  is 
resolved  to ≤ Grade 1 or baseline.  
• If the AE is resolved within 14 days, then study treatment should be restarted at the 
reduced  dose as described in Table 4.  
• If the AE does not resolve to ≤  Grade 1 or baseline after holding study treatment for 
22 days, study treatment may be resumed only after discussion with the m edical 
monitor/sponsor. Refer to Section 10.10.3 for the medical monitor contact details.  
Should the same ≥ Grade 3 AE  recur at the reduced dose, and the AE  is considered related to the 
study treatment , study treatment may be permanently discontinued following discussion with the 
medical monitor/sponsor.  
An unscheduled visit may be performed at any time during the study. Assessments to be performed at the unscheduled visit will be determined by the investigator. 
Table 4 Dose Modifications or Interruptions for Selected Toxicities  
Toxicity (NCI CTCAE)  Intervention  
Gastrointestinal Toxicities  
Grade ≥ 3 diarrhea persisting for ≥ 3 days 
despite maximal medical therapy  Decrease dose to 100 mg BID 
Grade ≥ 3 nausea persisting for ≥ 3 days 
despite maximal medical therapy  Decrease dose to 100 mg BID 
Grade ≥ 3 vomiting persisting for ≥ 3 days 
despite maximal medical therapy  Decrease dose to 100 mg BID 
Reproductive system toxicities  
Grade ≥ 2 premature menopause / primary 
ovarian insufficiency Decrease do se to 100 mg BID2 
Other toxicities  
Grade ≥ 3 skin toxicity1 Decrease dose to 100 mg BID 
Grade ≥ 3 hypophosphatemia persisting for 
≥ 7 days despite maximal replacement 
therapy and in the absence of symptoms Decrease dose to 100 mg BID 
Any c linically s ignificant Grade ≥ 3 non-
hematological toxicities  Decrease dose to 100 mg BID 
Grade ≥ 3 hematological toxicities  Decrease dose to 100 mg BID. 
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 54 Toxicity (NCI CTCAE)  Intervention  
Anaphylaxis Permanently discontinue 
Grade ≥ 3 hypersensitivity reaction Permanently discontinue 
Hepatic toxicities  Refer to Section  7.1.1  
1Refer to the study reference manual for guidel ines on managing the AE of skin rash.  
2A dose reduction is not required for events of premature menopause / primary ovarian insufficiency but may be 
considered for symptomatic participants based on the individual benefit / risk profile.  A dose interruption  is not 
required prior to a dose reduction for reproductive system toxicities.  
 
 Treatment after the End of the Double -Blind Study  
6.7.1. Optional Ope n-Label Extension Phase  
Eligible participants will have the option to enter the OLE phase of the study. R efer t o the OLE 
SoA ( Section  1.3.2)  for study visits and timing of assessments, and Section  4.1.2 and Table 7 for 
overall design and additional det ails of the OLE phase. 
6.7.2. Inclusion Criteria  - Open -Label Extension Phase  
Participants are eligible to be included in the OLE  phase only if all  the following criteria apply:  
1. Participant is  enrolled in the double-blind phase when a ll the required number of PFS  
events have been observed and the primary PFS analysis has been completed; 
OR 
Participant is randomized to receive placebo in the double-blind phase and Central 
Imaging Review determines that the participant has  radiographic progressive disease 
(using RECIST v1.1);  
OR 
Participant is randomized to receive nirogacestat in the double-blind phase and Central 
Imaging Review determines that the participant has  radiographic progressive disease 
(using RECIST v1.1) but the participant is  deriving clinical benefit w ithout significant 
toxicity  (as determined by the investigator ). 
2. Participant has adequate organ and bone marrow function as outlined in the double-blind inclusion criteria  9 (based off hematology and serum chemistry results within 14 days 
prior to enrollment in the OLE phase). 
3. Participant a grees to use contraception as outlined in the d ouble-blind inclusion 
criteria  11. 
4. Participa nt is c apable of giving signed informed consent specific to the OLE phase, as  
described in Section 10.1.3, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.  
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 55 6.7.3. Exclusion Criteria  - Open -Label Extension Phase  
Participants are excluded from the OL E phase of the study if any of the following criteria apply: 
1. Participant requires surgery to prevent organ dysfunction. 
2. Participant has prematurely discontinued from the double-blind phase for any reason 
other than radiographic progressive disease (as determ ined by C entral Imaging R eview  
using RECIST v1.1). 
3. Participant developed a concurrent illness/condition that, in the opinion of the investigator, would represent a risk to overall health if they enroll in this study. 
4. Participant has initiated a new treatment for DT/AF including tyrosine kinase inhibitors, other antineoplastic therapy, including cytotoxic agents, targeted agents, endocrine therapy or other antibodies; and/or any investigational treatment for DT/AF after  the 
Central Imaging Review determines that a participant has  radiographic progressive 
disease (using RECIST v1.1). 
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 56 7. DISCONTINUATION OF STUDY TREATMENT  AND 
PARTICIPANT DISCONTINUATION/WITHDRAWAL  
 Discontinuation of Study Treatment  
It may be necessary for a participant to permanently discontinue study treatment  (nirogacestat or 
placebo) early . In this case, the pa rticipant will return to the site  for an EOT visit and a post dose 
follow-up visit (refer to SoA tables in Section 1.3 for a complete lis t of required assessments to 
be conducted). 
Reasons for discontinuation of study treatment  early may include: 
• Central Imaging Review determines that a participant has  radiographic progressive 
disease (using RECIST v1.1) in the double-blind phase and the participant do es not enter  
the OLE phase ; 
• Central Imaging Review determines that a participant has radio graphic progressive 
disease ( using RECIST v1.1); 
• The i nvestigator determines the participant is experiencing  clinical progression which  is 
defined as the onset or worsening of symptoms resulting in a global deterioration of 
health status causing the permanent discontinuation from study treatment and the initiation of emergent treatment ( e.g., radiotherapy, surgery, or systemic therapy 
including chemotherapy or tyrosine kinase inhibitors) f or DT/AF ; 
• Occurrence of any medical condition or circumstance that exposes the participant to substantial risk and/or does not allow the participant to adhere to the requirements of the protocol; 
• Participant’s s tudy treatment is unblinded for safety reasons or any reason other than 
radiographic progressive disease as  determined  via central review  (Section  6.3.2.1);  
• Any SAE  (refer to Section 10.3.2 for SAE criteria) , clinically significant AE  (refer to 
QTcF stopping criteria, Section 7.1.2), severe laboratory abnormality (refer to liver 
chemistry stopping criteri a, Section 7.1.1), any grade ≥ 3 hypersensitivity reaction, 
anaphylaxis, Section 6.6), intercurrent illness, or other medical condition which indicates to the investigator that continued participation is not in the best interest of the participant; 
• Pregnancy  (refer to Section s 8.3.5 and  10.4 for additional details ); 
• Requirement of prohibited concomitant medication  or procedure ( Section  6.5.1.2);  
• Participant failure to comply with protocol requirements or study- related procedures; or  
• Termination of the study by the sponsor or the regulatory authority. 
7.1.1. Liver Chemistry Stopping Crite ria 
Discontinuation of study treatment  for abnormal liver function should be considered by the 
investigator when a participant  meets  one of the conditions outlined in Figure 1 or if the 
investigator believes that it is in  the best interest of the participant . 
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 57 Figure 1 Liver Chemistry Stoppi ng Criteria and Increased Monitoring Algorithm 
 
Abbreviations: ALT = alanine transaminase; INR = international normalized ratio; SAE = serious adverse event; ULN = upper 
limit of normal.  
7.1.2. QTc F Stopping Criteria  
If a clinically significant finding is identified (including, but not limited to changes from baseline 
in QT interval corrected using Fridericia’s formula [ QTcF ] after enrollment ), the investigator or 
qualified  designee will determine if the participant can continue in the study and  if any change in  
participant  management is needed . This  review of the ECG s printed at the time of collection  
must be documented. Any new clinically relevant finding must be reported as an AE.  
A participant who meets either of the following bulleted criterion based on the average of triplicate ECG readings will be withdrawn from study treatment : 
• QTcF > 500 msec  
• Change from baseline of QTcF > 60 msec 
Table 5 describes the discontinuation criteria for participants with underlying bundle branch block. 
 If participant is to be monitored weekly, must refer to Liver Safety : Suggested  Actions and 
Follow -up Assessments ( Section 10.6) 
 Must refer to Liver Safety: Suggested Actions and Follow -up Assessments (Section  10.6) 
 Report as an SAE if possible Hy’s Law case: ALT ≥ 3xULN and Bilirubin ≥ 2xULN (> 35% 
direct) or INR > 1.5, if measured*  
*INR value not applicable to participants on anticoagulants 
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 58 Table 5 Bundle Branch Block Discontinuation Criteria  
Baseline QTc F with Bundle Branch Block  Discontinuation QTc F Threshold with 
Bundle Branch Block  
< 450 msec > 500 msec 
450 to 480 msec ≥ 530 msec  
See the SoA  for data to be collected at the time of study treatment  discontinuation and follow-up, 
and for any further evaluations that need to be completed . 
7.1.3. Pregnancy  
A female participant who becomes pregnant will be withdrawn from study tre atment. See 
Section  10.4 and  Section  8.3.5 for additional details. 
 Participant Discontinuation/Withdrawal from the Study  
• A participant  may withdraw from the study at any time at their  own request or  may be 
withdrawn at any time at the discretion of the investigator for safety, behavioral, 
compliance, or administrative reasons. This is expected to be uncommon. 
• At the time of discontinuing from the study, if possible, the EO T vis it should be 
conducted. See So
A (Section 1.3)  for specific data to be collected at the time of study 
discontinuation, as well as f ollow-up for any further evaluations that need to be 
completed.  
• If a parti cipant  withdraws consent for disclosure of future information, the sponsor may 
retain and continue to use any data collected before such a withdrawal of consent. 
• If a participant withdraws from the study, they  may request destruction of any samples 
taken and not tested. The sponsor must be notified if the participant requests destruction of sample, and the investigator must document this in the site study records. 
 Lost to Follow  up 
A participant  will be considered  lost to follow -up if they repeatedly fail to return for scheduled 
visits and is unable to be contacted by the study site. 
The following actions must be taken if  a participant fails to return to the site  for a required study 
visit:  
• The site must attempt to contact the participant and reschedule the m issed visit as soon 
as possible, counsel the participant  on the importance of maintaining the assigned visit 
schedule, and ascertain whether  the participa nt wishes to and/or should continue in the 
study. 
• Before a participant  is deemed lost to f ollow up, the investigator or designee must make 
every effort to regain contact with the participant  (where possible, 3 telephone calls and, 
if necessary , a certified letter to the participant ’s last known mailing address or local 
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 59 equivalent methods). These contact attempts must be documented in the participant ’s 
medical record . 
• Should the participant  continue to be unreachable, they  will be considered to have 
withdrawn from the study.  
Discontinuation of specific sites or of the study as a whole is  handled as part of Section  10.1.8. 
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 60 8. STUDY ASSESSMENTS AND PROCEDURES  
• Study procedures and their timing are summarized in the SoA (Section 1.3).  
• Protocol waivers or exemptions are not allowed.  
• Immediate  safety concer ns should be discussed with the medical monitor/sponsor 
immediately upon occurrence or awareness to determine if the participant should 
continue or discontinue study treatment  (nirogacestat or placebo) . 
• Adherence to the study design requirements, including those specified in the SoA, is essential and req uired for study conduct. 
• All screening evaluations must be completed and reviewed to confirm that potential participants meet all eligibility criteria  (Sections  5.1, 5.2, 6.7.2, and 6.7.3) . The electronic 
data capture ( EDC ) will capture all participants who sign  the ICF, including all screen -
failures.  
• The amount of blood collected from each part icipant will be approximately 218 mL  each 
year  throughout the double-blind phase and  180 mL each year throughout the OLE 
phase. This does not include any extra assessments that may be required  for unscheduled 
assessments. Repeat or unscheduled samples may be taken for safety reasons or for 
technical issues with the samples.  
• In the event that a study site or participant is unable to complete a study visit or procedure due to restrictions caused by a public health emergency such as COVID-19, the following accommodations may be a llowed temporarily with prior approval from the 
medical monitor / sponsor. Any deviations from the study protocol due to a public health 
emergency should be documented in the source data and eCRF and reported to the IRB/EC in accordance with the ir reportin g requirements.  
o If a study participant cannot attend a study visit onsite due to a public health emergency, they may be able to attend a local hospital/clinic or arrange for a telehealth or home healthcare visit.  
o Clinical laboratory a ssessments may be performed locally with results and local 
laboratory normal values entered into the eCRF. 
o  
o Electrocardiograms may be performed locally. If ECGs are performed locally , 
ECG tracings should be collected and the investigator (or designee) assessment should be documented. Every effort should be made to perform ECGs in triplicate; however, a single ECG will be allowed if necessary due to a public health emergency.  
o Study imaging including CT and/or MRI should be performed per the schedule in 
the SoA at a qualified imaging facility; however, local imaging may be allowed 
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 61 with prior sponsor approval. Local imaging will nee d to be uploaded for Central 
Imaging Review.   
Table 6 Double -Blind Phase Study Visit s 
This table supplements the SoA and highlights key study visit reminders. Refer to the double-
blind phase SoA table (Section 1.3.1) for the complete list of study assessments, and the study 
reference manual for study visit checklists which will include the recommended sequence of 
assessments for each study visit.  
Screeni ng (double -blind phase)  
Operational visit reminders:  
• Refer to the SoA table for a complete list of required study assessments  (Section 1.3.1).  
• Screening assessments may occur up to 28 days prior to first dose of study treatment 
with a minimum screening period of 14 days to allow for participant completion of the screening and baseline ePRO assessments.  
• An extension to the screening period may be permitted on a case-by- case basis 
following discussion between the investigator and the medical monitor / sponsor (refer to Section 10.10.3 for medical monitor contact information) . The reason(s) for the 
extension must be clearly documented. 
• The date the participant signs the ICF will be Day 1 of the screening period. 
• The participant will be assigned a study identification number at the screening visit. This number can be found on the screening laboratory requisition form in the Subject Requisition Binder and will be entered into the IRT at the screening visit. This participant identification number will be utilized for the duration of the study.  
ePRO reminder s: 
• On Day 1 of the screening period, participants will receive training on how to use the home ePRO device (provided by the sponsor), which will include a practice questionnaire to be com pleted prior to the participant leaving the site. The participant 
will then begin the screening PRO assessments later  that same day. Refer to Table 8 for 
details on the ePRO assessment administration schedule.  
• If the participant screen fails during the screening period, they should be reminded to return the device bac k to the site.  
Imaging r eminders:  
Pre-randomization scans: 
• To meet inclusion criteria 2 , participants must have had two scans (MRI or CT) that 
show  ≥ 20% disease progression as measured by  RECIST v1.1 within 12 months of the 
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 62 screening visit scan (which will serve as the participant’s baseline  scan for the study) . 
Pre-randomization scans will be evaluated locally (not subject to central review).  
• As part of documenting that participants have satisfied inclusion criteria  2, sites are 
required to complete a Pre -Randomization RECIST v1.1 Calculation Worksheet 
(provided by the sponsor) (Section 8.1.1.1). The worksheet must be submitted to the 
sponsor ’s designee during the screening period as soon as the data are available to 
complete the worksheet . All worksheets must be received no later than 7 days prior to 
C1D1 to allow for review prior to randomization (refer to study reference manual) . 
Screening visit scan (s): 
• An MRI scan (no contrast required) will be acquired during the 28-day screening 
period, prior to the participant’s first  dose of study treatment.  
• A CT scan (contr ast required unless contraindicated) is only required  if CT is the chosen 
modality for RECIST v1.1 tumor assessment  (modality to be determined by the 
investigator). If CT is the chosen modality for RECIST v1.1, then a CT scan must be acquired during the 28-day screening period, prior to the participant’s first dose of study treatment . 
• Whichever modality is used at screening (CT or MRI) for tumor assessment  (RECIST 
v1.1) , the same modality  must continue to be used at each subsequent visit throughout 
the study. 
• If applicable, CT and MRI assessments may be conducted on the same day. However, MRI with no contrast must be performed prior to CT with contrast. 
• The scan(s) conducted at the screening visit will serve as the participant’s baseline for the study. Therefore, scans should be submitted to the central imaging core laboratory as early in the screening period as pos sible to confirm scan quality is  acceptable for 
analy sis prior to randomization. The scan(s) conducted at the screening visit should also 
be read locally .  
• Standard of care scan(s) acquired prior to participant signing ICF may be used as screening visit sc an(s) if obtained within 28 days of the first dose of study treatment and 
the quality of the scans are acceptable for analysis (as determined by central ima ging 
core laboratory). These standard of care scans will then be collected, stored, and documented as the screening visit scan (s). No other pre- enrollment images will be 
collected  for central reading . 
Tumor biopsy reminders : 
• Core needle biopsy is only required if archival tissue is not available for study procedures (Section 8.1.3 ). 
• If tumor biopsy and MRI are performed during the same study visit, the biopsy must be done after MRI. 
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 63 • Tumor biopsy will be reviewed centrally to reconfirm diagnosis, but participant 
enrollment is not dependent on central review. 
Baseline and Cycle  1 Day 1 (double -blind phase)  
Operational visit reminders: 
• Refer to the SoA table for a complete list of required study assessments (Section 1.3.1).  
• The baseline visit may occur up to 48 hours prior to first dose of study tre atment 
(nirogacestat or placebo).  
• Cycle 1 Day 1 will be defined as the first dose of study treatment.  
• The following baseline assessments are to be conducted prior to the first dose of study 
treatment: 
o Physical examination  and ECOG performance status  (Secti on 8.2.2);  
o Vital signs  and weight (Section 8.2.4); 
o Pre-dose 12- Lead ECGs  (Section  8.2.3) ; 
o Urinalysis  and urine pregnancy for women of childbearing potential (WOCBP)  
(Secti on 8.2.6) ; 
o Blood draws for safety lab  parameters , hormone levels , (Sections  8.2.5 and  
10.2) , genotyping (Section 8.7)  and optional pharmacogenomic sample  (Sections  
8.8 and 10.5) ; 
o Concomitant medication and AE/SAE review; and 
o Single pre -dose PK blood draw. 
• After all of the pre- dose baseline assessments (as noted above) have been completed 
and the participant ’s eligibility has been confirmed  (Sections  5.1 and 5.2) , the 
participant  will be randomized  and the first dose of study treatment (150 mg) will be 
administered at the site.   
• The following baseline assessments are to be conducted after  the first dose of study 
treatment: 
o Triplicate 12 -Lead ECGs (Section 8.2.3) to be conducted approximately 1-hour 
post-dose; 
o PK sampling (Section 8.5) to be conducted at 0.25-, 0.5-, 1-, 1.5-, 2-, 3-hours 
post-dose; and 
o 3-hour observation period following the first dose of study treatment. 
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 64 ePRO reminders:  
• Baseline ePRO assessments will begin 7 days prior to the scheduled Cycle 1 Day 1 
study visit. 
• Refer to  Table 8 for details on the ePRO assessment administration schedule.  
Cycle 1 Day 8, 15 , 22, and Cycle 2 Day 28  (double -blind phase)  
Operational visit reminders:  
• Refer to the SoA table for a complete list of required study assessments (Section 1.3.1).  
• Visit window s are ± 2 days. 
• At Cycle 1 Day 8, t riplicate 12 -Lead ECGs are required 1-hour ( ± 10 minutes) post-
dose. Therefore, study treatment must be taken in the cl inic at this visit. 
• A trough PK sample is  required  at each study visit. Therefore , the evening before the 
study visit, the participant will record the exact time study treatment was taken  in the 
home ePRO device. Participant will not  take their planned morning dose the day of the 
study visit. The morning dose will be taken following the pre-dose PK blood draw. 
• Urine pregnancy tests for participants of WOCBP must be performed at Cycle 1 Day 22 and Cycle 2 Day 28. 
Cycle 4 Day 1 , Cycle 7 Day 1 and Every 3 Cyc les (double -blind phase)  
 Operational visit reminders: 
• Refer to the SoA table for a complete list of required study assessments (Section 1.3.1).  
• Visit window s are ± 7 days. 
• A trough PK sample is  required at each study visit. Th erefore, the evening before the 
study visit, the participant will record the exact time study treatment was taken in the home ePRO device. Participant will not ta ke their planned morning dose the day of the 
study visit. The morning dose will be taken following the pre-dose PK blood draw.  
• The site should submit scans  to the central imaging core laboratory for C entral Imaging 
Review  as soon as possible following the study visit. Scans should also be read locally 
per RECIST v1.1.  
• MRI for tumor volume is required starting with Cycle 7 and then every 6 cycles throughout the study. If MRI for tumor volume assessment and CT for tumor 
assessment ( RECIST  v1.1) are conducted on the same day, MRI with no contrast must 
be performed prior to CT with contrast. 
• Beginning at the Cycle 4 Day 1 visit, participants will return all used  / unused study 
treatment , and will be dispensed new study treatment using  the IRT at e very applicable 
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 65 study visit. Accountability must by counting the returned study treatment tablets  and 
docume nt compliance in the eCRF . 
End of Treatment (EOT) (double -blind phase)  
The EOT visit will occur when : 
1. A participant has met the study endpoint of radiographic progression using 
RECIST  v1.1 (determined by Central Imaging Review) or is experiencing clinical 
progression as assessed by the investigator ; 
2. Participant prematurely  discontinues study treatment for any other reason; 
3. Study is stopped by the sponsor for any reason; or 
4. All required number of PFS events have been observed and the primary PFS analysis has been completed.  
Operational visit reminders: 
If Central Imaging Review determines that a participant has radiographic p rogressive disease 
(using RECIST v1.1) during the double-blind phase of the study, the following steps will occur: 
1. Site will be notified by the central imaging core laboratory that Central Imaging Review 
has as determined the participant has radiographic progressive disease (using RECIST v1.1). 
2. Participant will return to the site for an  EOT visit within 14 days of the site receiving 
the radiographic progressive disease notification from the central imaging core laboratory. 
3. Participant should be instructed to remain on study treatment until the EOT visit (if 
possible). 
4. All double-blind EOT study assessments will be completed in a blinded m anner (refer 
to SoA table Section 1.3.1 for complete list of assessments).  
5. All ongoing AEs/SAEs from the double-blind phase will be assessed for causality by the investigator (or qualified designee) in a blinded manner and recor ded in the eCR F. 
6. Sponsor designee will confirm that the above criteria have been met and only then will the IRT allow the participant’s study treatment assignment to be unblinded. 
7. Eligible p articipant s may enter the OLE phase at this time . The EOT visit sh ould be 
conducted on the same day  as, or 24 hours prior to, the C1D1 visit for the OLE phase. A 
longer window between the double-blind EOT and OLE C1D1 visit may be allowed with prior medical monitor approval; however, r epeat assessments may be required with 
medical monitoring guidance depending on the length of time between double-blind EOT and OLE C1D1.  
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 66  
If a participant discontinues study treatment for any reason other than radiographic progressive 
disease as determined via central review the following steps will occur: 
1. Participant will return to the site for an EOT visit as soon as possible. 
2. Participant should be instructed to remain on study treatment until the EOT visit (if possible). 
3. All double-blind EOT study assessments will be completed in a blinded manner (refer to SoA table Section 1.3.1 for complete list of assessments).  
4. The participant’s s tudy treatment allocation will not  be unblinded. 
Imaging reminders:  
5. Scan(s) only required if not performed within the past 3 months. 
Tumor biopsy reminders: 
6. Tumor biopsy at  EOT visit is optional if the participant consented for pharmacogenomic 
research (Section  8.1.3).  
7. If tumor biopsy and MRI are performed during the same study visit, the biopsy must be done after MRI. 
Follow -Up (double -blind phase)  
Visit is a pplicable only if participant is not continuing onto the optional OLE phase. 
Operational visit reminders: 
• Participant will return to the site for the follow -up visit 30 days (+7 days) after the last 
dose of study treatment. 
• ePROs are to be completed 7 days prior to the scheduled follow-up visit ( Table 8).  
• Participant will return the home ePRO device.  
Monthly Wellness Checks (double -blind phase)  
• Monthly telephone or email contact is required throughout the study.  
• May be replaced by a face -to-face interaction when study visits occur, provided the 
wellness information can be obtained during the visit.  
• Refer to Section 8.2.7.  
Monthly Urine Pregnancy Tests (double -blind phase)  
• Assessment a pplicable to women of child-bearing potential (WOCBP) only. 
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 67 • In between study visits, participants will be required to return to the site  for a monthly 
urine pregnancy test . If it  is more convenient for the participant, they may alternatively  
visit a local  laboratory that has been pre-approved by the sponsor (or designee) for this 
assessment  (refer to study reference manual for additional details) . 
• Refer to Section 8.2.6. 
Monthly PRO Assessments (double -blind phase ) 
• The home ePRO device (supplied by the sponsor) will be programmed to prompt the 
participa nt to complete the questionnaires monthly throughout the study, and always 
prior to a study visit when applicable. 
• Refer to Section  8.1.2 and  Table 8.  
Unscheduled Visits  (double -blind phase)  
Additional tests may be performed at any time during the study as determined necessary by the investigator or required by local regulations. 
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 68 Table 7 Open -Label Phase Study Visits 
This table supplements the SoA and highlights key study visit reminders. Refer to the OLE  phase 
SoA table (Section 1.3.2) for the complete list of study assessments, and the study reference 
manu al for study visit checklists which will include the recommended sequence of assessments 
for each study visit. 
Cycle 1  Day 1 (OLE phase)  
The OLE phase allows  eligible participants to receive open- label study treatment (nirogacestat).  
Refer to Sections 6.7.2 and 6.7.3 for OLE specific eligibility criteria . 
The OLE Cycle 1 Day 1  visit should be conducted on the same day  as, or within 24 hours after , 
the double-blind EOT visit. A longer window between the double-blind EOT and OLE C1D1 
visit may be allowed with prior medical monitor approval; however, r epeat assessments may be 
required with medical monitoring guidance depending on the length of time between double-blind EOT and OLE C1D1. 
Operational visit reminders: 
• All double-blind EOT visit assessments described in the double-blind SoA ( Section 
1.3.1 ) will be conducted prior to unblinding the participant’s study treatment assignment 
and prior to the first dose of open- label study treatment.  The following OLE baseline 
assessments must be conducted prior to administration of the first dose of open- label 
study treatment: 
o Obtain participant ’s consent using OLE phase  specific ICF ; 
o Confirm participant meets all I/E criteria specific to the OLE phas e (refer to 
Sections 6.7.2 and 6.7.3);  
o Draw blood for hematology and ser um chemistry safety  assessment s for local lab 
processing (only if labs not done within the past 14 days); hormone levels  do not 
need to be repeated if performed at EOT for the double-blind phase of the study. 
o Note:  if hematology and serum chemistry safety labs have not been 
conducted within the past 14 days prior to baseline, an additional blood draw will be required for same day local laboratory processing to reconfirm adequate organ and bone marrow function (refer to OLE  inclusion 
criteria   2) 
o Enroll participant in the OLE phase using the IRT and dispense  study treatment; 
o Draw a single pre -dose PK blood draw (only applicable for participants who were 
previously randomized to placebo in the double-blind phase); 
• After the OLE pre -dose baseline assessments (as noted above) have been completed, the 
first dos e of open -label study treatment will be administered  at the site for participants 
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 69 who were previously randomized to placebo in the double -blind phase. Participants who 
were randomized to nirogacestat may take their first dose at home.  
• The following OLE bas eline assessments will be conducted after the first dose  (only 
applicable for participants who were previously randomized to placebo in the double-
blind phase): 
o Conduct serial PK sampling  at 0.25-, 0.5-, 1-, 1.5-, 2-, and 3-hours post-dose;  
o Conduct t riplicate 12 -Lead ECG s approximately 1-hour post-dose; and  
o Complete the 3-hour observation period following the first dose of study treatment. 
Cycle 1 Day 8, 15, 22 and Cycle 2 Day 28 (OLE phase)  
Visits are a pplicable only to partic ipants who were previously randomized to receive placebo in 
the double-blind phase. 
Operational visit reminders: 
• Refer to the SoA table for a complete list of required study assessments (Section  1.3.2).  
• Visit windows are ± 2 days. 
• At Cycle 1 Day 8, tripli cate 12 -Lead ECGs are required 1 -hour (± 10 minutes) post-
dose. Therefore, study treatment must be taken in the clinic at this visit.  
• A trough PK sample is required at each study visit. Therefore, the evening before the study visit, the participant will re cord the exact time study treatment was taken in the 
home ePRO device. Participant will not take their planned morning dose the day of the study visit. The morning dose will be taken following the pre-dose PK blood draw. 
• Urine pregnancy tests for participants of WOCBP must be performed at Cycle 1 Day 22 and Cycle 2 Day 28. 
Cycle 4 Day 1 and Every 3 Cycles (OLE phase)  
Visit s are applicable to all participants.  
Operational visit reminders: 
• Refer to the SoA table for a complete list of required study assessm ents (Section 1.3.2).  
• Visit windows are ± 7 days. 
• CT or MRI scan required every 3 cycles until Cycle 13 Day 1, and then required every 6 cycles thereafter.  
• A trough PK sample is required at each study visit. Therefore, the evening before the study visit, the participant will record the exact time study treatment was taken in the home ePRO device. Participant will not take their planned morning dose the day of the study visit. The morning dose will be taken following the pre-dose PK blood draw. 
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 70 • The site should submit scans to the central imagi ng core laboratory for Central Imaging 
Review as soon as possible following the study visit. Scans should also be read locally 
per RECIST v1.1. 
• Beginning at the Cycle 4 Day 1 visit, participants will return all used  / unused study 
treatment, and will be dispensed new study treatment using the IRT at every applicable study visit. Accountability must be performed on the returned tablets. 
End of Treatment (EOT) (OLE phase)  
The EOT visit will occ ur when: 
• A participant has met the study endpoint of radiographic progression using RECIST  v1.1 (determined by Central Imaging Review); 
• The investigator determines that the  participant is  experiencing clinical progression 
defined as the onset or worsening of symptoms resulting in a global deterioration of health status causing the permanent discontinuation from study treatment and the initiation of emergent treatment ( e.g., radiotherapy, surgery, or systemic therapy 
including chemotherapy or tyrosine kinase in hibitors) for DT/AF ; 
• Participant discontinues study treatment for any reason; 
• Study is stopped by the sponsor for any reason; 
• Participant qualifies for Sponsor’s Continued Access Plan; or 
• Nirogacestat becomes commercially available.  
Operational visit r eminders: 
• Participants will be encouraged to return to the site as soon as possible to complete the EOT visit assessments (Section 1.3.2).  
• If possible, participants should be encouraged to remain on study treatment until the EOT  visit.  
Follow- Up (OLE phase)  
Visit is a pplicable only if participant is not transitioning directly to commercial nirogacestat (or 
sponsor’s Continued Access Plan) at the time of discontinuation. 
Operational visit reminders: 
• Participant will return to the site for the follow -up visit 30 days (+7 days) after the last 
dose of study treatment. 
• ePROs to be completed 7 days prior to the scheduled follow-up visit ( Table 9). 
• Participant will return the home ePRO device.  
Monthly Wellnes s Checks (OLE phase)  
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 71 • Monthly telephone or email contact is required throughout the study. 
• May be replaced by a face- to-face interaction when study visits occur, provided the 
wellness information can be obtained during the visit.  
• Refer to Section  8.2.7.  
Monthly Urine Pregnancy Tests (OLE phase)  
• Assessment a pplicable to women of child-bearing potential (WOCBP) only. 
• In between study visits, participants will be required to return to the si te for a monthly 
urine pregnancy test. If it is more convenient for the participant, they may alternatively  
visit a local  laboratory that has been pre-approved by the sponsor (or designee) for this 
assessment  (refer to the study reference manual for additi onal detail) . 
• Refer to Section  8.2.6.  
Monthly / Quarterly PRO Assessments (OLE phase)  
• The home ePRO device (supplied by the sponsor) will be programmed to prompt the 
participant to complete the questionnaires monthly for the first year and then quarterly thereaft er, and always prior to a study visit when applicable. 
• Refer to Section  8.1.2 and  Table 9.  
Unscheduled Visits (OLE phase)  
Additional tests may be performed at any time  during the study as determined necessary by the 
investigator or required by local regulations. 
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 72 
 Efficacy Assessments 
Planned time points for all efficacy assessments are provided in the SoA (Section 1.3) . 
8.1.1. Tumor Imaging 
Central Core Imaging Laboratory: 
Sites will submit all CT and MRI scans to the central imaging core laboratory  for C entral 
Imaging Review. The purpose of the Central Imaging Review is to provide an independent, 
unbiased and objective review of the CT and MRI data throughout the study. 
Sites will be provided an Imaging Acquisition M anual  and an I maging Submission Ma nual, 
which describe the imaging methods and submission process that must be follow ed.  
All image data submitted to the central imag ing core laboratory must be de-identified prior to 
submission. The participant identifiers on the image data must be consist ent with all study-
related documents  throughout the study. See imaging manuals for details on the de- identification 
requirements.  
Site Qualification and Training: 
Before sites are activated and able to enroll participants, they will be trained on the protocol imaging requirements and provided guidance on how to submit scans.  
In addition, a ll sites  are required to submit qualification  scans to the central imaging core 
laboratory prior to study initiation. These qualification scans will be evaluated for ima ge quality 
and adherence to study protocol parameters. Once the site qualification scan s have passed image 
quality control , a site q ualification certificate will be issued. The site must file this certificate 
with their  site study documents.  
On Study Scans: 
It is important for the site to make every effort to use the same scanner(s) that have been 
qualified (as described above) throughout the double-blind and OLE phases of the study. If the 
same scanner is unavailable, another qualified scanner of the same model  should be used with 
the same settings.  Study imaging including MRI  and/or CT  should be performed per the schedule 
in the SoA at a qualified imaging facility; however, in the event that a study site or participant is unable to complete a study visit or procedure due to restrictions caused by a public health 
emergency such as COVID -19, local imaging may be allowed with prior sponsor approval.  
The screening visit scans will be submitted to the central imaging core laboratory and reviewed 
by Central Imaging Review. H owever, participant enrollment will not be dependent on central 
review.   
Standard of care scan (s) acquired prior to the participant signing ICF may be used as the 
participant’s  screening visit scans if they were obtained within 28 days of the first dose of 
double-blind study treatment  administration. The scan(s) will then be collected, stored, and 
documented as the scree ning visit scan s. No other pre- enrollment images will be collected for 
central reading.   
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 73 All scans should be submitted to the central imaging core laboratory as soon as possible after 
acquisition. This will allow the central imaging cor e laboratory to assess the scans for quality and 
query the site if necessary. If the scans are deemed unacceptable for analysis, the site will be 
queried, and a replacement scan will be requested.  
If necessary, both CT and MRI assessments may be conducted on the same day , but MRI with no 
contrast must be performed prior to the CT with contrast.  
Whenever disease progression is suspected (e.g., symptomatic deterioration) throughout the 
study, unscheduled scans may be acquired and submitted to the central imaging core laboratory for Central Imaging Review. 
8.1.1.1. Pre-Randomization RECIST v1.1 Calculation Worksheet  
As part of documenting that participants have satisfied inclusion criteria 2 for the double-blind 
phase , sites are required to complete the Pre- Randomization RECIST v1.1 Calculation 
Worksheet (provided by the sponsor). The worksheet must be submitted to the sponsor ’s 
designee during the screening period as soon as the data are available to complete the worksheet , 
and no later than 7 days prior to C1D1 to allow for review prior to randomization.  
8.1.1.2. Tumor Assessment Using RECIST Version 1.1 Criteria 
Tumor assessment for primary an d secondary endpoints (PFS and ORR , respectively ) as 
measured by CT (contrast required unless contraindicated) or MRI (no contr ast required) , will be 
evaluated by C entral Imaging R eview for all participants using RECIST v1.1 ( Eisenhauer, 2009) 
at the following timepoints:  
• At the double-blind and OLE phases as specified  in the SoA (Sections  1.3.1 and  1.3.2); 
and  
• Whenever disease progression is suspected (e.g., symptomatic deterioration ).  
The i maging modality will be determined by the investigator and the same imaging modality 
used to measure the identified and reported lesion  at screening in the double-blind phase must be 
used at each subsequent visit throughout the double-blind and OLE phases.  
The location of the target tumor(s) will be selected by the investigator as the basis for inclusion 
in the trial and will be documented on the Pre-Randomization RECIST v1.1 Calculation Worksheet. The target tumor(s) will be provided to Central Imaging Review and will be used for assessment of the primary endpoint. 
While tumor assessments performed by Central Imaging Review will be used for primary and 
secondary endpoints, t umor measurement s will also be performed locally using RECIST v1.1 
using the same target lesion(s) identified on the Pre-Randomization RECIST v.1.1 Calculation 
Worksheet  as specified in the SoA (Sections 1.3.1 and 1.3.2) and whenever disease progression 
is suspected (e.g., symptomatic deterioration) .  
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 74 8.1.1.3. Volumetric Assessment  
Tumor volume assessment and T2 hyperintensity imaging will be acquired only by MRI and 
only applicable in the double-blind phase of the study as spe cified in the SoA (Section  1.3.1). 
Refer to the Imaging Acquisition Manual for details. 
8.1.2. Definition and Assessment of Clinical Progression  
Clinical progression is defined as  the onset or worsening of symptoms resulting in a globa l 
deterioration of health status causing the permanent discontinuation from study treatment  and the 
initiation of emergent treatment ( e.g., radiotherapy, surgery, or systemic therapy including 
chemotherapy or tyrosine kinase inhibitors) for DT/AF. 
The date of clinical progression will be the earliest date of onset or worsening of symptoms 
resulting in a global deterioration of health status. In addition, AEs and SAEs associated with clinical progression and concomitant medications and procedures initiated f or the treatment of 
DT/AF within 30 days of the last dose of study treatment will be documented in the eCRF. A clinical progression narrative will also be developed by the PI for events of clinical progression which will be documented in EDC and include a description of onset or worsening of symptoms 
resulting in a global deterioration  of health status, the location of progressing lesions, and 
evidence of vital structure involvement (as reported by the PI), as applicable.  
When disease progression is suspected (e.g., symptomatic deterioration), imaging should be 
performed  and submitted to the central imaging core laboratory for Central Imaging R eview.  If 
progressive disease is not determined  radiologically  via central review of RECIST v1.1 per 
Section  8.1.1.2,  but the participant meets the definition of clinical progression, the participant 
may be discontinued for clinical progression. Study participants who discontinue due to clinical progression will NOT be unblinded at the EOT visit and will NOT be eligible for participation in the optional OLE phase.  
Imaging data from participants who discontinue due to clinical progression will be evaluated for 
changes in tumor characteristics or involvement of vital organ structure at the si te of progression , 
which may include: 
1. Individual tumor measurements including all available planes of measurement 
2. Volumetric MRI, if available  
3. T2 hyperintensity, if available 
Events of clinical progression will be adjudicated by an independent blinded central clinical 
review committee which will qualify events of clinical progression for inclusion in the primary 
analysis of PFS prior to study unblinding according to a Central Clinical Review Charter.  
8.1.3. Patient -Reported Outcomes  
Participants will complete the P RO questionnaires using their home ePRO devices (supplied by 
the sponsor). These home ePRO devices will be provided to participants at the screening visit 
and will be returned to the site at the end of study participation.  
The home ePRO device will be pro grammed to always administer the PROs in a particular order 
and at specific timepoints throughout the study (refer to  Table 8 and Table 9) . 
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 75 The following PRO assessments will be conducted during the double-blind phase: 
• Screening  PRO assessment:  
o On Day 1 of the screening visit, participants will receive training by the site 
staff on how to use the home ePRO device, which will include a practice questionnaire to be completed by the participant prior to leaving the site.  
o Participants will then begin the screening PROs assessments  that same day .  
o The Patient Global Impression of Change ( PGIC ) is intentionally omitted 
from the screening PRO assessments . 
• Baseline PRO assessment:  
o The baseline PRO assessments will begin 7 days prior to the Cycle 1 Day 1 visit.  
o The PGIC is intentionally omitted  from the baseline PRO assessments. 
• Monthly PRO assessments are required throughout the study (Cycle 2, 3, 4 and on). 
The following PRO assessments will be conducted during the OLE phase : 
• Monthly PRO assessments are required for the first year (Cycle 2 -12). 
• Quarterly PRO assessments are required after the first year (Cycle 13, 16, 19 and on). 
 
SpringWorks Therapeutics              Protocol NIR- DT-301 
      Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 76 Table 8 Double -Blind Phase: PRO Assessment Administrati on Schedule  
PROs  Screening PRO Assessments  
First 7 days of screening period   
 Baseline PRO Assessments  
7 day prior to baseline visit  
 Base -
line 
Visit  Monthly PRO Assessments  
7 days prior to Cycle X/FU  
(X = Cycles 2, 3, 4 & on) 
 Cycle 
X/FU 
Visit  
d 
1 d 
2 d 
3 d 
4 d 
5 d 
6 d 
7 d 
-7 d 
-6 d 
-5 d 
-4 d 
-3 d 
-2 d 
-1  d 
-7 d 
-6 d 
-5 d 
-4 d 
-3 d 
-2 d 
-1  
GODDESS (symptom scale)  X X X X X X X X X X X X X X  X X X X X X X  
BPI short form  X X X X X X X X X X X X X X  X X X X X X X  
PROMIS PF short form 10a plus 3  
additional items from the PROMIS 
item banks        X       X        X  
GODDESS  (impact scale)        X       X        X  
EORTC  
QLQ -C30       X       X        X  
PGIS        X       X        X  
PGIC                       X  
BPI = brief pain inventory;  d = day; EORTC QLQ -C30 = European Organisation for Research and Treatment of Cancer Quality of Life Ques tionnaire -Core 30; FU  = 
follow -up; GODDESS = GOunder/DTRF DEsmoid Symptom/Impact Scale; PGIC  = patient global impression of change ; PGIS = patient global impression of severity;  
PRO = patient -reported outcome; PROMIS PF= Patient -Reported Outcomes Measurement Information System Physical Function   
SpringWorks Therapeutics              Protocol NIR- DT-301 
      Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 77 Table 9 OLE Phase: PRO Assessment Administration Schedule  
PROs  Monthly PRO Assessments  
7 days prior to Cycle X  
(X = Cycles 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12)  
 Cycle 
X Quarterly PRO Assessments  
7 day prior to Cycle X  
(X = Cycles 13, 16, 19, 2 2 & on)  
 Cycle 
X Follow -Up PRO Assessments  
7 days prior to the FU visit 
FU 
Visit  
d 
-7 d 
-6 d 
-5 d 
-4 d 
-3 d 
-2 d 
-1 d 
-7 d 
-6 d 
-5 d 
-4 d 
-3 d 
-2 d 
-1 d 
-7 d 
-6 d 
-5 d 
-4 d 
-3 d 
-2 d 
-1 
GODDESS  
(symptom scale)  X X X X X X X  X X X X X X X  X X X X X X X  
BPI short form  X X X X X X X  X X X X X X X  X X X X X X X  
PROMIS PF short 
form 10a p lus 3 
additional items from 
the PROMIS item 
banks        X        X        X  
GODDESS   
(impact scale)        X        X        X  
EORTC QLQ -C30       X        X        X  
PGIS        X        X        X  
PGIC        X        X        X  
BPI = brief pain i nventory;  d = day; EORTC QLQ -C30 = European Organisation for Research and Treatment of Cancer Quality of Life Questi onnaire -Core 30; FU  = follow -
up; GODDESS = GOunder/DTRF DEsmoid Symptom/Impact Scale; PGIS = patient global impression of severity;  PRO = pa tient- reported outcome; PROMIS PF= Patient -
Reported Outcomes Measurement Information System Physical Function   
 
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 78 8.1.3.1.  GODDESS  
The GOunder/DTRF DEsmoid Symptom/Impact Scale (GODDESS) tool was developed by 
Memorial Sloan Kettering Cancer Center (MSKCC) and Desmo id Tumor Research Foundation 
(DTRF) to measure signs and symptoms of desmoid tumors and their impact on patients’ lives . 
The tool consists of items assessing the severity of key signs and symptoms (11 items), including pain, fatigue, swelling, muscle weakness, difficulty moving, and tumor location- specific 
signs/symptoms; the impact of these symptoms on functioning and daily living (17- items).  
The signs and symptoms items are evaluated on an 11-point numeric rating scale ( NRS ) from 0 -
10 to measure severity  from “none” to “as bad as you can imagine,” with a 24-hour recall period. 
The impact items are evaluated either on an 11 -point NRS to measure severity, or a 5-point 
Likert Scale ranging from “none of the time” to “all of the time” to measure frequency, with a 7 -
day recall period.  
8.1.3.2. BPI Short Form 
The Brief Pain Inventory (BPI) short f orm is a measurement tool for assessing clinical pain and 
allows patients to rate the severity of their pain and the degree to which their pain i nterferes with 
common dimensions of feeling and function. T he short form version of the BPI consists of 
9 questions and will utilize an 11-point NRS from 0-10 with a 24-hour recall period.  8.1.3.3. PROMIS PF Short Form 10a Plus 3 Additional Items from PROMIS Item Banks   
The Patient -Reported Outcomes Measurement Information System Physical Function ( PROMIS 
PF) instruments measure self -reported capability rather than actual performance of physical 
activities. This includes the functioning of one’s upper extremit ies (dexterity), lower extremities 
(walking or mobility), and central regions (neck, back), as well as instrumental activities of daily 
living, such as running errands.  
The PROMIS PF short form 10a version 2.0 will be used in this study with a 7- day recal l period. 
This PRO assessment consists of 10 questions and was constructed with a focus on representing 
the range of the trait and the content of the item bank, as well as mapping the questions in the instrument to qualitative evidence of the physical function concepts important to patients. To supplement the PROMIS PF short form 10a, 3 additional questions representing other elements of physical function found to be important to patients, were selected from the PROMIS Physical Function, Upper Extremity, an d Ability to Participate item bank s. 
8.1.3.4. EORTC QLQ-C30  
The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 ( EORTC QLQ -30) is a quality of life (QoL) questionnaire used for 
assessing the health -related quality  of life of cancer patients participat ing in international clinical 
trials.  
EORTC QLQ -C30 version 3.0 will be used in this study with a 7 -day recall period. It consists of 
30 questions overall with a 4-point scale and incorporates 5 functional scales (physi cal, role, 
cognitive, emotional and social), 3  symptom scales (fatigue, pain, and nausea and vomiting), a 
global health status/QoL scale, and a number of single items assessing additional symptoms 
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 79 commonly reported by cancer patients (dyspnea, loss of appetite, insomnia, constipation and 
diarrhea) and perceived financial impact of disease.  
8.1.3.5. PGIS  
The Patient Global Impression of Severity  (PGIS ) is a single item scale that evaluates the 
participant’s perception of the overall severity of their  desmoid related symptoms over the past 
week  on a 4 -point scale ranging from “none” to “severe.” The PGIS will have a 7 -day recall 
period. 
8.1.3.6. PGIC  
The Patient Global Impression of Change ( PGIC ) is a single item scale that evaluates the 
participant’s perception of the overall change in their overall status sinc e the start  of the study 
treatment on a 7-point scale ranging from “very much better” to “very much worse.” The PGIC 
will have a 7 -day recall period.  
8.1.4. Tumor Biopsy  
For a ll participants: 
• Tumor samples will be used to reconfirm desmoid diagnosis for all parti cipants. 
However, participant enrollment will not be dependent on central review.  
• Additionally, archival or fresh tumor biopsies collected at screening will be used for somatic genotyping (unless prohibited by local regulations) (Section 8.7).  
• Ideally, 2 core s will be collected during the screening period (prior to study treatment 
initiation).  
• Archival tissu e may be used in place of fresh tumor biopsies only if the tissue has been 
well preserved and there is a sufficient amoun t of tissue available
1.  
• When applicable, fresh tumor biops ies must be taken  after  MRI  if both of these 
assessments occur at the same visit.  
 For participants consenting to optional pharmacogenomics research: 
• For participants consenting to the optional pha rmacogenomics research, an additional 
tumor biopsy will be collected at the EOT visit.  
• Refer to Section  8.8 for details on biomarkers. 
1Tumor specimens will be stored as formalin -fixed , paraffin embedded (FFPE) blocks at room 
temperature. If the FFPE block cannot be made available, approximately 20 unstained slides 
should be used in place of 2 cores.   
Instructions for handling, processing and shipment of tumor biopsies are provided in the central laboratory manual.
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 80  
 Safety Ass essments  
Planned time points for all safety assessments are provided in the SoA (Section 1.3) . 
8.2.1. Demographics Data and Medical History 
Demographic data will include age or date of birth, sex, and self- reported race/ethnicity.  
Medical history includes any history of clinically significant disease, surgery, or cancer history; 
reproductive status (i.e., WOCBP or no WOCBP ); history of alcohol consumption (i.e., presence 
or absence); and  collect ion of concomitant medications . For wo men, the medical history should 
also include a detailed menstrual history including the date of the last menstrual cycle and any history of amenorrhea, menstrual irregularities, or infertility . Any history of infertility in male 
participants should also be recorded as part of the medical history.  
Cancer history will include an assessment of prior surgery, prior radiotherapy, prior drug therapy, including start and stop dates, best response and reason for discontinuation. Radiographic studies performed prior to study entry may be collected for review by the investigator. 
8.2.2. Physical Examinations and Eastern Cooperative Oncology Group Performance 
status  
Physical examinations, as well as height/weight, and assessment of ECOG performance status 
(Section  10.7) will be required throughout the study as described  in the SoA. Height to be 
measured at screening only. 
A physical examination should include, at a minimum, assessments of the Skin, Cardiovascular, 
Respiratory, Gastrointestinal and Neurological systems.  
Investigators must pay special attention to clinical signs related to previous serious illnesses , and 
changes from baseline will be recorded in the source document ation . New or worsened clinically 
significant abnormalities  must be recorded as AEs on the eCRF page.  
Refer to Section  8.3 regarding AE definitions and reporting and follow- up requirements.  
8.2.3. Electrocardiograms  
Triplicate 12- Lead ECG s readi ngs ( approximately  2-3 minutes apart and averaged) will be 
obtained using an ECG machine that automatically calculates the heart rate and measures PR, 
QRS, QT, and QTcF intervals , at the timepoints described in the SoA. Prior to the ECG 
assessments, p articipants should rest in a semi -recumbent supine position for at least 5 minutes.  
For safety monitoring purposes, the investigator must review, sign, and date all ECG tracings. Paper or electronic copies of ECG tracings will be kept as part of the source document ation  at 
the site.   
Refer to Section  7.1.2 for QTc F withdrawal criteria and any additional QTc F readings that may 
be necessary.  
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 81 8.2.4. Vital Signs  
Body temperature, pulse rate, respiratory rate, and blood pressure will be assessed  throughout the 
study as described  in the SoA.  
Blood press ure and pulse measurements will be assessed with a completely automated device. 
Manual techniques will be used only if an automated device is not available.  
Blood pressure , respiratory rate, pulse rate and b ody temperature should be preceded by at least 
5 minutes of rest for the participant in a quiet setting without distractions (e .g., television, cell 
phones). 
8.2.5. Clinical Safety Laboratory Assessments 
All protocol- required, central  laboratory assessments  as defined in  Section 10.2, must be 
conducted in accordance with the central laboratory manual and the SoA. Please note, ALL 
participants , regardless of their gender or childbearing potential, are required to have hormone 
level  assessments per the SOA (Section 1.3). 
In the event of a public health emergency, clinical laboratory assessments may be performed locally with results and local laboratory normal values entered into the eCRF. 
The investigator must review the central laboratory re port, document this review, and record any 
clinic ally relevant changes occurring during the study on the AE page of the eCRF. The 
laboratory reports must be filed with the source documents. Clinically significant abnormal 
laboratory findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. 
All laboratory tests with abnormal values considered to be clinically significant during 
participation in the study or within 30 days after the last dose of study treatment  should be 
repeated until the values return to normal or baseline or are no longer considered clinically 
significant by the investigator or m edical monitor. If such values do not return to normal/baseline 
within a period of time judged reasonable by the investigator, the etiology should be identified,  
and the sponsor notified.  
If laboratory values from non-protocol specified laboratory assessments performed at the 
institution’s local laborato ry require a change in participant management or are considered 
clinically significant by the investigator (e .g., SAE or AE or dose modification), then the resul ts 
must be recorded in the e CRF , and the local laboratory report must be assessed by the 
investigator and included in the participant’s medical records . 
8.2.6. Pregnancy Testing  
Pregnancy testing will only be required for women of childbearing potential ( WOCBP ) (refer to 
Section 10.4 for definition of WOCBP and additional details on contraceptive guidelines and collection of pregnancy information).  
A negative s erum pregnancy test at screening and a negative urine pregnancy test at baseline 
(prior to first dose of double-blind study treatment ) will be required to  meet study ent ry criteria.   
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 82 Monthly urine pregnancy tests will be required for WOCBP throughout the duration of the 
double-blind and OLE phases. In between study visits, participants will be required to return to 
the site  for a monthly urine pregnancy test. If it is more convenient to the participant, they may 
alternatively visit a local laboratory  that has been pre-approved by the sponsor (or designee) for 
this assessment  (refer to study reference manual for additional detail). 
Serum pregnancy tests may be conducted in place of urine pregnancy tests throughout the study if required by local regulations.  
8.2.7. Monthly Wellness Check s 
Monthly telephone or email contact is required throughout the double-blind and OLE phases of 
the study and m ay be replaced by a face- to-face interaction when study visits occur and  the 
information can be obtained during the vi sit.  
A copy of the telephone report or email must be documented in the source documentation. Email must not replace direct follow -up by phone or in -clinic  visits  for clinical ly significant AEs  or 
other emergent issues.  Adverse events and concomitant medic ations changes will be captured in 
the associated eCRFs.  
 Adverse Events and Serious Adverse Events  
The definitions of an AE, SAE , adverse reaction (AR), suspected adverse reaction (SAR), and a 
suspected unexpected serious adverse reaction (SUSAR)  can be found in Section 10.3. 
An AE will be reported by the participant (or, when appropriate, by a caregiver, surrogate, or the participant's legally a uthor ized representative).  
The investigator and any qualified designees are responsible for detecting, documenting, and recording events that meet the definition of an AE or SAE and remain responsible for following up on AEs that are serious, considered related to the study treatmen t or study procedures, or that 
caused the participant to discontinue the study treatment  (Section 7). 
8.3.1. Time Period and Frequency for Collecting AE a nd SAE Information  
All SAEs and AEs w ill be collected from the time of signing ICF until 30 days after the last dose 
of study treatment  at the time points specified in the SoA (Section  1.3) throughout the double-
blind and OLE study phases. 
Medical occurrences that  begin before the start of study treatment  but after obtaining informed 
consent will be recorded as AEs . 
All SAEs wi ll be recorded and reported to the sponsor’s safety group (‘Safety’) immediately and 
under no circumstance should this exceed 24 hours, as i ndicated in  Section 10.3.4. The 
investigator will submit any updated SAE data to Safety within 24 hours of it being available. 
To report the SAE, a paper SAE form must be completed, scanned and emailed  to Safety  at 
PV@ springworkstx.com. The paper SAE form can be found in the study reference manual. Refer 
to Section  10.3.4 for more details on reporting SAEs to the sponsor. 
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 83 Refer to Section 8.3.6 for details on AEs of special interest (AESI) reporting guidelines. 
Investigators are not obligated to actively seek AEs and/ or SAE s after conclusion of the study 
participation . However, if the investigator learns of any SAE, including a death, at any tim e after 
a participant has been discharged from the study, and considers the event to be reasonably related 
to the study treatment  or study participation, the investigator must promptly notify the sponsor. 
8.3.2. Method of Detecting AEs and SAEs  
The method of recording, evaluating, and assessing causality of A Es and/or SAE s, and the 
procedures for completing and transmitting SAE reports are provided in Section 10.3.3. 
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open-ended and 
non-leadin g verbal questioning of the participant is the preferred method to inquire about 
AE occurrences . 
8.3.3. Follow- up of AEs and SAEs  
After the initial AE/SAE  report, the investigator is required to proactively follow each participant 
at subsequent visits/contacts. A ll SAEs  and adverse events of special interest (AESI) (as defined 
in Section 8.3.6) will be followed until resolution, stabilization, the event is otherwise explained, or the participant is lost to follow -up (as defined in Secti on 7.3).  
Within 24 hours of receipt of SAE follow-up information, the investigator must complete a paper follow-up SAE form and submit any supporting documentation if requested to Safety . Further 
information on follow-up procedures is given in Section 10.3.3. 
8.3.4. Regulatory Reporting Requirements for SAEs  
Prompt notification by the investigator to the sponsor of a n SAE is essential so that legal 
obligations and ethical responsibilities towards the safety of participants and the safety of a study 
treatment  under clinical investigation are met.   
The sponsor has a legal responsibility to notify both the local regulatory authority and other regulatory agencies about the safety of a study treatment under clinical investigation. The sponsor will comply with country- specif ic regulatory requirements relating to safety reporting to 
the regulatory authority, Institutional Review Boards (IRB)/Independent Ethics Committees (IEC) , and investigators.  
Investigator safety reports must be prepared for S uspected Unexpected Serious Adverse 
Reactions according to local regulatory requirements and sponsor policy and forwarded to investigators as necessary.   
An investigator who receives an investigator safety report describing an SAE or other specific safety information (e.g., summary or listing of SAEs) from the sponsor will review and then file it along with the Investigator’s Brochure and will notify the IRB/IEC, if appropriate according to local requirements . 
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 84 8.3.5. Pregnancy  
Details  of all pregnancies in female participants and female partners of male participants will be 
collected after the start of study treatment  and until 30 days after the last dose of study treatment . 
If a pregnancy is reported, the investigat or must inform the sponsor within 24 hours of learning 
of the pregnancy by completing a paper pregnancy form and submitting to Safety  (refer to 
Section  10.4 for reporting details).  
Abnormal pregnancy outcomes (e.g., spontaneous abortion, fetal death, stillbirth, congenital 
anomalies, ectopic pregnancy) are considered SAEs.  
8.3.6. Adverse Events of Special Interest  
Adverse events of special interest (AESI)  are selected non -serious and serious AEs that must be 
reported regardless of relationship to study treatment. Refer to  Table 10 for the AESIs identified 
for this study. AESIs will be followed until resolution or return to baseline.  
Serious AESIs must be reported to Safety  immediately and under no circumstance should this 
exceed 24 hours, as indicated in Section 10.3.4. 
Non-serious AESIs must be reported to the sponsor (by entering the AESI into the eCRF and 
submitting a paper SAE/AESI report form to Safety) as soon as possible, but no later than 
5 business days of awareness .  
Following medical evaluation , sites may be contacted to provide supplemental information (such 
as medical history, concomitant medications, investigations, etc.) about the event. Please note 
this table lists known AESI; additional events may be identified during the course of the study.  
Table 10 Adverse Events of Special Interest (AESI)  
Skin Rash (reported as AESI if clinically significant Grade 2 and all Grade ≥  3, per 
CTCAE v. 5 ) 
1. Maculopapular rash  
2. Pruritic rash  
3. Erythematous rash 
4. Folliculitis  
5. Hidradenitis suppurativa 
Elevated Liver Enzymes (reported as AESI if Grade ≥ 2, per CTCAE v. 5 ) 
1. AST  
2. ALT  
3. Alkaline Phosphatase 
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 85 Electrolyte Insufficiency (reported as AESI if Grade ≥ 3, per CTCAE v. 5 ) 
1. Hypophosphatemia 
2. Hypokalemia 
3. Hypomagnesemia 
Drug Reactions (reported as AESI for any grade) 
1. Allergic reaction  
2. Anaphylaxis 
Reproductive System Disorders (reported as AESI if ≥  2, per CTCAE v. 5)1 
1. Amenorrhea 
2. Premature menopause / Primary ovarian insufficiency  
1  Females reporting AEs/AESIs/SAEs of primary ovarian insufficiency (POI) and/or amenorrhea will have hormone 
levels assessed every 3 months until event resolution (or for at least 90 days after discontin uing study treatment).  
 Treatment of Overdose  
For this study, any dose of study treatment  greater than 450 mg  daily dose of study treatment  
within a 24-hour period will be considered an overdose. 
In the event of an overdose, the investigator will: 
1. Conta ct the m edical m onitor immediately  (refer to Section 10.10.3 for contact 
information). 
2. Closely monitor the participant for any AE/SAE and laboratory abnormalities for at least  
4 days. 
3. Document the quantity of the excess dose as well as the duration of the overdose in the 
eCRF.  
Decisions regarding dose interruptions or modifications will be made by the investigator in consultation with the m edical monitor based on the clinical evaluation of the participant. 
 Pharmacokinetics  
• Serial and trough PK samples will be collected during the study, as described in the SoA 
(Section  1.3) t o inform development of a population PK model of nirogacestat. Refer to 
Table 11 for PK blood draw schedule.  To minimize the amount of time a participant is 
required to remain onsite during a public health emergency such as COVID-19, the 3-
hour C1D1 PK sample may be omitted with prior medical monitor / sponsor approval. 
• Whole blood samples of approxima tely 4 mL each will be collected for measurement of 
serum  concentrations of nirogacestat  as specified in the SoA . 
• The actual date and time (24-hour clock time) of each sample will be recorded. 
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 86 • Instructions for the collection , handling, and shipment of phar macokinetic  samples will 
be in  the central laboratory manual . 
• Samples will be used to evaluate the PK of nirogacestat  and associated metabo lites. 
• Genetic analyses will not  be performed on these samples.  
• Participant confidentiality will be maintained.  
• Drug  concentration information that would unblind the study will not be reported to 
investigative sites or blinded personnel until the study has been unblinded.  
• Any changes in the timing or addition of time  points for any planned study assessments 
must be documented and approved by the relevant study team member and then 
archived in the sponsor and site study files but will not constitute a protocol amendment. The IRB/IEC will be informed of any safety issues that require alteration of the safety monitoring scheme or amendment of the ICF.  
Table 11 PK Blood Draw Schedule  
Visit  Timepoint  
Cycle 1 Day 13 Serial PK1 (pre-dose, 0.25 -, 0.5-, 1-, 1.5-, 2-, and 3 -hour post dose ) 
Cycle 1 Day 83 Trough PK2 (pre-dose)  
Cycle 1 Day 153 Trough PK2 (pre-dose)  
Cycle 1 Day 223 Trough PK2 (pre-dose)  
Cycle 2 Day 283 Trough PK2 (pre-dose)  
Cycle 4 Day 1 and  
Every 3 c ycles  Trough PK2 (pre-dose)  
1Serial PK:  
• Double -blind phase: required for all participants.  
• OLE phase: required for participants who were p reviously randomized to placebo in the double -blind phase 
only.  
• All efforts will be made to obtain the pharmacokinetic samples at the exact nominal time relative to dosing. 
However, samples obtained within 10% of the nominal time (e.g., within 6 minutes of  a 60- minu te sample) 
from dosing will not be captured as protocol deviations if the exact time of the sample collection is noted 
on the source document and eCRF.  
2Trough PK:  
• Required for all participants.  
• The evening before the study visit, participant wil l record the exact time study treatment was taken in the 
home ePRO device. Participant will not take their planned morning dose the day of the study visit. The morning dose will be taken following the pre -dose PK blood draw.  
3OLE C ycle 1 and 2 PK assessmen t are not applicable for participants who were previously randomized to 
nirogacestat in the double -blind phase.  
 Pharmacodynamics  
Optional blood and tumor samples will be collected for the evaluation of pharmacodynam ic 
biomarkers (refer to Section 8.8).  
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 87 
 Genetics  
• A blood sample and tumor biopsy (arc hival sample may be used ; Section 8.1.3) will be 
collected from all participants (unless prohibited by local regulations) prior to the first 
dose of study treatment to perform genotyping for germline and somatic mutation in APC and  CTNNB1 genes to determine the frequency of these mutations in desmoid 
tumors. Response to study treatment based on mutational status may be evaluated. 
• In the event of DNA e xtraction failure, a replacement genetic blood sample may be 
requested from the par ticipant.  
• Details on processes for collection and shipment and destruction of these samples can be found in the central laboratory manual. 
• Samples may be stored for a maximu m of 10 years (or according to local regulations) 
following the last participant’s last study visit at a facility selected by the sponsor to enable further analysis of biomarker responses to nirogacestat. 
• Refer to Section 10.5 for information regarding genetic research. 
 Biomarkers  
• Participation is optional for genetic research and those who do not wish to participate may still enroll in the study.  
• The following optional tumor and blood samples for biomarker research will be collected from consenting participants only, as specified in the SoA (Section 1.3). 
o Before study treatment initiation samples : 
 Pharmacogen omic  blood sample  
 Archival or fresh tumor tissue sample (Section 8.1.3) 
o After study treatment initiation sample: 
 Fresh tumor tissue sample 
• Analyses may include the following: (1) expression analysis of genes and proteins 
associated with the Notch pathway, (2) molecular analysis of genomic alterations 
associated with Notch signaling (for example, Notch 1 mutations), (3) levels of NICD, (4) molecular profiling of tumor cells to identify potential markers of response/resistance to nirogacestat .  
• Additional biomarkers may also be measured, based on eme rging clinical and literature 
data pertaining to Notch biology. Full details regarding collection, processing, storage and shipping of all PD biomarker samples will be provided in the central laboratory manual.  
• S
amples may  be tested for expression on Notch pathway genes to evaluate their 
association with the observed clinical responses (e.g., PFS or ORR) to study treatment . 
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 88 • Samples may  be stored for a maximum of 10 years (or according to local regulations) 
following the last participant’s last study visit a t a facility selected by the sponsor to 
enable further analysis of biomarker responses to nirogacestat. 
8.8.1. RNA Transcriptome Research
  
Transcriptome studies may be conducted using microarray and/or alternative equivalent 
technologies, which facilitates the si multaneous measurement of the relative abundances of 
thousands of RNA species resulting in a transcriptome profile for each blood and tumor  sample. 
This will enable the evaluation of changes in transcriptome profiles that may correlate with biological re sponse relating to desmoid tumors or the action of nirogacestat . 
The same samples may also be used to confirm findings by application of alternative technologies. 
8.8.2. RNA Expression Research of a Subset of RNA 
 Species  
RNA expression studies may be conducted using quantitative reverse transcriptase polymerase chain reaction, and/or alternative equivalent technologies, which can facilitate the simultaneous measurement of the relative abundances of RNA species resulting in an RNA expression profile for each blood and tumor  sample. The RNAs assay ed may be those involved with the 
pathogenesis of desmoid; the absorption, distribution, metabolism, or excretion of nirogacestat ; 
or in the participant’s response to nirogacestat . In addition, continuing research may identify 
other proteins or regulatory RNAs that may be involved in the response to nirogacestat  or the 
pathogenesis of desmoid. The RNAs that code for these proteins and/or regulatory RNAs may also be studied. This will enable the evaluation of changes in RNA expression profiles that may correlate with biological response relating to desmoid or the action of nirogacestat . 
8.8.3. Proteome Research
  
Plasma and tumor proteome studies may be performed by 2-D gel separation, and/or peptide mass mapping, or an alternative equiva lent procedure. Proprietary algorithms and standard 
statistical techniques, such as analysis of variance and analysis of covariance, may  be used to 
identify individual proteins exhibiting statistically significantly different changes in their levels between sam ples and/or between groups of samples. These differentially expressed proteins will 
be identified by mass spectrometry or equivalent technology. This will enable the evaluation of changes in proteome profiles that may correlate with biological respons e relating to desmoid and 
medically related conditions or the action of nirogacestat . 
The samples may also be used to confirm findings by application of alternative technologies. 
 Health Economic s OR Medical Resource Utilization and Health 
Economic s 
Health E conomics/Medical Resource Utilization and Health Economics parameters are not 
evaluated in this study. 
 
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 89 9. STATISTICAL CONSIDERATIONS  
 Statistical Hypotheses  
Nirogacestat treatment  will increase the  time to progression compared to placebo in participants 
with desmoid tumors.  
The following hypothesis will be tested using a stratified log- rank test:  
H0: PFS(t)placebo = PFS(t)nirogacestat  
Ha: PFS(t)placebo < PFS(t) nirogacestat  
where PFS(t) represents the progression free survivorship function at time, t 
 Sample Size Determination  
The study sample size is based on the PFS endpoint. A total of 51 events will provide 90% 
power and a 1 -sided type 1 error rate of 0.025 (1 -side hypothesis) to detect a dif ference between 
nirogacestat and placebo, assuming the median PFS in the nirogacestat group is 20 months and 
8 months in the placebo group (corresponding to a hazard ratio of 0.4 relative to placebo). 
Assuming a 10% dropout rate and a 20% spontaneous regression rate, 118 participants will be 
randomized in a 1:1 ratio to observe the required number of events.  
The assumptions selected for sample size estimate are based partially on the results reported in 
Gounder, 2018. As outlined in Section 2.2.3, a randomized double-blind P hase 3 study was 
conducted in desmoid participants comparing sorafenib to placebo. The study established a median  PFS of 11.3 months for the placebo participants; but the population enrolled wa s a more 
heterogeneous desmoid population with only approximately 43% of the placebo participants having progressing tumors. The NIR- DT-301 study will only enroll progressing participants; 
therefore , a shorter median of 8 months PFS for placebo was used to calculate the sample size.  
 Populations for Analyses  
For purposes of analysis, the following populations are defined: 
Population Description  
Enrolled  All participants who sign the ICF . 
Intent- to-Treat (ITT)  The Intent- to-Treat (ITT) P opulation will consist of all 
participants who are enrolled and randomized to study treatment  
(nirogacestat or placebo) . Participants will be an alyzed according 
to the treatment  they were randomized  to and the strata to which 
they have been assigned. Pa rticipants  who were randomized but 
did not subsequently go on to receive study treatm ent are 
included in the ITT population. 
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 90 Population Description  
Per-Protocol Population The Per -Protocol Population will be defined for supportive 
analysis and will consist of those participants who have no major 
protocol deviations, including mis-randomizations or mis -
stratific ations . Participants  will be analyzed according to the 
study treatment  actually received  (i.e., at least 1 dose of the study 
treatment ). 
Safety  The S afety Population will consist of a ll participants randomly 
assigned to study treatment and who take at least 1 dose of study treatment . Participants will be analyzed according to the 
treatment  they actually received . 
 Statistical Analyses  
The statistical analysis plan (SAP) will be developed and finalized before database lock and will describe the particip ant populations to be included in the analyses, and procedures for accounting 
for missing, unused, and spurious data. Detailed methodology for summary and statistical analys es of the data collected in this study will be documented. In addition, strategies on dealing 
with protocol deviations due to C OVID -19 will be detailed in the SAP.  This section is a 
summary of the planned statistical analyses of the primary and secondary endpoints. 
9.4.1. Efficacy Analyses 
Endpoint  Statistical Analysis Methods 
Primary  The primary efficacy endpoint is PFS, which is defined as the time from 
randomization until the date of assessment of progression or death by any cause (whichever occurs first) . Progression will be determined 
radiographically by independent, blinded C entral Imagin g Review using 
RECIST  v1.1 ( Eisenhauer, 2009) as described in Section 8.1.1 or clinically by 
an investigator whose assessment is qualified  via independent blinded central 
clinical review as described in Section  8.1.2. Participants who have not 
progressed or died will be censored at the date of the last response assessment. Participants who do not have any response assessments will be censored at the date of randomization. Se nsitivity analysis utilizing alternative censoring 
methods will be described in the SAP.  
The primary efficacy endpoint, PFS, will be analyzed using a 1-sided 
stratified log-rank test to compare the distributions between nirogacestat and 
placebo at a 1 -sided alpha level of 0.025.  
The primary analysis of PFS will be performed on the ITT Population, 
defined as all participants who are randomized to study treatment  after the 
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 91 required number of PFS events have been observed. Participants  in the ITT 
Population will be analyzed in the study treatment  arm to which they are 
randomized. 
Progression- free survival data will be summarized with Kaplan -Meier 
methodology. Two-sided 95% CIs for the median time- to-event in each study 
treatment  arm, th e event rates at specif ic time points, and the hazard rate ratio 
will be computed. 
There will be a C entral Reader Agreement provided to Central Imaging 
Review and an Imaging R eview Charter provided to the sponsor that will 
clearly detail the entire process.  
Secondary  Secondary endpoints include: 
• Overall response rate, defined as the proportion of participants with 
CR + PR assessed via central reader using RECIST v1.1; 
• Change in tumor volume from baseline as assessed by MRI volumetric; 
• Change in PRO measures ( GODDESS [symptom scale], BPI short 
form,  PROMIS PF 10a short form plus 3 additional items from the 
PROMIS item banks, GODDESS [ impact scale ] and EORTC QLQ -
C30) from baseline; and  
• D
uration of response for participants whose best response is CR or PR. 
In order to preserve th e total type I error for the study, secondary endpoints 
will be evaluated in a hierarchical fashion according to the order that will be 
outlined in the SAP. Testing will only be performed if the null hypothesis of the primary endpoint is rejected. 
Overall response rate will be calculated for each treatment arm and the proportions will be compared using the Cochran -Mantel -Haenszel test 
stratified by randomization factor. 
Duration of response will be calculated as 
the time from the first response until progression or the last date of response assessment and will be summarized descriptively.  
Change in tumor volume assessed by MRI will be analyzed using a repeated measures model adjusting for baseline tumor volume and  randomization 
strata .  
The change from basel ine in total score for PRO assessment endpoints listed 
above will be analyzed using a repeated measures mixed model adjusting for fixed and random factors. Total scores will be calculated according to the published guidance for each specific scale if avail able. In addition, the change 
from baseline in the QLQ-C30 questions regarding rating of overall health 
and overall quality of life will be compared between treatment groups. The 
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 92 total scores and sub -scores at each time -point will be s ummarized with 
descri ptive statistics and displayed graphically.  
All data collected after crossover to nirogacestat (for participants who were 
previously randomized to placebo in the double-blind phase and receive nirogacestat in the OLE phase after radio graphic disease progr ession) will be 
analyzed and reported separately.  
Exploratory Will be described in the SAP finalized before database lock . 
9.4.2. Safety Analyses 
All safety analyses will be performed on the Safety Population. 
Endpoint  Statistical Analysis Methods 
Safety Endpoints  The safety and tolerability of nirogacestat will be evaluated by means of study treatment -related AE  reports, physical examinations, and laboratory safety 
evaluations. Adve rse events will be graded by the investigator according to 
the CTCAE v5.0 and coded using the Medical Dictionary for Regulatory Activities.  
The focus of AE summaries will be on Treatment Emergent A Es, those with 
initial onset or increasing in severity after the first dose of study treatment  
through 30 days after the last dose of study tr eatment . The number and 
percentage of participants who experienced any AE, SAE, treatment related 
AE, and treatment related SAE will be summarized according to worst toxicity grades.  
Clinical laboratory parameters, vital signs, and ECG parameters will be 
summarized by treatment group and study visit. Descriptive statistics for the actual values (and/or change from baseline) or frequencies of clinical laboratory parameters over time. Incidence of abnormalities and shift tables will be presented.  
9.4.3. Other Analyses  
Sensitivity analyses, pharmacokinetic, pharmacodynamic, and biomarker exploratory analyses will be described in the statistical analysis plan finalized before  database lock. The population 
PK analysis and pharmacodynamic analyses will be present ed separately from the main clinical 
study report. 
 Interim Analyses  
One interim analysis may be performed after 26 PFS events (corresponding to approximately 50% of the total events) have been observed. Progression will be determined by independent, blinded C entral Imaging R eview  determination for this analysis . A Lan -DeMets alpha-spending 
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 93 function with an O’Brien-Fleming stopping boundary will be used for the interim analysis of 
PFS. The study may be stopped for overwhelming efficacy or futility.  
At the interim analysis, the study may be stopped for futility if the observed hazard ratio is 
greater than 0.91 or stopped for overwhelming efficacy if the hazard ratio is less than or equal to 0.31 in favor of nirogacestat. This is equivalent to a Z- score greater than -0.252 for futility or less 
than -2.96 for efficacy.  The alpha spent for the interim testing is 0.002 and the remaining 0.023 
alpha will be allocated to the final analysis.   
The analysis will be  conducted by an independent committee consisting of at least 1 statistician. 
Results of the interim analysis will not be disseminated among investigators or anyone directly involved in study conduct. 
The i nterim analysis plan will describe the planned interim analyses in greater detail . 
9.5.1. Data Monitoring Committee  
The study will utilize an independent data monitoring committee ( DMC ) and will opera te 
according to an established C harter. The committee will be composed of approximately 3 to 
4 members including physicians knowledgeable in the treatment of desmoid tumors and an 
independent statistician  knowledgeable about statistical methods for clinical trials and sequential 
analysis  of trial data . Sponsor employees will not be voting members of the DMC. The DMC 
will be responsible for ongoing monitoring of the unblinded safety and benefit/risk profile of participants  in the study. Reviews will include aggregate safety, targeted medic al events of 
special interest, serious AE dat a and aggregate endpoint data. 
Following each data review, the DMC may recommend 1) no changes to the study are needed, 2) changes to the protocol or informed consent based on clinical safety findings, or 3) early termination of the study based on safety analyses. The recommendations made by the DMC to alter the conduct of the study will be forwarded to the sponsor for final decision. Additionally, the DMC may be asked to assist the sponsor in evaluating the impact of data from other company-sponsored studies or other published studies.   
The DMC C harter will outline the frequency of meeti ngs and detail all aspects of DMC’s scope 
of review  and procedures . 
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 94 10. SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS  
 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations  
10.1.1. Regulatory and Ethical Considerations 
This study will be conducted in accordance with the protocol and with the following: 
• Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical Sciences International Ethical Guidelines;  
• Applicable  International Council for Harmonisation (ICH) Good Clinical Practice (GCP) 
Guidelines ; and  
• Applicable laws and regulations. 
The protocol, protocol amendments, informed consent form ( ICF), Investigator Brochure, and 
other relevant documents (e.g., advertisements) must be submitted to an institutional review board/independent ethics committee ( IRB/ IEC) by the investigator and reviewed and approved 
by the IRB/IEC before the study is initiated.  
Any amendments to the protocol will require IRB/IEC approval before implementation of 
changes made to the study design, except for changes necessary to eliminate an immediate hazard to study participants. 
The investigator will be responsible for the following: 
• Providing written summaries of the status of the study to the IRB/IEC annually or more frequently in accordance with the requirements, policies, and procedures established by the IRB/IEC ; 
• Notifying the IRB/IEC of serious adverse event  or other significant safety findings as 
required by IRB/IEC procedures ; and  
• Providing oversight of the conduct of the study at the site and adherence to r equirements 
of 21 Code of Federal Regulations ( CFR ), ICH guidelines, the IRB/IEC, European 
regulation 536/2014 for clinical studies (if applicable), and all othe r applicable local 
regulations. 
10.1.2. Financial Disclosure  
Investigators and sub- investigators will p rovide the s ponsor with sufficient, accurate financial 
information as requested to allow the s ponsor to submit complete and accurate financial 
certification or d isclosure statements to the appropriate regulatory authorities. Investigator s are 
responsible for providing information on financial interests during the course of the study and for 1 year after completion of the study. 
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 95 10.1.3. Informed Consent Process  
• The investigator or their representative will explain the nature of the study to the 
participant or their legally authorized representative and answer all  questions regarding 
the study. 
• Participants must be informed that their participation is voluntary. Participants  will be 
required to sign a statement of informed consent that meets the requirements of 
21 CFR  50, local regulations, ICH guidelines, Health Insurance Portability and 
Accountability Act requirements, where applicable, and the IRB/IEC or study center. 
• The medical record must include a statement that written informed consent was obtained before the participant was enrolled in the study and the date the written consent was obtained. The authorized person obtaining the informed consent must also sign the informed consent form ( ICF). 
• Participants mu st be re-consented to the most current version of the ICF(s) during their 
participation in the study as required by the IRB/I EC. 
• Consent is required for the collection of pharmacogen omic  samples ( blood and tumor 
biops ies). 
• A copy of the ICF(s) must be provided to the participant or the participant’s legally authorized representati ve. 
10.1.4. Data Protection 
• Participants will be assigned a unique identifier by the sponsor. Any participant records or dataset s that are transferred to the sponsor will contain the identifier only; participant 
names or any information which would make the participant identi fiable will not be 
transferred.  
• Participant s must be informed that their  personal study- related data will be  used by the 
sponsor in accordance with local data protection law. The level of disclosure must also be explained to the participant. 
• Participant s must be informed that their  medical records may be examined by Clinical 
Quality Assurance auditors or other authorized personnel appointed by the sponsor, by appropriate IRB/IEC members, and by inspectors from regulatory authorities. 
10.1.5. Committees Structure  
The study will utilize an independent data monitoring committee (DMC) and will operate according to an establi shed C harter (Section 9.5.1 ). In addition, a steering committee will be 
established to support the development of nirogacestat for the treatment of desmoid tumor/aggressive fibromatosis. The purpose and provisions of the DMC  will be specified in the 
DMC C harter.  
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 96 10.1.6. Data Quality Assurance 
• All participant data relating to the study will be entered  into the electronic case report 
form s (eCRF s) unless transmitted to the sponsor or designee electronically (e.g., 
laboratory data). The investigator is responsible for verifying that data entries are 
accurate and correct by electronically signing the e CRF.  
• The investigator must maintain accurate docu mentation (source data) that supports the 
information entered in the e CRF.  
• The investigator m ust permit study -related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct a ccess to source data documents.  
• Monitoring details describing strategy methods, responsibilities and requirements, including handling of noncompliance issues and monitoring techniques (central, remote, or on- site monitoring)  will be indicated in the monitoring plan to ensure the protocol 
and GCP is foll owed . 
• The sponsor or designee is responsible for the data management of this study including quality checking of the data. 
• The sponsor assumes accountability for actions delegated to other individuals (e.g., Contract Research Organizations).  
• Study monitors will perform ongoing source data verification to confirm that data entered into the e CRF by authorized site personnel are accurate, complete, and 
verifiable from source documents; that the safety and rights of participants are being protected; and that the study is being conducted in accordance with the currently approved protocol and any other study agreements, ICH GCP, and all applicable regulatory requirements. 
• Records and documents, including signed ICFs, pertaining to the conduct of this study must be retained by the investigator according to specifications in the ICH guidelines, local regulations, or as specified in the clinical trial agreement, which ever is longer. No 
records may be destroyed during the retention period without the written approval of the sponsor. No records may be transferred to another location or party without written notification to the sponsor. 
10.1.7. Source Documents  
• Source documents provide evidence for the existence of the participant and substantiate the integrity of the data collected. Source documents are filed at the investigator’s site.  
• Data reported in the eCRF that ar e transcribed from source documents must be 
consistent with the source documents or the discrepancies must be explained. The investigator may need to request previous medical records or transfer records, depending on the study. Also, current medical records must be available.  
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 97 • Investigator s will maintain  records separate from the eCRFs in the form of clinical 
charts, medical records, original laboratory, radiology and pathology reports, pharmacy 
records, etc. The i nvestigator will document in the clinic char t or medical record the 
date on which the participant  signed informed consent prior to participation in the study. 
Source documents must completely reflect the nature and extent of the participant’s medical care and must be available for sou rce document ve rification against entries in 
the eCRFs when the sponsor’s monitor visit s the site. In order to meet  data integrity 
requirements, source documentation should be attributable, legible, contemporaneous, accurate, available/accessible, original, complete and credible. A ll information obtained 
from the se documents will be kept in strict confidentiality.  Defi nition of what 
constitutes source data can be found in the study reference manual . 
10.1.8. Study and Site Closure  
The sponsor reserves the right to close the study site or terminate the study at any time for any reason at the sole discretion of the sponsor. Study sites will be closed upon study completion. A study site is considered closed when all required documents and study supplies have been collected and a study -site closure visit has been performed. 
Study- site closure prior to completion of the study should be avoided. The investigator and 
sponsor will agree to the circumstances that could cause early study- site closure.  
Conditions that may warrant early study-site closure or study termination may include, but are not limited to:  
• The discovery of an unexpected, serious, or unacceptable risk to participants 
participating in the study; 
• A negative change in the risk/benefit assessment;  
• Failure of the investigator to comply with the protocol, the requirements of the IRB/IEC or local health authorities, the sponsor's procedures, or GCP guidelines; 
• Inadequate recruitment of participants by the investigator; or 
• The decision on the part of the sponsor to suspend or disco ntinue nirogacestat  
development. 
Should the study be terminated, and/or the site closed for whatever reason, all documentation 
and study treatment pertaining to the study must be returned to the sponsor or its representative, and the Investigators, IRB/IEC  and Regulatory Authorities will be promptly informed of the 
termination and the reason for the decision. The Investigator should promptly inform the 
participants and assure appropriate therapy and follow-up. 
  
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 98 
 Appendix 2: Clinical Laboratory Tests  
• The tests detailed in Table 12 will be performed by the central laboratory . 
• Local  laboratory results are only required in the event that the central laboratory results 
are not available in time for either study treatment  (nirogacestat or placebo) 
administration and/or response evaluation. If a local sample is required, it is important 
that the sample for central analysis is obtained at the same time.  Additionally, if the local 
laboratory results are used to make either a study treatment decision or response evaluation, the results must be entered into the electronic case report form . In the event of 
a public health emergency, clinical laboratory assessments may be performed locally with results and local laboratory  normal values entered into the eCRF . 
• Protocol-specific requirements for inclusion and  exclusion of participants are detailed in 
Section 5 and Section s 6.7.2 and 6.7.3 protocol. 
• Additional tests , as part of unscheduled visits, may be performed at any time during the 
study as determined necessary by the investigator or required by local regulations. 
• Pregnancy testing (urine or serum as described in the SoA ; Section 1.3) will be conducted 
at monthly intervals during the double-blind and OLE study treatment  phases. 
• Urine pregnancy testing (will be conducted at monthly intervals during the double-blind and OLE study treatment phases for women of child-bearing potential. Refer to Section 8.2.6 for more details on the monthly pregnancy testing requirements.  
• Serum pregnancy tests may be conducted in place of urine pregnancy tests throughout the study if required by local regulations. 
• Additional serum or urine pregnancy tests may be performed, as determined necess ary by 
the investigator or required by local regulation, to establish the absence of pregnancy at any time during the participant 's participation in the study. 
• Investigators must document their review of each laboratory safety report.
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 99 Table 12 Protocol- Required Safety Laboratory Assessments  
Hematology  Chemistry2 Urinalysis  Serology5 Hormon e Levels6 
• HGB  
• HCT  
• PLT count  
• RBC count  
• RBC Indices:  
o MCV  
o MCH  
• % Reticulocytes  
• WBCC with 
Differential1: 
o neutrophils  
o lymphocytes  
o monocytes  
o eosinophils  
o basophils  • AST/SGOT  
• ALT/SGPT  
• D-BIL 
• TBIL 
• GGT  
• Sodium  
• Chloride  
• Potassium  
• Bicarbonate 
• Inorganic 
phosphorus  
• Alkaline phosphatase  
• Creatinine
3 
• Estimated 
glomerular filtration rate 
• BUN  
• Glucose (non-fasting)  
• Uric acid  
• Albumin  
• Total protein  • Specific gravity  
• Bilirubin  
• Glucose  
• Leukocyte esterase  
• Nitrite  
• Protein  
• Urobilinogen  
• Blood 
• Ketones  
• pH 
• Microscopy
4 • HIV antibody  
• HBV  
o HBsAg  
• HCV  
o hepatitis C antibody (HCV PCR  
if hepatitis C antibody positive)  Females:  
• TSH
7 
• Prolactin7 
• AMH 
• LH 
• FSH 
• Estradiol 
• Progesterone  
 
Males:  
• Total testosterone  
• Free testosterone 
• Progesterone 
• FSH 
• LH 
ALT = alanine aminotransferase; AMH = anti -müllerian hormone; AST = aspartate aminotransfer ase; BUN = blood urea 
nitrogen; D -BIL = direct bilirubin; FSH = follicle stimulating hormone; GGT = gamma-glutamyl transferase; HBsAg = 
hepatitis B surface antigen; HBV = hepatitis B virus; HCT = hematocrit; HCV = hepatitis C virus; HGB = hemoglobin; HIV =  
human immunodeficiency virus; LH = luteinizing hormone; MCH = mean cell hemoglobin; MCV = mean cell volume; PCR 
= polymerase chain reaction; PLT = platelet; RBC = red blood cell; SGOT = serum glutamic-oxaloacetic transaminase; SGPT 
=serum glutamic-pyruvic  transaminase; TBIL = total bilirubin; TSH = thyroid stimulating hormone; WBCC = white blood 
cell count  
1) Manual microscopic review is performed only if white blood cell count and/or differential values are out of 
reference range.  
2) Details of liver stop ping criteria and required actions and follow -up assessments after liver stopping or 
monitorin g event are given in Sections 7.1.1  and 10.6. 
3) If creatinine > 1.5 × ULN then calculated creatinine clearance must be ≥ 60 mL/min (using the Cockcroft -
Gault formula).  
4) Microscopy examination is performed only if blood or protein is abnormal.  
5) Serology only required at screening.  
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 100 Hematology  Chemistry2 Urinalysis  Serology5 Hormon e Levels6 
6) Hormone level  assessments for both fema les and males are required per the SoA in Section  1.3. Females 
reporting AEs/AESIs/SAEs of primary ovarian insufficiency (POI ) and/or amenorrhea will have hormone levels 
assessed every 3 months until event resolution (or for at least 90 days after discontinuing study treatment).  
7) Female hormone levels for TSH and  prolactin are only required at Screening and EOT .  
 
 Appendix 3: Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting  
10.3.1. Definition of A dverse E vent (AE ) 
AE Definition  
• An AE is any untoward medical occurrence in a patient or clinical study participant, 
temporally associated with the use of study treatment , whether or not considered 
related to the study treatment. 
• NOTE: An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment . 
Events Meeting  the AE D efinition  
• Any abnormal laboratory test results (hematology, clinica l chemistry, hormone levels , 
or urinalysis) or other safety assessments (e.g., electrocardiograms , radiological scans, 
vital signs measurements), including those that worsen from baseline, considered clinically significant in the medical and scientific jud gment of the investigator (i.e., not 
related to progression of underlying disease). 
• Exacerbation of a chronic or intermittent pre-existing condition including either an increase i n frequency and/or intensity of the condition. 
• New conditions detected or diagnosed after study treatment  administration even though 
it may have been present before the start of the study.  
• Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction.  
• Signs, symptoms, or the clinical sequelae of a suspected overdose of either study treatment  or a concomitant medication. Overdose per se will not be reported as an AE 
or serious adverse event ( SAE ) unless it is an intentional overdose taken with possible 
suicidal/self -harming intent. Such overdoses should be reported r egardless of sequelae.  
• “Lack of efficacy ” or “failure of expected pharmacological action” per se will not be 
reported as an AE or SAE. Such instances will be captured in the efficacy assessments. However, the signs, symptoms, and/or clinical sequelae resulting from lack of efficacy will be reported as AE or SAE if they fulfil the definition of an AE or SAE.  
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 101 Events NOT  Meeting the AE D efinition  
• Any clinically significant abnormal laboratory findings or other abnormal safety 
assessments which are associated  with the underlying disease, unless judged by the 
investigator to be more severe than ex pected for the participant’s condition. 
• The disease/disorder being studied or expected progression, signs, or symptoms of the disease/disorder being studied, unless more severe than expected for the participant’s condition. 
• Medical or surgical procedure (e.g., endoscopy, appendectomy): the condition that leads to the procedure is the AE. 
• Situations in which an untoward medical occurrence did not occur (social and/or convenience admission to a hospital). 
• Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present or 
detected at the start of the study that do not worsen. 
10.3.2. Definition of SAE  
If an event is not an AE per definition above, then it cannot be an SAE even if serious conditions are met (e.g., hospitalization for signs/symptoms of the disease under study, death due to progression of disease). 
A SAE is defined as any untoward medical occurrence that, at any dose:  
Results in death 
Is life -threatening  
• The term 'life -threatening' in the definition of 'serious' refers to an event in which the 
participant was at risk of death at the time of the event. It does not refer to an event, which hypothetically might have caused death, if it were more s evere.  
Requires inpatient hospitalization or prolongation of existing hospitalization 
• In general, hospitalization signifies that the participant has been detained (usually involving at least an overnight stay) at the hospital or emergency ward for observation and/or treatment that would not have been appropriate in the physician’s office or outpatient setting. Complications that occur during hospitalization are AEs. If a complication prolongs hospitalization or fulfills any other serious criteria, the event is serious. When in doubt as to whether “hospitalization” occurred or was necessary, the AE should be considered serious. 
• Hospitalization for elective treatment of a pre -existing condition that did not worsen 
from baseline is not considered an AE. 
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 102 Resul ts in persistent disability/incapacity  
• The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions. 
• This definition is not intended to include experiences of relatively minor medical significance such as uncomp licated headache, nausea, vomiting, diarrhea, influenza, 
and accidental trauma (e.g., sprained ankle) which may interfere with or prevent everyday life functions but do not constitute a substantial disruption. 
Is a congenital anomaly/birth defect  
Other s ituations: 
• Medical or scientific judgment should be exercised in deciding whether SAE reporting is appropriate in other situations such as important medical events that may not be immediately life -threatening or result in death or hospitalization but may j eopardize the 
participant or may require medical  or surgical treatment to prevent one of the other 
outcomes listed in the above definition. These events should usually be considered serious. 
Examples of such events include invasive or malignant cancers, intensive treatment in 
an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospitalization, or development of drug dependency or drug abuse.
 
10.3.3. Recording and Follow-U p of AE and/or SAE  
AE and SAE Record ing 
• When an AE/SAE occurs, it is the responsibility of the investigator to review all 
documentation (e.g., hospital progress notes, laboratory reports, and diagnostics reports) related to the event.  
• All required information pertaining to the AE/SAE will be recorded  in the electronic 
case repo rt form (e CRF ). SAEs will require additional information to be reported to 
Safety utilizing a paper SAE form that must be scanned and emailed or faxed to Safety immediately, without undue delay, under no circumstances later than 24 hours after  becoming aware of the event (refer to Section 10.3.4 for further SAE reporting d etails ). 
• It is not  acceptable for the investigator to send photocopies of the participant’s medical 
records to Safety  in lieu of completion of the SAE eCRF page /paper SAE form . 
• There may be instances when copies of medical records for certain cases are requested by Safety  for reported SAEs. In this case, all participant identifiers, with the exception 
of the participant number, will be redacted on the copies of the medical records before submission to Safety . 
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 103 • The investigator will attempt to establish a dia gnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not t he 
individual signs/symptoms) will be documented as the AE/SAE.  
Assessment of Intensity  
The intensity  of all  SAEs/AEs will be graded according to the Common Terminology Criteria 
for Adverse Events (CTCAE) version 5.0. For those SAEs/AEs  not listed in the  CTCAE, the 
following grading system will be used:  
• CTCAE Grade 1  Mild ; asymptomatic or mild symptoms; clinical or diagnostic 
observations only; treatment  not indicated. 
• CTCAE  Grade 2  Moderate; minimal, local or noninvasive treatment  indicated; 
limiting ag e-appropriate inst rumental activities of daily living ( ADL )*. 
• CTCAE  Grade 3  Severe or medically significant but not immediately life -threatening; 
hospitalization or prolongation of hospitalization indicated; disabling; limiting self -care 
ADL**.  
• CTCAE Grade 4 Life -threatening  consequences; urgent treatment  indicated. 
• CTCAE Grade 5  Death  related to AE . 
*Instrumental ADL refer to preparing meals, shopping for groceries or clothes, using the 
telephone, managing money, etc. 
**Self -care ADL refer to bathing, dres sing and undressing, feeding self, using the toilet, 
taking medications, and not bedridden. 
An event is defined as ‘serious’ when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE (Section 10.3.2), not when it is rated as severe.  
Assessment of Causality  
• The investigator is obligated to assess the relationship between study treatment (nirogacestat or placebo) and each occurrence of each AE/SAE.  
• A “reasonable possibility” of a relationship c onveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot be ruled out. 
• The investigator will use clinical judgment to determine the relationship.  
• Alternative causes, such as underlying disease(s), concomitant therapy, and other risk factors, as well as the temporal relationship of the event to study treatment  
administration will be considered and investigated. 
• The investigator will also consult the Investigator’s Brochure, when making an assessment.  
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 105 • In rare circumstances in the absence of email or facsimile equipment, notification by 
telephone is acceptable with a copy of the SAE form sent by overnight mail or courier 
service. However, initial notification via telephone does not replace the n eed for the 
investigator to complete and sign the SAE form within the designated reporting time frames.  
• After the study is completed at a given site, the eCRF  system  will be locked  to prevent 
the entry of new data or changes to existing data.  
• If a site receives a report of a new SAE from a study participant or receives updated data on a previously reported SAE after the eCRFs have been locked, then the site can report this information on a paper SAE form to the Safety  by telephone/ email /fax. 
• Contacts for SAE reporting can be found in Section  10.10.4. 
10.3.5. Definition of AR, SAR and SUSAR  
Adverse Reaction (AR):  
An AR is any noxious and unintended response to a medical product or procedure, for which a causal relations hip with the product or procedure is at least a reasonable possibility (i.e., the 
relationship cannot be ruled out). 
Serious Adverse Reaction (SAR) : 
A SAR is an SAE for which a causal relationship with the product or procedure is at least a 
reasonable po ssibility (i.e., the relationship cannot be ruled out). 
Suspected Unexpected Serious Adverse Reaction (SUSAR):  
A SUSAR is a  SAR that is judged as unexpected . An event is considered “unexpected” if it is 
not listed as expected in the reference safety info rmation (RSI) section of the investigator 
brochure (IB) or summary of product characteristics. 
 
  
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 106 
 Appendix 4: Contraceptive Guidance and Collection of Pregnancy 
Information  
Definitions:  
Wom en of Childbearing Potential (WOCBP) is defined as a woman that  is  considered fertile 
following menarche and until becoming post- menopausal unless permanently sterile ( see b
elow ). 
If fertility is unclear (e.g. , amenorrhea in adolescents or athletes) and a menstrual cycle cannot be 
confirmed before first dose of study treatment  (nirogacestat or placebo) , additional evaluation 
should be considered. 
Women in the following categories are not considered WOCBP: 
1. Premenarchal  
2. Premenopausal female with 1 of the following: 
• Documented hysterectomy ; or 
• Documented bilateral salpingectomy ; or 
• Documented bilateral oophorectomy. 
For individuals with permanent infertility due to an alternate medical cause other than the 
above, (e .g., Mullerian agenesis, androgen insensitivity), investigator discretion should be 
applied to determining study entry. B ilateral tubal occlusion  is not considered to be a 
permanent form of infertility . 
Note: Documentation can come from the site personnel’s review of the participant’s medical records, medical examination, or medical history interview. 
3. Postmenopausal female  
• A postmenopausal state is defined as no menses for 12 months without an alternative medic al cause.  
• A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy (HRT). However, in the absence of 12 months of amenorrhea, confirmation with more than one FSH measurement is required.  
• Females on HRT and whose menopausal status is in doubt will be required to use one of the non-estrogen hormonal highly effective contraception methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of postmenopausal status before study enrollment.
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 107 Contraception Guidance:  
CONTRACEPTIVESa ALLOWED DURING THE STUDY INCLUDE:  
Highly Effective Methodsb That Have  Low User Dependency Failure rate of <  1% per 
year when used consistently and correctly.  
• Implantable progestogen-only hormone contraception associated with inhibition of 
ovulationc 
• Intrauterine device  
• Intrauterine hormone- releasing system  
• Bilateral tubal occlusion  
• Vasectomized partner  
(Vasectomized partner is a highly effective contraceptive method provided that the partner is the sole sexual partner of the WOCBP  and the absence of sperm has been 
confirmed. If not, an additional highly effective method of contraception should be used. 
Spermatogenesis cycle is approximately 90 days.)  
Highly Effective Methodsb That Are User Dependent Failure rate of <  1% per year when 
used consistently and correctly.  
• Combined (estrogen - and progestogen -containing) hormonal contraception associated 
with inhibition of ovulationc 
o Oral 
o Intravaginal 
o Transdermal 
o Injectable 
• Progestogen-only hormone contraception associated with inhibition of ovulationc 
o oral 
o injectable 
• Sexual abstinence  
(Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatment. The reliability of sexu al abstinence needs to be evaluated in relation to the 
duration of the study and the preferred and usual lifestyle of the participant.)  
a) Contraceptive use by men or women should be consistent with local regulations regarding the use of 
contraceptive met hods for those participating in clinical studies.  
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 108 b) Failure rate of < 1% per year when used consistently and correctly. Typical use failure rates differ from those 
when used consistently and correctly.  
c) Barrier method s such as  condoms (male or female) o r occlusive cap (diaphragm or cervical/vault caps) with 
spermicidal foam/gel/film/cream or vaginal suppository must be used in addition to hormonal 
contraception. If locally required, in accordance with Clinical Trial Facilitatio n Group (CTFG) 
guidelines, acceptable contraceptive methods are limited to those which inhibit ovulation as the primary 
mode of action.  
Note: Periodic abstinence (calendar, symptothermal, post -ovulation methods), withdrawal (coitus interruptus), 
spermicide s only, and lactational amenorrhea  method are not acceptable methods of contraception. Male 
condom and female condom should not be used together (due to risk of failure with friction)  
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 109 Collection of Pregnancy Information: 
Male participants w ith partners who become pregnant  
• The inve stigator will attempt to collect pregnancy information on any male participant’s 
female partner who becomes pregnant while the male participant is in this study. This 
applies only to male participants who receive study treatment . 
• After obtaining the necess ary signed informed consent from the pregnant female partner 
directly, the investigator will record pregnancy information on the appropriate form and submit it to the sponsor within 24 hours  of learning of the partner’s pregnancy. The female 
partne r will a lso be followed to determine the outcome of the pregnancy. Information on the 
status of the mother and child will be forwarded to the sponsor. Generally, the follow-up will be no longer than 6 to 8 weeks following the estimated delivery date. Any t ermination 
of the pregnancy will be reported regardless of fetal status (presence or absence of anomalies) or indication for the procedure.  
Female P articipants who become pregnant  
• The investigator will collect pregnancy information on any female participant who becomes pregnant while participating in this study. Information will be recorded on the appropriate form and submitted to the sponsor within 24 hours of learning of a participant's pregnancy.  
• The participant will be followed to determine the outcome of the pregnancy. The investigator will collect follow -up information on the participant and the neonate and the 
information will be forwarded to the sponsor. Generally, follow-up will not be required for longer than 6 to 8 weeks beyond the estimated delivery date. Any termination of pregnancy will be reported, regardless of fetal status (presence or absence of anomalies) or indication for the procedure. 
• While pregnancy itself is not considered to be an AE or SAE, any pregnancy complication or elective terminatio n of a pregnancy will be reported as an AE or SAE. A spontaneous 
abortion is always considered to be an SAE and will be reported as such. Any post-study pregnancy related SAE considered reasonably related to the study treatment  by the 
investigator will be reported to the sponsor as described in Section 8.3.4. While the investigator is not obligated to actively seek this information in former study participants, he or she may learn of an SAE through spontaneous reporting. 
• Any female participant who becomes pregnant while participating in the study will discontinue study treatment  or be withdrawn from the study. 
  
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 110 
 Appendix  5: Genetics  
Use and analysis of deoxyribonucleic acid ( DNA ): 
• Genetic variation may impact a partici pant’s response to study treatment  (nirogacestat 
or placebo) , susceptibility to, and severity and progression of disease. Variable response 
to study treatment  may be due to genetic determinants that impact drug absorption, 
distribution, metabolism, and excretion; mechanism of action of the drug; disease 
etiology; and/or molecular subtype of the disease being treated. Therefore, where local regulations and institutional research board s/independent ethic committee s allow, DNA 
analysis will be collected from  participant’s blood sample (referred to as the optional 
pharmacogenetic blood sample in the SoA [ Section 1.3.1]) and participant’s tumor 
biopsy required for disease confirmation at baseline if archival tissue not availa ble, and 
optional tumor biopsy at the EO T visit will be collected fro m consenting participants . 
• DNA samples will be used for research related to nirogacestat  or desmoid  and related 
diseases. They may also be used to develop tests / assays including diagnostic tests related to nirogacestat or treatment s of this drug class and desmoid. Ge netic research 
may consist of the analysis of one or more candidate genes or the analysis of genetic markers throughout the genome. 
• DNA samples will be analyzed for  the pres ence of known mutations. Additional 
analyses may be conducted if it is hypothesized that this may help further understand the clinical data.  
• The samples may be analyzed as part of a multi -study assessment of genetic factors 
involved in the response to niro gacestat  or study treatment s of this class to understand 
study disease or related c onditions. 
• The results of genetic analyses may be reported in the clinical study report or in a separate study summary. 
• The sponsor will store the DNA samples in a secure storage space with adequate measures to protect confidentiality. 
• The samples will be retained while research on nirogacestat  continues but no longer 
than 10 years or other period as per local requirements. 
 
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 111 
 Appendix 6: Liver Safety: Suggested Actions and F ollow-up 
Assessments  
Liver Chemistry Stopping Criteria and F ollow- Up Assessments 
  Liver Chemistry Stopping Criteria  
ALT -absolute  ALT ≥ 5xULN  
ALT Increase  ALT ≥ 3xULN persists for ≥ 4 weeks  
Bilirubin1, 2 ALT ≥ 3xULN and bilirubin ≥ 2xULN (>  35% direct bilirubin)  
INR2 ALT ≥3xULN and INR >  1.5, if INR measured  
Cannot 
Monitor ALT ≥ 3xULN and cannot be monitored weekly for 4 weeks  
Sympt omatic3 ALT ≥ 3xULN associated with symptoms (new or worsening) believed to 
be related to liver injury or hypersensitivity 
Suggested Actions and Follow -up Assessments  
Actions  Follow -Up Assessments  
• Immediately discontinue study treatment  
(nirogacestat o r placebo)  
• Report the event to the sponsor within 24 
hours  
• Complete the liver event in the e CRF  and 
complete the SAE  eCRF form  if the event also 
met the criteria for an SAE2 
• Perform liver chemistry follow -up 
assessments 
• Monitor the participant until liver chemistry te
st abnormalities resolve, stabilize, or return 
to baseline ( see M
ONITORING ) 
•
 Rest
art/rechallenge is not allowed per 
protocol and not granted , permanently 
discontinue study treatment  and continue 
participant in  the study for any protocol 
specified follow up assessmentsMONITORING:  
If ALT ≥  3xULN AND bilirubin ≥ 2xULN or 
INR >  1.5:  
• Repeat liver chemistry tests (include ALT,  
AST, alkaline phosphatase, bilirubin and INR)  • Viral hepatitis serology4 
• Obtain INR  and recheck with each 
liver chemistry assessment until the transaminases values show downward trend  
• Serum CPK and LDH 
• Fractionate bilirubin, if total bilirubin ≥ 2xULN 
• Obtain complete blood count with differential to assess eosinophilia 
• Record the appearance or worsening of clinical symptoms of liver injury, or hypersensitivity, on the AE eCRF page 
• Record use of concomitant medications (including acetaminophen, h erbal remedies, and 
other over- the-counte r medications) 
on the concomitant medications e CRF  
page. 
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 112 and perform liver event follow -up assessments 
within 24 hours  
• Monitor participa nt twice weekly until liver 
chemistry test abnormalities resolve, stabilize, 
or return to baseline 
• A specialist or hepatology consultation is recommended  
If ALT ≥  3xULN AND bili rubin <  2xULN and 
INR ≤ 1.5:  
• Repeat liver chemistry tests (include ALT, 
AST, a lkaline phosphatase, bilirubin and INR) 
and perform liver chemistry follow -up 
assessments within 24 to 72 hours. 
• Monitor participants weekly until liver 
chemistry abnormalities resolve, stabilize, or return to baseline.  • Record alcohol use on the liver event 
alcohol intake e CRF  
 ALT ≥ 3xULN AND bilirubin ≥ 2xULN 
or INR >1.5: 
• Anti-nuclear antibody, anti-smooth 
muscle antibody, Type 1 anti- liver 
kidney microsomal antibodies, and quantitative total IgG or gamma globulins. 
• Serum acetaminophen adduct H PLC 
assay (quantifies potential acetaminophen contribution to liver injury in participants with definite or likely acetaminophen use in the preceding week [James , 2009]). 
• Liver imaging (ultrasound, magnetic resonance, or computerized tomography) and/or liver biopsy to evaluate liver disease; complete liver  
AE = adverse event; ALT = alanine aminotransferase; AST = aspartate aminotransferase; CPK = creatine phosphokinase ; eCRF 
= electronic case report form; HPLC =  high performance liquid chromatography; IgG = immunoglobulin G ; INR = international 
normalized ratio ; LDH = lactate dehydrogenase; SAE = serious adverse event; ULN = upper limit of normal;  
1. Serum bilirubin fractionation should be performed if testing is available. If serum bilirubin fractionation is not 
immediately available, discontinue study treatment  if ALT ≥ 3xULN and bilirubin ≥ 2xULN. Additionally, if serum 
bilirubin fractionation testing is unavailable, record the absence/presence of detectable urinary bilirubin on 
dipstick  which is indicative of direct bilirubin elevations suggesting liver injury.  
2. All e vents of ALT ≥ 3xULN and bilirubin ≥ 2xULN (>  35% direct bilirubin) or ALT ≥ 3xULN and INR >  1.5 may 
indicate severe liver injury (possible ‘Hy’s Law’) and must be reported as an SAE (excluding studies of hepatic impairment or cirrhosis) . The INR  stated threshold value will not a pply to participants receiving anticoagulants.  
3. New or worsening symptoms believed to be related to liver injury (such as fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, or jaundice) or hypersensitivity (such as fever, rash or eosinophil ia). 
4. Includes: Hepatitis A immunoglobulin M (IgM) antibody; hepatitis B surface antigen  and hepatitis B core antibody ; 
hepatitis C RNA; cytomegalovirus IgM antibody; Epstein -Barr viral capsid antigen IgM antibody (or if unavailable,  
heterophile antibody or monospot testing); and hepatitis E IgM antibody.  
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 113 Liver Chemistry Increased Monitoring Criteria with Continued Study  Treatment  
Liver Chemistry Increased Monitoring Criterion and Follow -Up 
Criterion  Actions  
ALT ≥ 3xULN and  < 5xULN  and 
bilirubin < 2xULN , without  
symptoms believed to be related to 
liver injury or hypersensitivity, and  
who can be monitored weekly for 4 weeks  • Notify the medical monitor within  24 hours  of 
learning of the abnormality to discuss participant safety.  
• Parti cipant can continue study treatment  
• Participant must return weekly for repeat liver chemistry tests (ALT, AST, alkaline phosphatase, bilirubin) until the abnormalities resolve, stabiliz e 
or return to baseline.  
• If at any time, the participant meets liver  
chemistry stopping criteria, proceed as described in Section 7.1.1. 
• If, after 4 weeks of monitoring, ALT < 3xULN and bilirubin < 2xULN, monitor participants twice monthly until liver chemistry tests resolve, 
stabilize, or retu rn to baseline.  
References  
Jame s LP, Letzig L, Simpson PM, Capparelli E, Roberts DW, Hinson JA, Davern TJ, Lee WM. Pharmacokinetics of 
Acetaminophen -Adduct in Adults with Acetaminophen Overdose and Acute Liver Failure. Drug Metab Dispos 
2009; 37:1779- 1784. 
  
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 114 
 Appendix 7: Eastern Cooperative Oncology Group Performance  
Grade  Description  
0 Normal activity. Fully active, able to carry on all pre -disease performance without 
restriction.  
1 Symptoms, but ambulatory. Restricted in physically strenuous activity,  but 
ambulatory and able to carry out work of a light or sedentary nature (e.g., light 
housework, office work). 
2 In bed <  50% of the time. Ambulatory and capable of all self -care, but unable to 
carry out any work activities. Up and about more than 50% of waking hours. 
3 In bed >  50% of the time. Capable of only limited self -care, confined to bed or chair 
more than 50% of waking hours. 
4 100% bedridden. Completely disabled. Cannot carry on any self -care. Totally 
confined to bed or chair. 
5 Dead.  
Source : Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative 
Oncology Group. Am J Clin Oncol. 1982;  5:649- 655 
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 115 
 Appendix 8: RECIST (Response Evaluation Criteria in  Solid 
Tumors) Version 1.1 Guidelines 
Adapted from E. A. Eisenhauer, et al: New response evaluation criteria in solid tumours: 
Revised RECIST guideline (version 1.1). European Journal of Cancer 45 ( 2009) 228–247 
Categorizing lesions at Baseline: 
• Only participants  with measurable disease (i.e. , at least one measurable lesion) at 
screening are included.  
Measurable lesion  – Lesion that can be accurately measured in at least one dimension (longest 
diameter [ LD]) in the plane of measurement is to be recorded) and with longest diameter at least 
twice the slice thic kness and at least 10 mm when assessed by computed tomography ( CT) or 
magnetic resonance imaging  (MRI )  
• Measurable disease will be assessed by CT or MRI.  
• The same method of assessment (CT or MRI) and the same technique will be used to 
characterize each identi fied and reported lesion at screening and during follow-up.  
• Target Lesion  - The i nvestigator will select up to 5 target lesions in total, representative 
of all involved organs at Baseline. 
• Non-target Lesion --All other lesions (or sites of disease) will be identified as non- target 
lesions and should also be recorded at baseline. Measurements of these lesions are not 
required, but the presence or absence of each should be noted throughout follow-up. 
Methods of Measurement  
CT or MRI must be used to measure ta rget lesions selected for response assessment. 
Conventional CT and MRI will be performed with cuts of 10 mm or less in slice thickness contiguously. Spiral CT should be performed using a 5 mm contiguous reconstruction algorithm.  This applies to tumors of the chest, abdomen and pelvis. Head and neck tumors and those of extremities usually require specific protocols.  
Recording Tumor Assessment s 
All sites of disease must be assessed at screening. Screening assessment must be done within 28 days of starting study treatment (nirogacestat or placebo) . For an adequate screening 
assessment, all required scans must be done within 28 days prior to firs t dose of study treatment 
and all disease must be documented appropriately. Participants must have progressive diseas e 
(PD) within a 12 -month period prior to the s creening visit scan . 
At follow -up, disease site must be assessed using the method (CT or MRI) and same technique 
as screening, including consistent administration of contrast (CT only) and timing of scanning. I f 
a change needs to be made the case must be discussed with the sponsor. 
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 116 Unequivocal new lesions will be recorded at follow-up time points. Measurement of new lesions 
is not required. If a new lesion is equivocal, for example because of its small size, continued therapy and follow- up evaluation will clarify if it represents truly new disease. If repeat scans 
confirm there is definitely a new lesion, then progression should be declared using the date of the initial scan.  
Response Criteria : 
Evaluation of target lesions  
Complete Response (CR):  Disappearance of all target lesions . 
Partial Response (PR):  At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum of LD . 
Progressive Disease (PD):  At least a 20% increase i n the sum of the LD of target lesions, 
taking as reference the smallest sum of LD recorded since the treatment started or the appearance of one or more unequivocal new lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.  
Stable Disease (SD):  Neither sufficient shrinkage to qualify for PR nor sufficient 
increase to qualify for PD, taking as reference the smallest sum LD since the treatment started . 
 
Evaluation of best overall response The best overall response is the best response recorded from the start of the study treatment until 
disease progression/recurrence (taking as reference for PD the smallest measurements recorded 
since the start of study treatment). The participant 's best resp onse assignment will depend on the 
achievement of both measurement and confirmation criteria (defined below).  
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 117 Time point resp onse: patients with target disease  
Target lesions  Non-Target lesions  New Lesions  Overall response 
CR CR No CR 
CR Incomplete 
response/SD No PR 
CR Not Evaluated  No PR 
PR Non-PD or not all 
evaluated  No PR 
SD Non-PD or not all 
evaluated  No SD 
PD Any Yes or No  PD 
Any PD Yes or No  PD 
Any Any Yes PD 
 
Participants  with a global deterioration of health status requiring discontinuation of study 
treatment without objective evidence of disease progression at that time will be classified as 
having “symptomatic deterioration”. Every effort should be made to document the objective progression even after discontinuation of treatment.  
Confir mation 
• Conf irmation of progression:  assessment of PD will be confirmed and documented by 
Central Imaging Review ( an independent, blinded central radiological review 
committee) .  
• Confirmation of response: 
o The main goal of confirmation of objective response is to avoid overestimating 
the response rate observed. In cases where confirmation of response is not feasible, it should be made clear when reporting the outcome of such studies that the responses are not confirmed. 
o To be assigned a status of PR or CR, changes in tumor measurements must be confirmed by repeat assessments that will be performed no less than 4 weeks after the criteria for response are first met.  
• Confirmation of SD:  in the case of SD, follow- up measurements must have met the SD 
criteria at least o nce after study entry at a minimum interval of 8 weeks. 
Duration of overall response 
• The duration of overall response is measured from the time measurement criteria are met for CR or PR (whichever status is recorded first) until the first date that r ecurre nce or PD 
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 118 is objectively documented, taking as reference for PD the smallest measurements 
recorded since the treatment started.  
Duration of stable disease 
• SD is measured from the start of the treatment until the criteria for disease progression are m et, taking as reference the smallest measurements recorded since the treatment 
started.   
o The clinical relevance of the duration of SD varies for different tumor types and grades. Therefore, it is highly recommended that the protocol specifies  the 
minimal time interval required between two measurements for determination of SD. This time interval should consider the expected clinical benefit that such a status may bring to the population under study.  
 
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 119 
 Appendix 9: Abbreviations  
Abbreviation  Definition  
AE Adverse event  
AESI  Adverse event of special interest  
ADL  Activities of daily living  
ALT  Alanine aminotransferase  
AMH  Anti-müllerian hormone  
APC  Adenomatous polyposis coli  
AR Adverse reaction  
AST  Aspartate aminotransferase  
BID Twice daily  
BPI Brief pain inventory  
BUN  Blood urea nitrogen  
C1D1  Cycle 1 Day 1  
CFR  Code of Federal Regulations  
CI Confidence interval  
ConMed  Concomitant medication  
CPK  Creatine phosphokinase  
CR Complete response  
CT Computed tomography  
CTCAE  Common Terminology Criteria  for Adverse Events  
CTFG  Clinical Trial Facilitation Group  
CTNNB1  β-catenin  
CYP 3A4 Cytochrome P450 3A4  
D-BIL Direct bilirubin  
DDI Drug-drug interaction  
DMC  Data monitoring committee  
DNA  Deoxyribonucleic acid,  
DT/AF  Desmoid tumors/aggressive fibromatosis  
DTP  
DTRF  Direct to participant  
Desmoid Tumor Research Foundat ion 
ECG  Electrocardiogram  
ECOG  Eastern Cooperative Oncology Group  
eCRF  Electronic case report form  
EDC  Electronic data capture  
EFS Event free survival  
EORTC QLQ -30 European Organisation for Research and Treatment of Cancer 
Quality of Life Questionnai re-Core 30  
EOT  End of treatment  
ePRO  Electronic patient report outcome  
FAP Familial adenomatous polyposis  
FDA  Food and Drug Administration  
FFPE  formalin -fixed, paraffin embedded  
FSH Follicle stimulating hormone  
FU Follow -up 
GCP  Good Clinical Prac tice 
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 120 Abbreviation  Definition  
GGT  Gamma -glutamyl transferase;  
GODDESS  GOunder/DTRF DEsmoid Symptom/Impact Scale  
GS Gamma -secretase  
HBsAg  Hepatitis B surface antigen  
HBV  Hepatitis B virus  
HCT  Hematocrit  
HCV  Hepatitis C virus  
Hes1  Hairy and enhancer of split -1 
HGB  Hemoglobi n 
HIV Human immunodeficiency virus  
HPLC  High performance liquid chromatography  
HR Hazard ratio  
HRT  Hormonal replacement therapy  
ICF Informed consent form  
ICH International Council for Harmonisation  
I/E Inclusion/exclusion  
IEC Independent Ethics Com mittee  
IgM Immunoglobulin  M 
INR International normalized ratio  
IRB Institutional Review Board  
IRT Interactive response technology  
ITT Intent -to-Treat  
LD Longest diameter  
LDH  Lactate dehydrogenase  
LH Luteinizing hormone  
MCH  Mean cell hemoglobin  
MCV Mean cell volume  
MRI  Magnetic resonance imaging  
MSKCC  Memorial Sloan Kettering Cancer Center  
MSK/DTRF DTIS  Memorial Sloan Kettering/Desmoid Tumor Research 
Foundation Desmoid Tumor Impact  Scale  
MSK/DTRF DTSS  Memorial Sloan Kettering/Desmoid Tumor Rese arch 
Foundation Desmoid Tumor Symptom Scale  
MTD  Maximum tolerated dose  
NCI National Cancer Institute  
NICD  Notch intracellular domain  
NIR nirogacestat  
NSAID s Nonsteroidal anti -inflammatory drug  
OLE  Open -label extension  
ORR  Objective response rate  
PCR Polymerase chain reaction  
PD Progressive disease  
PFS Progression -free survival  
P-gp P-glycoprotein  
PGIC  Patient global impression of change  
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 121 Abbreviation  Definition  
PGIS  Patient global impression of severity  
PK Pharmacokinetic  
PLT Platelet  
POI Primary ovarian insufficien cy 
PopPK  Population pharmacokinetic  
PR Partial response  
PRO  Patient -report ed outcome  
PROMIS PF  Patient -Reported Outcomes Measurement Information System 
Physical Function  
QoL Quality of life 
QT Uncorrected QT interval  
QTcF  Corrected QT interval by Fr idericia  
QRS  QRS Complex  
RBC  Red blood cell  
RECIST  Response Evaluation Criteria In Solid Tumors  
RNA  Ribonucleic acid  
RP2D  Recommended Phase 2 dose  
SAE  Serious adverse event  
SAP Statistical analysis plan  
SAR  Serious adverse reaction   
SD Stable dise ase 
SGOT  Serum glutamic -oxaloacetic transaminase  
SGPT  Serum glutamic -pyruvic transaminase  
SoA Schedule of activities  
STSs  Soft-tissue sarcoma s 
SUSAR  Suspected unexpected serious adverse reaction  
TdP Torsades de Pointes  
TBIL  Total bilirubin  
TKI Tyro sine kinase inhibitors  
TSH  Thyroid stimulating hormone  
ULN  Upper limit of normal  
v Version  
WBCC  White blood cell count  
WOCBP  Women of childbearing potential  
 
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 122 
 Appendix 10: List of Contacts for Study  
10.10.1. Sponsor  
SpringWorks Therapeutics 
100 Washington Blvd Stamford, CT 06902 United States  
Telephone: 212-421-8012 Fax: 646-609-8816 

SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 123 11. REFERENCES 
Bo N, Wang D, et al. Analysis of β -catenin expression and exon 3 mutations in pediatric 
sporadic aggressive fibromatosis. Pediatr Dev Pathol. 2012 May Jun;15(3):173-8. 
Casali  PG, Abecassis  N, et al.; ESMO  Guidelines Committee and EURACAN . Soft tissue and 
visceral sarcomas: ESMO -EURACAN Clinical Practice Guidelines for diagnosis,  treatment and 
follow-up. Ann Oncol. 2018;  Epub ahead of print, May 28. 
de Camargo VP, Keohan ML, et al. Clinical outcomes of systemic therapy for patients with deep 
fibromatosis (desmoid tumor). Cancer. 2010 May 1;116(9):2258-65. 
Eisenhaur EA, Therasse P,  et al. New response evalu ation cri teria in solid tumours: Revised 
RECIST guideline (version 1.1). Eur J Cancer . 2009 Jan;45(2):228-47. 
Gounder, M., Mahoney M, et al. Phase III, randomized, double-blind, pl acebo -controlled trial of 
sorafenib in desmoid tumors J Clin Oncol 36, 2018 (suppl; abstr 11500).  
Hosalkar, H, Fox EJ, et al. Desmoid Tumors and Current Status of Management. Orthop Clin N 
Am 2006(37):53-63. 
Janinis J, Patriki M, et al. The pharma cological  treatment of aggressive fibromatosis: a 
systematic review. Ann Oncol. 2003 Feb;14(2):181-90. Kasper B, Baumgarten C, et al.; Desmoid Working Group. Management of sporadic desmoid 
type fibromatosis: a European consensus approach based on patients' and professionals' expertise- a sarcoma patients EuroNet and European Organisation for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group initiative. Eur J Cancer. 2015 Jan;51(2):127 36. 
Kasper B, Gruenwald V, et al. Imatinib induces sustained progression arrest in RECIST 
progressive desmoid tumours: Final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG). Eur J Cancer. 2017 May; 76:60-67. 
Kasper B, Ströbel P, et al. Desmoid tumors: clinical features and treatment opt ions for advanced 
disease. Oncologist. 2011;16(5):682-93. Klinakis A, Szabolcs M, et al. Myc is a Notch1 transcriptional target and a requisite for Notch1-
induced mammary tumorigenesis in mice. Proc Natl Acad Sci USA. 2006 Jun 13;103(24):9262-67. 
Kummar S,  O'Sullivan Coyne G , et al. Clinical activity of the γ -secretase inhibitor PF -03084014 
in adults with desmoid tumors (Aggressive Fibromatosis). J Clin Oncol. 2017 May 
10;35(14):1561-69. 
Lazar AJ, Tuvin D, et al. Specific mutations in the beta- catenin gene (CTNNB1) correlate with 
local recurrence in sporadic desmoid tumors. Am J Pathol. 2008 Nov;173(5):1518-27. Lewis JJ, Boland PJ, et al. The enigma of desmoid tumors. Ann Surg. 1999 Jun;229(6):866-72. 
SpringWorks Therapeutics  Protocol NIR- DT-301
  Amendment 5 (09Feb 2021) 
CONFIDENTIAL  Page 124 Messersmith WA, Shapiro GI, et al. A Phase I, dose finding study in patients with advanced 
solid malignancies of the oral γ -secretase inhibitor PF -03084014. Clin Cancer Res. 2015 Jan 
1;21(1):60-7. 
Penel N, Le Cesne A, et al. Surgical versus non-surgical approach in primary desmoid-type 
fibromat osis patients: A n ationwide prospective cohort from the French Sarcoma Group. Eur J 
Cancer. 2017 Sep; 83:125-31. 
Quintini C, Ward G, et al. Mortality of intra- abdominal desmoid tumors in patients with familial 
adenomatous polyposis: a single center review of 154 patients. Ann Surg. 2012 Mar;255(3):511-
6. 
Rampazzo E, Persano L, et al. Wnt activation promotes neuronal differentiation of glioblastoma. 
Cell Death Dis. 2013 Feb 21;4: e500. 
Rodilla V, Villanueva A, et al. Jagged1 is the pathological link between Wnt and Notch 
pathways in colorectal cancer. Proc Natl Acad Sci USA. 2009 Apr 14;106(15):6315-20. 
Schöffski P, Requilé A, et al. Assessment of physician's systemic treatment preferences for 
patients with advanced desmoid-type fibromatosis: experience- based  medicine in the a bsence of 
high-level evidence. Oncol Res Treat. 2018;41(4):214-19. 
Shang H, Braggio D, et al. Targeting the Notch pathway: a potential therapeutic approach for 
desmoid tumors. Cancer. 2015 Nov 15;121(22):4088-96. 
Sharma VM, Calvo JA, et al. Notch1 contributes to mouse T cell leukemia by directly inducing 
the expression of c-myc. Mol Cell Biol. 2006 Nov;26(21):8022-31. 
Skubitz KM. Biology and Treatment of aggressive fibromatosis or desmoid tumor. Mayo Clin 
Proc. 2017 Jun;92(6):947-64. 
Smith AJ, Lewis JJ, et al. Surgical management of intra -abdominal desmoid tumours. Br J Surg. 
2000 May;87(5):608-13. Tejpar S, Nollet F, et al. Predominance of beta-catenin mutations and beta-catenin dysregulation 
in sporadic aggressive fibromatosis (desmoid tumor). Oncogene. 1999 Nov 11;18(47):6615-20. 
Ungerbäck J, Elander N, et al. The Notch-2 gene is regulated by Wnt signaling in cultured 
colorectal cancer cells. PLoS One. 2011 Mar 18;6(3): e17957. 
Villalobos VM, Hall F, et al . Long- term follow -up of desmoid fibromatosis treated with PF-
03084014, an oral gamma secretase inhibitor. Ann Surg Oncol. 2018 Mar;25(3):768-75. 